Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
6-29-2017 12:00 AM

Evidence Reversal: An exploratory analysis of randomized
controlled trials from the New England Journal of Medicine
Riaz G. Qureshi, The University of Western Ontario
Supervisor: Dr. Janet Martin, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Epidemiology and Biostatistics
© Riaz G. Qureshi 2017

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Clinical Epidemiology Commons

Recommended Citation
Qureshi, Riaz G., "Evidence Reversal: An exploratory analysis of randomized controlled trials from the New
England Journal of Medicine" (2017). Electronic Thesis and Dissertation Repository. 4652.
https://ir.lib.uwo.ca/etd/4652

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

ABSTRACT
BACKGROUND: Evidence Reversal (ER) is the phenomenon whereby new and stronger
evidence contradicts previously established evidence.
OBJECTIVES: To quantify evidence reversals and to determine characteristics associated
with reversibility.
METHODS: Original articles from the New England Journal of Medicine (2000 to 2016)
were screened for three inclusion criteria: tested a clinical practice; Randomized
Controlled Trial design; and tested an established clinical practice. The proportion of
RCTs that represented ER was determined. Association of trial characteristics with
reversal was explored using logistic regression in order to inform a potential framework
of reversibility.
RESULTS: In total, 611 RCTs met the inclusion criteria, of which 54% were evidence
reversals. Based on variables associated with ER, a reversibility framework was
proposed, comprised of eight trial characteristics.
CONCLUSION: More than 50% of RCTs published in the NEJM that test established
practices are evidence reversals. The characteristics of RCTs that are associated with
reversal will inform future research to further understand reversibility.

KEYWORDS: Evidence Reversal, Medical Reversal, Evidence-Based Medicine,
Evidence Synthesis, Randomized Controlled Trials, Adoption, De-Adoption,
Implementation, De-Implementation, Decision-Making
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CHAPTER 1

Introduction to Evidence Reversal

Riaz Qureshi

Note:

After this chapter of this thesis was drafted, a manuscript to introduce concepts,
contained within this chapter was drafted for publication. As such, there are
many similarities in the sections of the paper and this chapter. However, I was
able to expand this chapter and go into more detail than the paper due to space
and formatting restrictions within the publication.

Citation: Qureshi R, Sutton D, & Martin J. (2016). Approaching Evidence Reversal and
Medical Reversal – When to say, “Enough is enough.” Ready for submission
for publication to Mayo Clinic Proceedings, Apr 2017.
Chapter summary: This chapter presents an introduction to the phenomenon of reversal
and describes some of the issues that surround research in this field, as well as
the current tools in the field of reversal research and the proposed rationale and
impact that this research will have on future research.

Riaz Qureshi
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CHAPTER 1
1.0

WHAT ARE MEDICAL REVERSAL AND EVIDENCE
REVERSAL?
A medical reversal is the phenomenon whereby a medical practice, procedure, or

technology that has been embraced by the medical community loses its standing when
better conducted studies show that it is not as effective as was thought, or even harmful to
the population.1–3 As medicine has advanced, so too has study methodology, and new
trials are often superior – through better design, greater power, or more appropriate
control groups – to the original studies of a medical practice.1,2 When such superior
studies are conducted to test the effectiveness of current clinical practices, they may
contradict the original studies – with results that are incongruent with the beliefs and
practices of the general medical community – and find that the current practice,
procedure, or technology, is inferior to a prior standard of care, does not produce the
promised results, or is even more harmful than beneficial to a patient’s health.2
Evidence reversal occurs when new evidence comes to light and shows that the
established evidence, often based on a combination of low quality research or limited
availability, is incorrect.1 While similar to the phenomenon of ‘medical reversal,’ the
phenomenon of ‘evidence reversal’ differs in two regards. Firstly, the term ‘medical
reversal’ limits the phenomenon to clinical practices, whereas ‘evidence reversal’
expands this definition beyond medicine alone to also include other fields relevant to
health and healthcare, such as public and population health. Secondly, ‘medical reversals’
refers only to practices that are already adopted and implies de-adoption after reversal,
whereas ‘evidence reversal’ refers only to the evidence for the practices as being reversed
and the practices, if already adopted, may continue. It is for this reason that we propose
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‘evidence reversal’ as being a more appropriate term to describe contradictory findings of
new studies, and consequently, more appropriate than ‘medical reversal.’
While evidence reversal may arise from the findings when a trial investigates an
already established intervention, there are several other possible outcomes when studying
interventions in general. When an established intervention is tested and found to be
inferior to what was originally believed, this is a reversal, as has previously been
established.4 As the counterpart to reversal: when an established intervention is tested by
newer studies and found to be as good as, or better than, was originally believed, this is
termed “evidence reaffirmation.”1,4 When a new practice, device, or intervention is being
tested and is found to be superior to an old standard of care, this constitutes an “evidence
replacement.”1,4 The counterpart to evidence replacement is sometimes referred to as
“back to the drawing board” – which occurs when a trial that tests a new practice, device,
or intervention finds it equal to or no better than an old standard of care.1,4
The term ‘medical reversal’– as applied to describing the phenomenon of new
trials contradicting clinical practice – was first used in 2011 by Prasad and colleagues.1
While the designation is still in its infancy and the term is not well known, physicians are
familiar with the phenomenon of evidence reversal and subsequent de-implementation of
established clinical practices.5 Awareness of the phenomenon is increasing, even within
the general public, as examples of reversals have been highlighted in the medical news of
the popular media.6,7

1.1

FREQUENCY OF MEDICAL REVERSAL
Given the frequency with which guidelines and practices change in the medical

literature, several researchers have tried to quantify the rate of reversal. Ioannidis and
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colleagues found that among highly influential studies published in the New England
Journal of Medicine (NEJM), Journal of the American Medical Association (JAMA), and
Lancet between 1990 and 2003 that have been cited more than 1000 times, 16% were
found to be contradicted by subsequent studies and an additional 16% were found to have
smaller effects than initially found.8 In further assessments of all original research articles
published in the NEJM, Prasad and colleagues suggest that reversal could be even more
prevalent. The proportion of trials published in 2009 that tested an established medical
practice and found contradictory evidence constituting a reversal was 46%.1 A similar
assessment over a 10-year period, from 2001 to 2010, found that 40.2% of trials found
contradictory evidence for their tested practice.4

1.2

EXAMPLES OF EVIDENCE AND MEDICAL REVERSAL
Three debated reversals include: stenting for stable coronary artery disease,

vertebroplasty for osteoporotic fracture, and hormone replacement therapy for prevention
of coronary heart disease.
1.2.1

Percutaneous coronary intervention for stable coronary artery disease

Ever since their invention, coronary artery stents – a small wire mesh tube
designed to expand and open an artery with stenosis – have been used to treat people with
myocardial infarction (MI). Placing a stent in an occluded artery at the site of blockage –
percutaneous coronary intervention (PCI) – opens the vessel and restores blood flow,
improving the chances of surviving the event. Due to their effectiveness in restoring flow
to a damaged artery, PCI was also used in the treatment of typical angina – recurring
chest pain with exertion that is experienced as a direct result of coronary artery disease
(CAD). The physiology and mechanism for action was logical, and patients reported
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feeling better after undergoing the procedure. However, a 2007 randomized, blinded trial
of PCI plus medical therapy versus medical therapy alone in patients with stable CAD
found that it did not reduce the risk of death (both cardiac and all-cause mortality),
recurrent MI, stroke, hospitalisation for acute coronary stenosis, or revascularization.9
This trial showed that while PCI for stable CAD relieved some symptoms, such as typical
angina, for a brief time, placing a stent did nothing to improve patient survival or risk of
future cardiovascular events and was therefore not as effective as was believed while
subjecting patients to the risks associated with surgical intervention, such as: anaesthesia,
infection of site wound, and hospital stay.9 Despite the findings of this trial, the practice
persists and is consequently more appropriately described as an evidence reversal than a
medical reversal.
1.2.2

Vertebroplasty for osteoporotic fracture

In the early 1990s, a simple outpatient procedure for the management of
osteoporotic spinal fractures became popular and gained widespread use. Vertebroplasty
involves the injection of medical cement into fractured spinal bone with the intention of
restoring original shape, stabilizing the fragments, and reducing pain from the fracture.10
The procedure appeared to work: patients who underwent the procedure experienced
drastically reduced pain and disability.10 Based on these reports and several early trials
that did not include controls, vertebroplasty was added to the list of Medicare-funded
procedures in 2001.11 Vertebroplasty quickly became a multi-million dollar industry and
the number of procedures performed each year increased from 14,142 in 2001, to 29,090
in 2005.11 However, the evidence for this procedure was reversed in 2009 when two
randomized and double-blinded trials of vertebroplasty versus a sham procedure (simple
salt water injection) found no difference between groups in response to treatment:
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saltwater injection caused just as much reduction in pain and disability as medical
cement.12,13 Although the two trials provided convincing evidence to discredit the
practice, its use has persisted and is consequently representative of evidence reversal.
1.2.3 Hormone replacement therapy for prevention of coronary heart
disease
Prescription of hormone replacement therapy (HRT) – a combination of estrogen
and/or progestin – to reduce the symptoms of menopause and as primary prevention for
coronary heart disease (CHD) has been routine since the mid-1960s.14–17 These
endogenous hormones are critical for a number of physiologic processes including the
reduction of osteoporotic bone loss, cardiovascular health, reproductive function, and
temperature regulation dependent on hormonal homeostasis.18 Following endogenous
estrogen reduction after menopause, women experience increased risk of osteoporosis
and bone fracture, MI, stroke, uterine and vaginal wall changes, and hot flushes.18,19
Treatment with exogenous estrogen and progestin was a physiologically sound solution
to improve bone mineral density and reduce the risk of MI, stroke, and other
perimenopausal symptoms. The therapy seemed to work for select symptoms such as hot
flushes and bone mineral density. However, two randomized controlled trials conducted
between in 1993 and 1998 reported that women receiving HRT were at significantly
higher risks for CHD, stroke, breast cancer, pulmonary embolism, and venous
thromboembolic events than women not receiving HRT.15,20 The risk-to-benefit ratio of
HRT was too great for a primary prevention of CHD and osteoporosis, and the therapy
quickly fell out of favour among post-menopausal women, although its use in other
population subgroups remains contested.14 While HRT use continues for some women,
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the contraindication and cessation of routine use in most post-menopausal women is what
designates it as an example of a medical reversal.

1.3

WHY SHOULD WE CARE ABOUT REVERSALS?
Reversals of evidence, whether in medicine or other health-related disciplines are

an important phenomenon to the scientific community and the population as a whole.
Society should care about this phenomenon because reversals pose several real dangers to
clinical practice if left unchecked. Minimizing the impact and occurrence of reversals
caused by the premature adoption of practices would benefit society in several ways.
1.3.1

The dangers of unnecessary reversal

Although the phenomenon of evidence reversal is a natural consequence of the
scientific method – contradicting prior beliefs when new information and better methods
to test those beliefs are available – the premature implementation of practices (whether
they be medical, public health, or population based) that may have little to no benefit, or
are potentially harmful can lead to serious consequences for society. These risks of
premature adoption are often discussed in the literature as being the harms associated
with reversal.
One of the primary dangers of reversal is unnecessary cost (i.e. wasted resources).
Any technology or practice that does not work as intended, especially medical, has no
place in the market. However, new technologies are often promoted by industry without a
complete understanding of their effectiveness – often for uses for which they have not
been tested nor approved. Furthermore, it is not only industry that does this as
governments will support technologies or interventions that have a demonstrated need in
their population, based on whatever evidence is available at the time.21 The presence of
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reversed practices in medicine places an unnecessary burden on the healthcare system as
the government utilizes limited resources to provide services that are no better, or worse
than, previously implemented standards of care, placebo, or even no intervention.2,3,22
Another danger of reversals is the potential risk at which those who receive
reversed interventions have been placed for no benefit. Medical practice revolves around
the principles of beneficence and non-maleficence: doing what is best for one’s patient
and not causing undue harm. These must always be kept in balance when determining the
most suitable intervention: what level of risk is acceptable, given the expected benefit
that the patient should receive? When patients receive reversed medical practices, they
have undergone unnecessary risk for less benefit than they believed they were receiving,
and this is ethically and morally wrong.
Another danger of reversal in medicine is the undermining of trust in the medical
system. It is generally accepted that the public trusts that physicians know what treatment
is best for their health problems and will administer a suitable therapy that has their
interests in mind.23,24 The core tenet of evidence-based medicine (EBM) is the integration
of clinical expertise, best available evidence, and patient preferences in choosing the most
suitable intervention.25 However, all clinicians know that there are times when no clear
path is available and sometimes the best that can be done is an educated guess. When
patients receive multiple misdiagnoses or mistreatments they may lose faith in the
medical system. In addition, the media portrayal of medical uncertainty, changing
guidelines, and exaggerated claims of the benefits or risks of practices compound this
mistrust. This damage that is done to a patient’s or clinician’s faith in the medical system
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may be irreparable and undermine the ability of the system to help these people in the
future.26
A further danger of medical and evidence reversals lies in the difficulty associated
with removing an already established standard from the scientific community: deadoption.27 It is an established fact of knowledge translation that it takes many years for
practices to be implemented in clinical care or for a scientific technique to be adopted.
However, it is more difficult to remove an engrained intervention, technology, or
paradigm from practice because the scientific community is not unbiased.28,29
Practitioners will often justify the continued use of a popular standard or practice, despite
evidence that it does not work as was originally believed. Once something has been
reversed, there is no guarantee that it will cease to be used.
1.3.2

The benefits of eliminating unnecessary reversal

Premature uptake of practices, before sufficient evidence exists (leading to
subsequent unnecessary evidence reversals when better evidence accrues), is common in
medicine and poses a real risk to the health of the population. If the incidence of reversed
practices could be reduced, or the impact of the phenomenon minimized, all members of
society would benefit. The benefits of reducing the amount of medically reversed
practices and technologies are all complementary to the dangers that accompany reversal,
as discussed above.
Eliminating or reducing unnecessary evidence reversals due to premature
knowledge translation would improve the overall health of the population because
potentially harmful or ineffective practices may be stopped earlier or prevented from
implementation. Many medical practices that are reversed place the recipients at risk for
little to no benefit. It logically follows that reducing the number of practices that do not
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work as planned or are more harmful than originally believed would subsequently reduce
the burden of harm that is placed on the population.
If the number of reversals due to premature adoption were reduced, there would
be increased trust in the medical community. Fewer practices would be implemented that
later need to be de-adopted. This may lead patients to put more trust into their physicians
and to be more open to seeking medical care when it is necessary.
With a reduction in reversals due to premature adoption, government
administrators and policy makers may see an increase in available funding. This increase
may be possible if premature conclusions based on insufficient evidence could be
minimized, to prevent the premature uptake of practices. This prevention would lead to a
reduction in unnecessary expenditure as money that was previously wasted on
technologies and interventions that are no better or worse than placebo would be
available for use in areas based on adequate evidence and proven efficacy.

1.4

APPROACHING EVIDENCE REVERSAL
The phenomenon of evidence reversal is difficult to approach because of its

inherent ethical and logistic challenges. The primary dangers of reversal revolve around
the fact that practices and paradigms that need to be reversed are often already engrained
in the scientific community and/or widely believed. In approaching the phenomenon of
evidence reversal – and in consideration of these dangers – it is vital to consider where
the burden of proof may lie for identifying reversals.
Given the difficulties surrounding de-adoption of established practices, the most
effective approach to minimizing their impact is to stop them before they gain a strong
presence in clinical practice and population health. However, one of the difficulties in
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identifying reversals before they have been adopted is establishing where the
responsibility for identification lies.22,26 Using the arguments presented by Prasad and
Cifu for the identification of medical reversals, we believe that the burden of proof lies
primarily with manufacturers, researchers, and regulatory bodies who develop and
approve interventions and practices to ensure effectiveness before implementation.26
In asking this question, it is easiest to rule out where the burden of proof does not
lie, and this is with the patients. Undoubtedly, the general population that is served by the
medical community suffers when technologies that will be later reversed see widespread
dissemination and use. As has been outlined in previous sections, reversals have many
dangers and the public has the right to interventions that have proven efficacy.22
The burden of proof for identifying reversals must lie partly with physicians as the
administrators of therapies. However, beyond their physiological knowledge and personal
clinical experience and expertise, they can only know as much about the interventions
that they prescribe as is given to them by the researchers and industry. The burden of
proof lies in part with physicians, as they must be cognizant of the evidence for a
treatment’s efficacy before prescribing it to their patients. It is a physician’s ethical duty
to act in the best interests of the patient and when technologies are put into practice
before their effects are fully understood, physicians take a risk in their prescription as
they may be unknowingly putting the patient at increased risk of unnecessary harm.22
Following the description of the dangers of medical reversal, the rationale for why
the burden of proof lies primarily with the governmental institutions that support the
research and grant regulatory approval, the industry that creates the interventions, and the
researchers who study their effectiveness and efficacy in clinical practice is clear: 1) it is
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very difficult and costly to remove an already established practice from the field and it is
safer and more efficient to confidently determine an intervention’s efficacy and
effectiveness before it is implemented than after it has been implemented – which is the
responsibility of governmental institutions that support research and grant regulatory
approval; 2) the actual proportion of interventions that have clinically relevant and
significant impacts on patient important and meaningful outcomes is very low – which is
the responsibility of the industry that creates interventions; and 3) the implementation of
practices that may later be reversed is a waste of valuable health-care resources that could
be avoided by adequately studying their effects before promoting their use – which is the
responsibility of the researchers who study effectiveness and efficacy in practice and the
agencies that fund research.22

1.5

TOOLS FOR APPROACHING EVIDENCE REVERSAL
In knowing where the burden of proof lies, consideration must be given to the

methods and tools that are currently employed for identifying and reducing the impact of
evidence reversals. While standards of practice exist in all scientific disciplines, new
findings will always require knowledge dissemination before they can be implemented.
As such, there currently exist several tools that attempt to mitigate the effects of
unnecessary reversals by providing evidence-based recommendations: clinical guidelines,
knowledge translation, and various tools for de-implementation.
An ideal clinical guideline should serve to inform practitioners and patients of the
most appropriate treatment or course of action in any given circumstance. While there are
many faults with the current processes employed in creating clinical guidelines – faults
which themselves may sometimes lead to premature adoption and unnecessary reversal –
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an ideal clinical guideline that is rigorous, unbiased, and uses the best available evidence
should provide a recommendation for the most appropriate care within the context of the
quality and quantity of available evidence.
Similarly, an ideal translation of research findings into practice could lead to a
reduction in premature uptake of practices because clinicians and policy makers would
consequently know which practices have a proven efficacy and which do not. Despite
this, however, there remain a plethora of potential reasons as to why a practice may be
prematurely adopted or remain in use after it has been reversed.
In attempting to reduce the impacts of unnecessary reversals and premature
adoption, many different campaigns and programs have been developed to aid in the deadoption of reversed practices and increase awareness of the value of different practices.
These programs attempt to summarize the totality of evidence and provide
recommendations to practitioners and even the general public to inform better health care.
In providing these recommendations for the implementation of new practices or
de-adoption of established practices, an important consideration is the maturity of the
evidence base to support the practice. Sufficiency and stability are characteristics to
describe accumulated evidence and provide a measure of evidence maturity: the point at
which an intervention has been studied enough that conducting another test no longer
provides any information of value. There are several different methods of assessing the
sufficiency and stability of evidence to aid decision-making including: cumulative metaanalysis, trial sequential analysis / monitoring, Bayesian analysis, value of information
analysis, GRADE (Grades of Recommendation Assessment, Development, and
Education), and the fragility index. Chapter 7 provides a detailed discussion of the
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strengths and weaknesses of these tools and how the results of this thesis may be applied
to inform their development and use in the context of medical and evidence reversal.

1.6

CAUSES OF EVIDENCE REVERSAL
Evidence reversal is a complex phenomenon that occurs when new research

contradicts the established evidence for a claim or belief, suggesting it is not what was
originally believed. Evidence reversal has many causes. The causes of evidence reversal
are related to the characteristics of the original research itself – including characteristics
of the innovation being studied – that played a role in the misguided investment,
dissemination, and utilization of the practice, procedure, or technology that must
consequently be reversed.
One of the common causes of reversal has already been shown in previous
examples is a strong belief in the pathophysiological model that leads to the assumption
that intervening on parts of the pathophysiologic causal pathway will translate to
effectiveness, despite never demonstrating either effectiveness or efficacy with respect to
clinically meaningful outcomes in a trial setting. Placing a stent in an artery with severe
stenosis when someone is experiencing chest pain should prevent cardiac-related
mortality or MI, but it does not. Neither does injecting medical cement into fractured
bone to stabilize the fracture have an effect beyond a simple saline solution, even though
it theoretically should. These seemingly logical pathways that are common to many
evidence reversals are important to keep in mind because they demonstrate that unless
there is direct evidence of an effect on an important outcome of interest – particularly
clinically relevant outcomes – it is difficult to know the net effect a proposed intervention
will have on a population in practice.22
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There are many clinical practices that are established based on tradition and have
never truly been tested in a randomized trial.30 Such practices, sometimes called “sacred
cows,” are often based on positive observed effects within a pathophysiological model
that do not translate to meaningful clinical outcomes.31,32 Examples of practices that were
used without proven efficacy, until they were reversed by trials, include: non-invasive
measurement of blood pressure in children, oxygen administration for patients with
chronic obstructive pulmonary disorder, and supplemental oxygen administration for
acute MI.33 A further complexity that these “sacred cows” impose on health care is that
such practices are not easily tested to find their true value. Practices that have been used
for a long time and are engrained cannot easily have their efficacy assessed because they
are overwhelmingly believed to be effective, thus failing to satisfy the principle of
clinical equipoise that is necessary to ethically justify randomization to not receive the
therapy, and therefore would be seen as unethical by many practitioners.34
Trusting a physiological model may also lead to a related cause of evidence
reversal, which is overgeneralization to non-study populations.35 The expanded
application of interventions to populations for which they have never been tested is a
common cause of reversal.1 Some practices may only be reversed for a particular
indication (e.g. PCI is effective at saving the lives of those with MI, but has been reversed
for preventing future heart-related incidents among those with stable CAD).1,9
Over reliance on physiological models is also directly related to another cause of
medical reversals: the use of surrogate outcomes in trials that do not appropriately
represent important clinical outcomes.22,36 Surrogate outcomes (e.g. blood pressure, bone
mineral density, tumour growth) are often used as endpoints in studies of new
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interventions because they are cheaper and require less time to get results than using
clinically meaningful outcomes (e.g. all-cause mortality or health-related quality of life).
However, improvement in a surrogate outcome does not always correspond with an
improvement in outcomes that are clinically meaningful and important to patients. Some
examples of treatments that were implemented on positive effects on surrogate outcomes,
but were later reversed when their effectiveness was examined with regard to clinically
relevant outcomes, include: PCI for stable CAD, high-dose steroids for spinal cord injury,
administration of calcium during cardiac arrest, cyclo-oxegenase-2 (COX-2) inhibitors
for inflammation, a glycated haemoglobin (HbA1C) level of less than 7% for the
management of diabetes, and bevacizumab for metastatic breast cancer survival.22,36
It is commonly assumed that the most expensive option is the best: that a higher
price will result in better outcomes than a cheaper alternative, without considering the
known value of the intervention.37 This assumption can lead to unnecessary reversal
because newer and more expensive practices are adopted to replace older and cheaper
practices before the evidence has matured to support their use, leading to reversal when
they are not found to be any better than the older or cheaper standard.38
There are also several characteristics of research that can lead to poor quality
findings and an increased likelihood that the results are false or exaggerated, which in
turn may lead to future reversal.39 Increased financial interests or prejudices and the nondeclaration of conflicts of interest are both established reasons for questioning the
validity of research findings, as is novelty of a research field.23,39 Novelty of a field in
particular can create public pressure for early adoption of technologies that have not yet
been fully tested. This public pressure often comes in the wake of sensationalized media
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coverage of scientific breakthroughs which suggests that poor science reporting may also
play a role in the premature adoption of practice, leading to higher risk for future
reversal.40,41
The causes of reversal are not limited to suboptimal original research practices,
as is the case in many of the examples above. Reversal should be a respected
phenomenon and an expected element of scientific enquiry as new evidence emerges to
contradict prior beliefs and standards. Medical and evidence reversal can occur because
of newly discovered long-term side effects that could not have been known early in the
course of a new treatment, even with well conducted trials: the kinds of side effects that
require population-wide use over the longer term, as in Phase IV trials, to be
discovered.42 Reversals may occur over time because a practice that was a standard of
care is no longer worth the cost because cheaper alternatives with similar effectiveness
have since become available.42 There is also a logistic issue surrounding the study of
practices to the point of maturity before implementation, as the resources required to
conduct multiple, large, clinical trials that follow patients for a sufficient length of time to
determine the “true” effects of an intervention on patient-important outcomes make such
a goal infeasible for some interventions. It is for these reasons that eliminating reversal
entirely is impossible. However, reducing the impact of unnecessary reversals through
preventing premature adoption of practices before a reasonable level of evidence has
accrued would positively influence the harmful effects of reversal.
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EXPLORING THE CHARACTERISTICS OF EVIDENCE
REVERSAL
There are many factors that can contribute to the reversal of an established

practice and many characteristics of research that can lead to the immature
implementation of a practice before its true efficacy and effectiveness is understood.
However, despite the knowledge that these causes of reversal exist, there are no
frameworks that describe the characteristics of research that are associated with the
contradiction of already established practices.4,43,44
‘A decade of reversal: An analysis of 146 contradicted medical practices’ by
Prasad et al. was a major review of original research articles published in the New
England Journal of Medicine (NEJM) between 2001 and 2010 that explored the
prevalence of medical reversal in the medical literature.4 They estimated the rate of
contradiction over a 10-year period and found it to be approximately 40% of studies
testing an existing practice.4 They also provided descriptive statistics about the studies
collected in their search – including the prevalence of various study designs, authors’
conclusions, and the proportion of studies that tested medical practices that were new
versus existing – and detailed qualitative descriptions of the 146 studies that they
identified as reversals.4
While ‘A decade of reversal’ fulfilled a necessary and important step in moving
towards a better understanding of this new field, the data provided was insufficient to
accommodate an analytic assessment of the characteristics of research that may be
associated with reversal. Prasad et al. conducted no quality assessments of the included
studies, provided no details of study-level results (e.g. number of events and subjects in
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study groups), and provided insufficient description of methodology with regards to their
decision-making processes to facilitate reproducibility.4
However, these limitations provided a rationale for reproducing, updating, and
expanding this review: using the results to create a database upon which to conduct a
more quantitative analysis of the characteristics of reversal. The exploration of relevant
characteristics in a database of trials with a logistic regression model – the outcome being
the contradiction or reaffirmation of prior beliefs – will be one of the final steps in the
development of a framework for identifying when established practices have been
reversed: informing the framework with the strengths of associations that study
characteristics may have with reversal.
In her thesis – the body of which laid much of the groundwork for this current
thesis – Desirée Sutton proposed a framework of reversibility.45 This framework included
several summary measures of study quality covering question design and methodology,
reporting (i.e. PICOTS, ROB, and modified GRADE), and several other measures
including: modified optimal information size, fragility index, study abstract conclusions,
and the lengths of time from a trial’s start to its registration and from completion to
publication.45 These elements will be informed by our analyses and the framework will
be developed and adapted accordingly.

1.8

CONCLUSIONS, IMPACT, AND THESIS OUTLINE
Despite its complexity, there is a paucity of research concerning the

characteristics of reversal. Reversal imposes several dangers to the wellbeing of the
population and minimizing the impact of unnecessary reversal would have tangible
benefits. Overall health could be improved as potentially harmful practices may be
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stopped earlier or prevented from implementation, trust in the medical and scientific
communities would improve as fewer practices are redacted and undergo de-investment
and de-adoption, and unnecessary resource expenditure would be reduced.
The meta-research community has only recently begun to explore reversals in a
clinical context, hence the use of the term “medical reversal.” In this thesis we propose
the term “evidence reversal” as a more appropriate general term for the phenomenon of
contradictory findings, as well as proposing a framework to identify when a reversal of
evidence has occurred and several key areas of future research in the field of reversal.
This thesis provides an in-depth exploration of evidence reversal and the process of
developing a framework of reversibility. This exploration will contribute to the field of
evidence reversals by bringing together multiple themes – both philosophical and
practical – into a cohesive whole. This framework will promote consistent use of
terminology related to reversal and serve to provide guidance for researchers in designing
robust trials, potentially decreasing the risk of reversal in the future.
This first chapter has provided an overview of the concepts and theories that will
be explored in the following chapters. The second chapter provides an updated systematic
review on the concept of reversal and how it has been explored in the literature. The third
chapter presents the methodology for our update of ‘A decade of reversal’ and how data
extraction was conducted to create a database of trials and their characteristics. The
fourth chapter provides an in-depth discussion of the process that we used to build our
regression model and develop a framework of reversibility – from conceptualization and
the analysis plan, to building the framework. The fifth chapter will present all results of
our analysis of the characteristics of reversal including reproducing the descriptive
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statistics originally published by Prasad et al., as well as our expanded analyses (logistic
regression) and framework. The sixth chapter contains the discussion of our findings, as
well as the strengths and remaining limitations. The seventh chapter presents the impact
and possible future applications of our proposed framework of reversibility, as well as
introducing an initial toolbox for future reversal research and presenting the conclusions
of the overall thesis, wherein we review our findings and what we have learned from our
various reviews.
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CHAPTER 2

Unlocking Evidence Reversal – An updated systematic review
of Evidence Reversal terminology

Riaz Qureshi
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CHAPTER 2
2.0

INTRODUCTION
In 2011, Prasad and Cifu coined the term “medical reversal” for the phenomenon

of new evidence for an established practice that is methodologically stronger than
previously conducted research, finding that the clinical practice is less effective or more
harmful than was originally believed.1 When such evidence arises for an established
practice, it is “reversed” and steps should be taken to initiate its de-adoption, or removal,
from practice. A medical reversal does not mean that the practice must be removed in its
entirety; it is much more common that a reversal will provide a contraindication for a
particular use in a particular population. Hormone replacement therapy (HRT) and
percutaneous coronary intervention (PCI) still have clinical validity in an appropriate
population, but it is now widely recognized that HRT does not reduce the risk of
cardiovascular disease among post-menopausal women, and evidence shows that PCI for
stable CAD does not reduce the risk of future adverse cardiac events, even though these
practices were once though to provide net benefit.9,14
While ‘medical reversal’ is an appropriate term for the phenomenon that it
represents, it is conceptually clinically oriented and implies the cessation of the reversed
practice. The term may not always be appropriate as reversal occurs in non-medical
fields, such as public health, and a reversal of evidence does not guarantee de-adoption:
many practices continue after the evidence for them is contradicted.26,46 We propose a
new term, “evidence reversal” (ER), to describe the phenomenon in both medical and
non-medical fields and, more appropriately, when new evidence that is stronger than
preceding evidence contradicts the established evidence for a practice.
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Reversal in a medical or clinical context is very common.1 The percentage of
studies that investigate an established clinical practice and subsequently lead to reversal
may be as high as 40%.4 Although the term for the phenomenon is still being diffused
throughout the medical community, all physicians are familiar with the concept of
reversal through the ever-changing guidelines for clinical practice.
The desirable progression of medicine is for newer and better interventions to
replace older and less effective interventions.2 This replacement of therapies is ideal
because it implies that at any given time, patients are given a standard of care that is the
best available treatment at the time.2 However, despite reversal of evidence and
subsequent de-adoption being expected, there are four implied harms to patients and the
health care system as a whole. The first implication of reversal in a medical context is
that the patients who were treated with the reversed practice were placed at a greater risk
for, or actually experienced, unnecessary harm for little to no benefit.2 The second is a
risk that health care resources are being wasted because treatments that are unnecessary
or of low value are being utilized before they can be reversed.2,3 The third is an
undermining of the trust in the medical system that is held by the public and by those
who practice medicine.2 And the fourth risk associated with reversal is the difficulty in
de-adopting established practices from the medical community.2,28
In considering the challenge of de-adoption, beyond the medical community there
exists the same difficulty in removing a paradigm from common belief, no matter what
evidence may arise to contradict it. An example of the difficulties inherent in removing a
consistently and clearly disproven theory from the view of the public is the persistence of
the belief that vaccines cause autism.47 In spite of evidence to contradict and deny the

Chapter II

Unlocking Evidence Reversal

Riaz Qureshi

25

claim, the belief remains strong enough that there have been lowered rates of childhood
vaccination and an increase in the incidence of vaccine-preventable diseases in recent
years.47
In order to curtail the harms of unnecessary reversal, by minimizing early
conclusions that are based on insufficient evidence thereby preventing the premature
uptake of new practices and theories, we must first have an understanding of the way that
the phenomenon has been discussed and researched. In this systematic overview review,
we explore how the concepts surrounding evidence reversal have been explored in the
medical and non-medical literature. We create a compendium of terminology and
definitions that relate to evidence reversal with the goal of bringing a degree of cohesion
to this new and largely un-explored field.

2.1

METHODS
In 2014, Sutton and colleagues conducted a systematic literature review of the

terminology surrounding evidence reversal as part of her thesis.45 This systematic review
was conducted with the purpose of finding how reversal had been discussed thus far in
the scientific literature. As the term itself is new, and meta-research on the subject of the
reversal of practices is sparse, we thought it best to update the search by Sutton et al. to
include any new material from the two years since the search was last conducted. As this
was an updated systematic review we aimed to use the same search methodology that was
used in July of 2014. To this end, almost identical search strategies were applied to the
same databases and sources that were searched.
A modification to the original search strategies for PUBMED, OVID MEDLINE,
and EMBASE databases was devised under the supervision of a medical librarian. The
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modification was necessary as a small error in the strategies for these databases led to two
terms – “result” and “disinvest*” – being left out of the searches. After discussion, it was
decided that the use of the term “result” would return too many unrelated citations, but
“disinvest” would be added to the searches for these databases because it was highly
relevant to reversal and returned a small and manageable number of citations.
2.1.1

Search strategy

A systematic review of the two-year period from January 1st, 2014 until July 6th,
2016 was conducted of eight scientific and gray literature databases including:
PUBMED, Ovid MEDLINE, EMBASE, CINAHL, Web of Science, the Dissertations and
Thesis Database, The Canadian Health Research Collaboration (CHRC), and GOOGLE
ScholarTM. In addition to this systematic searching, hand searching was conducted for the
last two years for 27 blogs and websites and six journals.
Databases were searched using a combination of relevant subject headings and
keywords including: evidence-based practice, patient care management, guidelines,
clinical practice, practice guideline, physician’s practice pattern, evidence-based, and
disinvest*. In addition, searching by proximity was utilized using terms such as
publication, evidence, practice, guideline*, medical, standard, unexpected, or surprising,
paired with terms like revers*, change, contradict*, divest, or de-implement*. For the full
search strategies for each database including number of returned citations, please see
APPENDIX A.
2.1.2

Screening and inclusion criteria

All returned citations were imported into EndNote for screening, except for those
collected from the CHRC, which were imported into, and screened in, Microsoft Excel.
Screening was conducted at three levels: title, abstract, and full text. Due to time
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constraints and the breadth of the search strategy, which was developed for high
sensitivity and inclusion, screening was not conducted in duplicate. All new citations
retrieved for the update of the search were screened by RQ, and the citations returned by
DS were not duplicated. However, agreement was reached for final inclusion of articles
and disagreements were settled by discussion.
To be included in this systematic overview review, all articles had to meet two
criteria: they must have made some reference to the process of reversal or related
concepts – according to our operational definition of ER – and they must have been a
review article. Systematic reviews, meta-analyses, evidence syntheses, reviews, and
collections of studies were included. All reviews pertaining to the phenomenon of new
and stronger evidence contradicting current practice were included. These included direct
and indirect references to evidence reversal including: medical reversals, changes in
clinical practice guidelines or standards of care, and the disinvestment, deimplementation, or de-adoption of practices.
2.1.3

Quality assessment

Data extraction was performed independently with two authors (RQ and DS)
verifying the other’s work on a random subset of articles. Discrepancies were resolved
through discussion.
Quality assessment of included reviews was done using the AMSTAR rating tool.
The AMSTAR (A Measurement Tool to Assess Systematic Reviews) rating system is an
instrument for assessing the methodological quality of systematic reviews.48 It consists of
11 items and has been validated as a reliable quality assessment tool.49 The greater an
article’s score out of 11, the greater the confidence in the findings of that review or group
of reviews.48,49
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Two out of the eleven items on the AMSTAR instrument (“Appropriate pooling
of findings” and “Likelihood of publication bias”) were not applicable to the articles
included in our review because pooling of results across different Populations,
Interventions, Comparators, Outcomes, Timing and Study Designs (PICOTS) is illogical,
therefore it was determined that deviations from high methodological practice would not
appreciably bias results. As a result of this modification, the maximum number of points
that a review could achieve on AMSTAR was nine.

2.2

RESULTS
Systematic searches of the scientific and grey literature databases, and all hand

searching of journals, blogs, and websites yielded 8117 unique citations. These citations
were screened for exclusion criteria, resulting in 27 articles selected for inclusion after
title, abstract, and full text screening. Five of these articles (from 2014) were already
found from the search conducted two years ago. Duplication of these articles was
expected and their inclusion validates the replication of previous search methods.
Because five of these articles were already found, they were no longer counted as a part
of the results in this review update. Therefore, 22 new articles were identified for
inclusion in the systematic review. A further 8 articles were collected after screening the
bibliographies, cited by, and related articles of the 22 identified via the database searches.
Therefore, 30 new articles were added to the overall review through this update.
Combining these 30 new articles with the 57 retrieved from the 2014 search
resulted in a total of 87 articles for inclusion in the final review. Please refer to Figure 2.1
PRISMA Flow-Chart for details of the article selection process used for this systematic
review update (2014-July 2016).
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Identification

Records identified through
database searching
(n = 4552)

Records identified
from grey literature
(n = 5345)

Records identified
through hand searching
(n = 17)

Total records retrieved
(n = 9914)

Number of records after duplicate removal
(n = 8117)

Screening

Excluded (n = 7979)
Number of records after title screening
(n = 138)
Excluded (n = 69)
Does not fit definition
(n = 39)
Not a review (n = 30)
Number of records after abstract screening
(n = 69)
Excluded (n = 42)
Does not fit definition
(n = 18)
Not a review (n = 24)

Eligibility

Number of records after full-text screening
(n = 27)
[minus 5 old = 22 new)
Additional articles included
after screening bibliographies,
“cited by,” and related articles
of the 22 new articles (n=8)

Included

Number of records included after full text and
snowball screening
(n = 30)

Figure 2.1 PRISMA flow diagram of study selection
The PRISMA flow-chart for the full review (i.e. the manuscript submitted for
publication created by combining the original review and this update) may be found in
Appendix A. Apart from the PRISMA diagram outlining the screening performed in this
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update, the remaining results and discussion of findings presented are those of the full
review, representing the findings from all 87 included articles.
2.2.1

Description of studies

The most common type of article that we found discussing evidence reversal was
“collection of studies” (n = 58). These collections were mostly narrative and included
letters to the editor, editorials, and recommendations for clinical practice based on new or
important trial results. The majority of these collections of studies presented hand-picked
or selected examples from journals or other reviews that the authors were discussing.
Systematic reviews were the next most common type of article that we found (n = 24).
The majority of articles have been published since 2011 (n = 71) with only a handful
published in 2010 or before (n = 16).
Table 2.1 Characteristics of included studies
Characteristic

No. (%) of 87 Articles

Year of Publication
2001-2005
7 (8)
2006-2010
9 (10)
2011-2015
59 (68)
2016
12 (14)
Type of Article
Collection of Studies
58 (67)
Systematic Review
24 (28)
Overview Systematic Review
2 (2)
Systematic Scoping Review
1 (1)
Secondary Data Analysis and Review
1 (1)
Recursive Cumulative Meta-Analysis
1 (1)
Relationship to Reversal *
Phenomenon of Reversal
32 (37)
Consequence of Reversal
35 (40)
Target of Reversal
79 (91)
Potential Predictor of Reversal
8 (9)
AMSTAR Quality Rating
Very Low Quality (Score of 0 to 2)
63 (72)
Low Quality (Score of 3 to 5)
21 (24)
High Quality (Score of 6 to 8)
3 (3)
Very High Quality (Score of 9)
0 (0)
* Percentages do not sum to 100% due to the appearance of multiple terms within individual articles
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Terminology related to evidence reversal

The operational definition for evidence reversal that was used to find relevant
articles is: when new evidence – better powered, controlled, or designed than its
predecessors – contradicts previously established claims. We found 50 unique sets of
terms related to evidence reversal that we collated into four broader categories: a) terms
for the phenomenon of ER, those that describe the event of new and better evidence
contradicting older; b) terms for the consequences of reversal, the processes undertaken
to remove a practice that has been reversed; c) terms for the targets of reversal or
practices that are likely to be reversed in the future; and d) terms for potential predictors
of ER. Table 2.2 presents the full list of identified terms and their definitions. Table 2.3
presents the frequency of the use of terms and how they relate to evidence reversal.
APPENDIX B provides the complete data extraction for all included articles.
Table 2.2 Terms and associated definitions for evidence reversal
Year

Term used

2001

Uncertainty 50

2002
2003
2004

No Articles
Discrepancy 51
Ineffective or
harmful
interventions 52
Unfavourable or
favourable shifts
over time 53
Contradicted 8
Initially stronger
effects 8
Proteus
Phenomenon 54,55

2005

2006

Contradicted 56
Proteus
Phenomenon 56

Chapter II

Definition(s)
“How much the treatment effect has changed over time and how much
the pooled treatment effect will change the future.” 50
No Articles
“Magnitude of the genetic effect as it changes over time.” 51
“Treatments previously commonly practices, but not known to not work
or cause harm.” 52
“Changes in whether results become less or more favourable for the
experimental intervention over time.” 53
“Subsequent research contradicts efficacy claim.” 8
“Subsequent research shows smaller magnitude of efficacy claim.” 8
“Rapid, early succession of very contradictory conclusions.” 54
“Extreme between-study opposing estimates of effect in the results of
early studies followed by studies with diminishing between-study
variance.” 55
“Diminishing effects for the strength of research findings and rapid
alternations of exaggerated claims and extreme contradictions.” 56
“Rapid alternation between exaggerated claims and extreme
contradictions in early studies followed by studies with diminishing
effects for the strength of research findings.” 56
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Change in evidence
57

Disinvestment 58

Inconsistency 59
Non-replication 59
2008

Sacred Cows 31

2009

Assess new
intervention –
displace old 60
Class II
Recommendation 61

Class III
Recommendation 61
False positive result
62

Ineffective,
harmful, or noncost-effective
interventions 60
Legacy items 60
Technology
development 60
2010

Snake oil 63

2011

False positive and
inflated results 64
Medical reversal 1,2
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32
“Quantitative changes include differences of statistical significance or
≥50% effect change in magnitude for important outcomes. Qualitative
changes include differences in definition of effectiveness, new data on
harm, and caveats about previous evidence.” 57
“The processes of withdrawing (partially or completely) resources from
any existing healthcare practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain
relative to their cost, and thus are not efficient health resource
allocations.” 58
“Inconsistency occurs when there is large between-study heterogeneity
(diversity) in the magnitude of the genetic effects.” 59
“Occurs when the GWA (Genome Wide Association) study proposes
that there is a gene-disease association, but the accumulation of data
from subsequent studies find no genetic effect.” 59
“Practices are considered routine and beyond dispute.” 31
“A clinical practice despite research that shows that the practice is not
helpful and may even be harmful to the patients we serve.” 31
“When a new intervention is presented to the relevant committee(s)† for
regulatory assessment, and is considered a potential replacement for (an)
established comparator(s) for that indication, then that comparator for
that patient indication is automatically considered and assessed for
disinvestment” 60
“Class II: conditions for which there is conflicting evidence and/or a
divergence of opinion about the usefulness/efficacy of a procedure or
treatment.” 61
“Class IIa: weight of evidence/opinion is in favour of
usefulness/efficacy.” 61
“Class IIb: usefulness/efficacy is less well established by
evidence/opinion.” 61
“Class III: conditions for which there is evidence and/or general
agreement that the procedure/treatment is not useful/effective and in
some cases may be harmful.” 61
“Report a treatment effect when in reality there is not effect.” 62
“Ineffective, non-cost-effective or harmful interventions.” 60

“Long-established technologies that have never had their costeffectiveness assessed – look for coupling with other identification items.
Automatically considered and assessed for disinvestment.” 60
“When an intervention has evolved to the point that it differs markedly
from the initial or prototype intervention that was originally assessed or
funded, then the initial intervention should be reviewed (e.g., 256-slice
compared with four-slice computed tomography).” 60
“Nutritional supplements that are not worth it (inconclusive, slight, or no
evidence of efficacy).” 63
“Report a treatment effect when in reality there is no effect.” 64
“RRs were in opposite direction, larger, more than twice as large, more
than 4 times as large, or different beyond chance in the highly cited vs.
the largest study and in the highly cited study vs. the meta-analysis.” 64
“The phenomenon of a new trial – superior to predecessors because of
better design, increased power, or more appropriate controls –
contradicting superior clinical practice.” 1
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Recommendations
for practice 65
Sacred cows 32

2012

Disinvestment 28

Improper use 28
Low-value
practices 66
Medical reversal
3,26

“The phenomenon of a new trial – superior to predecessors because of
better design, increased power, or more appropriate controls –
contradicting superior clinical practice.” 2
“A medical practice falls out of favour not by being surpassed, but when
we discover that it did not work all along, either failing to achieve its
intended goal or carrying harms that outweighed the benefits.” 2
“Lack or presence of evidence” 65
“Practices are considered routine and beyond dispute.” 32
“A clinical practice despite research that shows that the practice is not
helpful and may even be harmful to the patients we serve.” 32
“The process of withdrawing health resources from any existing
healthcare practices, procedures, technologies and pharmaceuticals that
are deemed to deliver no or low health gain for their cost and thus [do]
not [represent] efficient health resource allocation.” 28
“The cessation or restriction of potentially harmful, clinically ineffective
or cost inefficient practices.” 28
“The process of taking resources from one service in order to use them
for other purposes (i.e. reallocation of resources).” 28
“Any existing healthcare practices, procedures, technologies and
pharmaceuticals that are deemed to deliver no or low health gain for their
cost and thus [do] not [represent] efficient health resource allocation’.” 28
“Ineffective and/or unsafe services, treatments not proven to be clinically
effective.” 66
“Established standards must be abandoned not because a better
replacement has been identified but simply because what was thought to
be beneficial was not.” 3
“Oftentimes, years after a practice was introduced, the medical
community puts it to the test in large, well done randomized trials.
Empirical evidence suggests that when this happens, nearly half of those
practices are contradicted. We call this phenomenon ‘medical reversal’.”
26

Negative list

28

“[practices] that have been superseded or demonstrated to
be ineffective or harmful.” 28
Obsolete/outmoded/a “Those that have been superseded or demonstrated to be ineffective or
bandoned
harmful.” 28
28
technologies
POEM likely to
“A study that is valid (avoids important biases), reports patient-important
change clinical
outcomes (such as morbidity, mortality, or quality of life) and changes
practice 67
clinical practice.” 67
Research updates
“Research updates most likely to change clinical practice.” 68,69
most likely to
change clinical
practice 68,69
Services not
“Any existing healthcare practices, procedures, technologies and
medically
pharmaceuticals that are deemed to deliver no or low health gain for their
necessary 28
cost and thus [do] not [represent] efficient health resource allocation.” 28
Things providers
“Wasteful or unnecessary medical tests, treatments and procedures” 70
and patients should
question 70
Unnecessary
“Wasteful or unnecessary medical tests, treatments and procedures” 70
medical tests,
treatments, and
procedures 70
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2013

Wasteful medical
tests, treatments,
and procedures 70
Disinvestment 71
Ineffective
technologies 71
Low-value
practices / health
care 72–76

Medical reversal
4,35,36,77

Obsolete
technologies 71
Overdiagnosis 78
Overused or
misused tests and
treatments 79
POEM likely to
change clinical
practice 80
Research updates
most likely to
change practice 81–

34
“Wasteful or unnecessary medical tests, treatments and procedures” 70
“The complete or partial withdrawal of resources from healthcare
services and technologies that are regarded as unsafe, ineffective or
inefficient.” 71
“Healthcare services and technologies that are regarded as unsafe,
ineffective or inefficient.” 71
“Clinical decisions that are of little value to patients, amenable to
improvement through standardization, and actionable by front-line
providers.” 72
“Ineffective or lack evidence on their effectiveness, negative risk-benefit
balance, more cost-effective alternatives exists, obsolete due to the
introduction of new technologies.” 73
“Interventions that robust evidence reveals are of no benefit, or even
harmful.” 74
“Health care services that provide little or no benefit – whether through
overuse or misuse.” 75
“…Not clinically effective for a given indication. It may be unsafe for
everyone, or for subgroups of patients with risk factors. It may have a
poor risk-benefit profile overall, or when used inappropriately.” 76
“Reversal was designated when a current medical practice was found to
be inferior to a lesser or prior standard.” 4
“The phenomenon of a new superior trial that contradicts current clinical
practice.” 36
“Medical reversal happens when new trials – better powered, designed or
controlled than predecessors – contradict current standard of care.” 77
“Modifications or even retractions, of important medical practice
recommendation… [which] challenge traditional medical opinion.” 35
“Healthcare services and technologies that are regarded as unsafe,
ineffective or inefficient.” 71
“Waste of resources on unnecessary care” 78
“Unnecessary tests and procedures that don’t benefit the patient and can
even cause harm.” 79
“A study that is valid (avoids important biases), reports patient-important
outcomes (such as morbidity, mortality, or quality of life) and changes
clinical practice.” 80
“Research updates most likely to change clinical practice.” 81–84

84

Sacred cows 33
Snake oil 85
Too much medicine
78

Unproven therapies
34

Waste 75
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“Practices are considered routine and beyond dispute.” 33
“A clinical practice despite research that shows that the practice is not
helpful and may even be harmful to the patients we serve.” 33
“Nutritional supplements that are not worth it (inconclusive, slight or no
evidence of efficacy).” 85
“Waste of resources on unnecessary care” 78
“No proven value by current Grading of Recommendations Assessment,
Development and Evaluation (GRADE) guidelines, US Preventive Task
Force Services criteria, or other similar criteria.” 34
“ Inappropriate overuse of an otherwise effective intervention.” 75
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2014

Change in
treatment
guidelines 86
Contradicted
established medical
practices 44
De-implementation
44

Inappropriate care
87

Medical reversal 88
POEM likely to
change clinical
practice 89
[Sacred Cows]
Practices not
supported by the
evidence 30
Snake oil 90
Research updates
most likely to
change practice 91–

35
“New RCT findings.” 86
“When large, well-done randomized trials have contradicted current
medical practice.” 44
“Abandonment of medical interventions.” 44
“Stopping practices that are not evidence-based.” 44
“That relating to the use or non-use of a health service intervention based
on the evaluation of (a) evidence of effectiveness; and/or (b) economic
implications; and/or (c) other health system impacts; and/or (d)
consideration of ethical implications and societal values.” 87
“A phenomenon in which ‘a medical practice is found to be inferior to
some lesser or prior standard of care.’” 88
“A study that is valid (avoids important biases), reports patient-important
outcomes (such as morbidity, mortality, or quality of life) and changes
clinical practice.” 89
“Practices are considered routine and beyond dispute.” 30
“A clinical practice despite research that shows that the practice is not
helpful and may even be harmful to the patients we serve.” 30
“Nutritional supplements that are not worth it (inconclusive, slight or no
evidence of efficacy).” 90
“Research updates most likely to change clinical practice.” 91–93

93

2015

Research waste 94
Unnecessary
treatments, tests,
and procedures 95

“Avoidable waste or inefficiency in biomedical research.” 94
“Do not add value to care … potentially expose patients to harm, leading
to more testing to investigate false positives and contributing to stress for
patients … increased strain on the resources of our health care system.”

Unproven medical
practice 30
Abandonment /
abandon* 96,97

“Many medical practices are largely untested or have insufficient
evidence unable to support or refute interventions.” 30
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“The discontinuation of a clinical practice after it was previously
adopted.” 97

[Change / decline /
change / drop in] in
use 96,97

Contradict* 96,97

Clinical redesign or
re-prioritization 97
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De-adoption / deadopt* 96,97

De-commission /
de-list 97
Decrease use /
reduc* 96,97

De-funding or
resource release 97
Discontinuation /
discontinu* 96,97

De-implementation
/ de-implement*
97,98

Disinvestment /
disinvest 96,97,99

Do-not-do 97
Harmful practices
98,100

Inappropriate care
101

Ineffective
[technology /
practice] 97,99
Low-value health
care / services /
practices 97,98,100,102
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“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Can involve overuse, underuse, and/or misuse of health services,
products, and resources.” 98
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The process of (partially or completely) withdrawing health resources
from any existing healthcare practices, procedures, technologies, or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and thus are not efficient health resource allocations.” 99
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Can involve overuse, underuse, and/or misuse of health services,
products, and resources.” 98
“Low value, unnecessary, or harmful to patients.” 100
“Treatments that evidence clearly shows should not be done routinely, or
at all.” 101
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Ineffective technologies are usually identified by evaluating their
effectiveness, safety, and cost-effectiveness. In addition, overuse or
misuse of technologies can lead to ineffectiveness.” 99
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Care that is avoidable/not necessary/of low value.” 102
“Can involve overuse, underuse, and/or misuse of health services,
products, and resources.” 98
“Low value, unnecessary, or harmful to patients.” 100
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Medical reversal
96,97,103–105

Misuse 96,97

Obsole* 96,97,99

Opportunity cost 96

Overdiagnosis 96

Overtreatment /
overmedicalization
/ Medical over use
96,97,106,107

POEM likely to
change clinical
practice 108
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“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“When an accepted practice – a diagnostic test, medication, or procedure
– is overturned. The practice is not replaced by something better, but
shown to be inferior to a pre-existing, less intensive, or less invasive
one.” 103
“Reversal of medical practice requiring significant changes in standards
of care, workflow, and decision making.” 104
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“When a current practice is found to be no better than, or inferior to, a
prior standard.” 105
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Obsolete technology: Any health technology in use for one or more
indications, whose clinical benefit, safety, and/or cost-effectiveness have
been significantly superseded by other available alternatives or are not
supported by evidence.” 99
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The provision of health care when the “risk of harm exceeds its
potential benefit,” when the benefits are negligible, or when fully
informed patients would forego care.” 107
“Treatment of overdiagnosed conditions, or treatment that has minimal
evidence of benefit or is excessive (in complexity, duration, or cost)
relative to alternative accepted standards.” 106,107
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“A study that is valid (avoids important biases), reports patient-important
outcomes (such as morbidity, mortality, or quality of life) and changes
clinical practice.” 108
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Practice-changing
evidence 109
Reappraisal 96,97

Reassess* or
[evidence-based /
health technology]
reassessment 96,97

Recommendations
for practice 110
Redeploy 97
Refute 97
Re-invest or
substitutional reinvestment 97
Relinquish* 97
Remov* 97
Replace 97
Resource reallocation 96,97

Sacred Cows 111
Selective
disinvestment 98
Stop* 97
Undiffusion 112
Waste 96

Withdraw* or
withdrawing from a
service and
redeploying
resources 97
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“Potential for practice change.” 109
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“New RCT findings.” 110
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Clinical practices so rooted in tradition that they are resistant to change,
despite reduced quality of care, patient outcomes, and greater costs
compared with newer practices.” 111
“Can involve overuse, underuse, and/or misuse of health services,
products, and resources.” 98
“The discontinuation of a clinical practice after it was previously
adopted.” 97
“Abandoning established practices found to be ineffective, disruptive, or
the cause of net harm — or when better practices come along.” 112
“Processes of withdrawing (partially or completely) health resources
from any existing health care practices, procedures, technologies or
pharmaceuticals that are deemed to deliver little or no health gain for
their cost, and are thus not efficient health resource allocations.” 96
“The discontinuation of a clinical practice after it was previously
adopted.” 97
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Do-not-Do
recommendations

“Clinical practices, identified during the development of guidance that
should be discontinued or not used routinely.” 113

Grade D
Recommendation

“The USPSTF recommends against the service. There is moderate or
high certainty that the service has no net benefit or that the harms
outweigh the benefits. Discourage the use of this service.” 114
“Possibly ineffective or low-value services.” 115

113

114

Ineffective services
115

I statement 114

Known uncertainty
116

Low-value health
care 115
Medical reversal
117,118

POEM likely to
change clinical
practice 119
Practice-changing
evidence 120
Translation failure
118

Trials likely to
change practice 121
Unnecessary waste
115

“The USPSTF concludes that the current evidence is insufficient to
assess the balance of benefits and harms of the service. Evidence is
lacking, of poor quality, or conflicting, and the balance of benefits and
harms cannot be determined” 114
“Uncertainties about the effects of treatments.” 116
“Possibly ineffective or low-value services.” 115
“An accepted medical practice, often widely adopted, that is later found
to be no better or worse than a previous standard of care.” 117
“Medical reversals occur when the results of preclinical, observational
and/or early phase studies fail to predict the results of subsequent
randomized clinical trials, but the practice has already gained widespread
acceptance.” 118
“A study that is valid (avoids important biases), reports patient-important
outcomes (such as morbidity, mortality, or quality of life) and changes
clinical practice.” 119
“Potential for practice change.” 120
“Translation failure occurs when the results of preclinical, observational
and/or early phase studies fail to predict the results of well done (i.e.
appropriately controlled, adequately powered, and properly conducted)
phase III or randomised clinical trials.” 118
“New RCT findings.” 121
“Ineffective or low- value services, which are possibly provided at the
expense of the social health insurance in Austrian primary care.” 115

Sixteen reviews used the term “Medical Reversal”, and the definitions that were
presented were nearly identical to our operational definition for evidence reversal.1–
4,26,35,36,77,88,96,97,103–105,117,118

The use of the term “contradicted,” in the context of

established medical practices, also had a similar definition, but with a focus on the
comparison of initial conceptual studies and subsequent research, as opposed to evidence
reversal which compares new evidence to previous evidence.8,44,97 Another term for the
comparison of initial conceptual, and often extreme, results with subsequent research –
but one that is used exclusively in the context of genome wide association studies – is the
Chapter II
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“Proteus Phenomenon.”54–56 Other terms that we found referring to the phenomenon of
ER include: “change in evidence”

57

; “opportunity cost”

96

; “overdiagnosis”

78,96

;

“practice changing evidence” 109,120; “refute” 97; “translation failure” 118; and “favourable
/ unfavourable shifts over time.”53 Each of these terms describes the phenomenon of new
evidence coming to light that changes a previously held belief about an established
practice.
Separate from terms that describe the phenomenon of evidence reversal are terms
for the processes of reversal, or the actions that should take place after a reversal has
occurred. These terms include: “abandonment” 96,97; “assess new interventions – displace
old or replace”

60,97

; “change in treatment [guidelines / practice]”

86,97,104

; “clinical

redesign or reprioritization” 97; “de-adoption or dis-adoption” 96,97; “decommission or delist” 97; “[decrease / decline / change / drop in] use” 96,97; “defunding or resource release”
97

; “disinvestment”

28,58,71,96–99

;

“overtreatment, medical overuse, overuse, misuse, or ‘too much medicine’”

78,96,97,106,107

;

96,97

;

; “de-implementation”

44,97,98

; “discontinuation”

96,97

“reassess*, [evidence-based / health technology] reassessment, or re-appraisal”
“recommendations for practice”
allocation, or redeploy”

96,97

65,110

; “re-invest, substitutional re-investment, re-

; “remov* or stop*”97; “undiffusion”

112

; and “withdraw,

withdrawing from a service and redeploying resources, or relinquish.”97
Another category of terms that are related to reversal, but do not refer to the
phenomenon or its consequences are those that describe targets. These terms refer to
practices that are known to be reversals or are likely to be reversed and are therefore
targeted for removal. These terms include: “Class II / IIa / IIb/ III recommendation”
“do-not-do recommendations”

Chapter II

97,113

; “grade D recommendations”

114

; “I statement”

61

;

114

;
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“[inappropriate / improper] [care / use]”
effective] [interventions / technologies]”

28,87,97,98,101

; “[Ineffective / harmful / non-cost-

52,60,71,97–100,115

[practices / health-care / services / intervention]”

; “legacy items”

66,72–76,97,98,100,102,115

60

; “low-value

; “negative list”

28

;

“[obsolete / outmoded / abandoned] technologies” 28,71,96,97,99; “[overused / misused] tests
and treatments”

79

; “[research updates most / trials / POEMS] likely to change clinical

practice” 67–69,80–84,89,91–93,108,119,121; “sacred cows” 30–33,111; “snake oil” 63,85,90; “technology
development”

60

; “things providers and patients should question or practices not

supported by evidence”

30,70

; “unnecessary medical [tests / treatments / procedures],

unnecessary [tests / treatments / procedures], or services not medically necessary” 28,70,95;
“unproven [therapies / medical practice]”

34,44

; and “waste, research waste, unnecessary

waste, or wasteful medical tests, treatments, and procedures.”70,75,94,96,115
The final category of terms that we propose is related to evidence reversal is
potential predictors of future reversal. These terms all refer to red flags in clinical
research: their presence could bring the efficacy and strength of the evidence surrounding
the investigated practice into question. Potential predictors of future reversal include:
“[Discrepancy / inconsistency / uncertainty] or known uncertainty”

50,51,59,116

; “[false

positive / inflated] results” 62,64; “initially stronger effects” 8; and “non-replication.”59
Table 2.3 Frequency of terms and their relation to evidence reversal
Term Set a

Abandonment / abandon*
Assess new interventions –
displace old or replace
Change in evidence
Change in treatment guidelines /
practice
Class II recommendation
Class III recommendation
Clinical redesign or reprioritization

Chapter II

No. (%) of
87 Articles b

Year of First
Appearance

Relationship
to Reversal

References

2 (2)
2 (2)

2015
2009

Consequence
Consequence

96,97

1 (1)
3 (3)

2007
2014

Phenomenon
Consequence

57

1 (1)
1 (1)
1 (1)

2009
2009
2015

Target
Target
Consequence

61

60,97

86,97,104

61
97
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Contradicted / contradict* / refute
/ contradictory result
De-adoption / de-adopt* / disadoption
Decommission / de-list
[Decrease / decline / change /
drop in] use or reduc*
Defunding or resource release
De-implementation / deimplement*
Discontinuation / discontinu*
Discrepancy / inconsistency /
uncertainty or known uncertainty
Disinvestment / disinvest*
Do-not-do recommendations
[False positive / inflated] results

5 (6)

2005

Phenomenon

8,44,56,96,97

2 (2)

2015

Consequence

96,97

1 (1)
2 (2)

2015
2015

Consequence
Consequence

97

1 (1)
3 (3)

2015
2014

Consequence
Consequence

97

2 (2)
4 (5)

2015
2003

96,97

7 (8)
2 (2)
2 (2)

2007
2007
2009

Grade D recommendations
I statement
[Inappropriate / improper] [care /
use]
[Ineffective / harmful / non-costeffective] [interventions /
technologies / practices]
Initially stronger effects

1 (1)
1 (1)
5 (6)

2016
2016
2014

Consequence
Potential
Predictor
Consequence
Target
Potential
Predictor
Target
Target
Target

8 (9)

2004

Target

52,60,71,97–

1 (1)

2005

Legacy items
Low-value [practices / health care
/ services / intervention]

1 (1)
11 (13)

2009
2012

96,97

44,97,98

50,51,59,116
28,58,71,96–99
97,113
62,64
114
114
28,87,97,98,101

100,115

Potential
Predictor
Target
Target

8
60
66,72–
76,97,98,100,102,
115

Medical reversal / reversal

16 (18)

2011

Phenomenon

1–
4,26,35,36,77,88,9
6,97,103–
105,117,118
28

2012

Target
Potential
Predictor
Target

1 (1)
2 (2)
5 (6)

2015
2013
2013

Phenomenon
Phenomenon
Consequence

96

1 (1)

2013

Target

79

2 (2)
3 (3)
2 (2)

2015
2005
2015

Phenomenon
Phenomenon
Consequence

109,120

Negative list
Non-replication

1 (1)
1 (1)

2012
2007

[Obsolete / outmoded /
abandoned] technologies
Opportunity cost
Overdiagnosis
Overtreatment or medical overuse
or “too much medicine” or
overuse or misuse
[Overused / misused] tests and
treatments
Practice changing evidence
Proteus phenomenon
Reassess* or [evidence-based /
health technology] reassessment
or re-appraisal

5 (6)
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78,96
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Recommendations for practice
Re-invest or re-allocation or
substitutional re-investment or
redeploy
Remov* or Stop*
[Research updates most / trials /
POEMS] likely to change clinical
practice

2 (2)
2 (2)

2015
2015

Consequence
Consequence

65,110

1 (1)
15 (17)

2015
2012

Consequence
Target

97

96,97

67–69,80–
84,89,91–
93,108,119,121

30–33,111
Sacred cows
5 (6)
2008
Target
63,85,90
Snake oil
3 (3)
2010
Target
60
Technology development
1 (1)
2009
Target
30,70
Things providers and patients
2 (2)
2012
Target
should question or practices not
supported by evidence
118
Translation failure
1 (1)
2016
Phenomenon
112
Undiffusion
1 (1)
2015
Consequence
53
Unfavourable or favourable shifts
1 (1)
2004
Phenomenon
over time
28,70,95
Unnecessary medical [tests /
3 (3)
2012
Target
treatments / procedures] or
unnecessary [tests / treatments /
procedures] or services not
medically necessary
34,44
Unproven [therapies / medical
2 (2)
2013
Target
practice]
70,75,94,96,115
Waste or research waste or
4 (5)
2012
Target
unnecessary waste or wasteful
medical tests, treatments and
procedures
97
Withdraw* or withdrawing from a
1 (1)
2015
Consequence
service and redeploying resources
or relinquish
a
*wildcard notation signifies multiple endings for the given term
b
Percentages do not total 100 due to the appearance of multiple terms within individual articles

2.2.3

Quality Assessment

The overall confidence in findings of included articles was very low with a mode
score of ‘1’, a median score of ‘2’, and a mean score of ‘2’. Most of the included articles
declared conflicts of interest, but none of them described the potential conflicts of the
examples that they presented. This led to the “conflicts of interest” item being uniformly
not present among the included articles. The next four AMSTAR items that were the least
present among included articles were: “list of included and excluded studies” (1%),
“publication status in inclusion” (8%), “quality of included studies” (11%), and
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“appropriate conclusions” (11%). The most present AMSTAR item among included
articles was “characteristics of included studies” (85%). The majority of articles
presented study characteristics in a non-table format (n = 47). The two AMSTAR items
that had the greatest uncertainty were “study selection and data extraction in duplicate”
and “comprehensive literature search,” the presence of which was unclear in 60% of
included articles. APPENDIX C contains the full AMSTAR evaluation for all included
articles.

Figure 2.2 AMSTAR quality assessment

2.3

Percent of Ratings

DISCUSSION
In this systematic overview review, we expected to find a wide range of terms for

the phenomenon of evidence reversal because the term “Medical Reversal” has only been
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in use since 2011, but the phenomenon has been present for longer.1 We found 50 unique
sets of terms. The true number of terms was greater (179), but some terms were
synonymous and were therefore grouped together (e.g. “[ineffective / harmful / non-costeffective] [interventions / technologies]” are six possible unique terms, but one unique
set). Furthermore, we were interested to find that not all of these sets of terms had the
same relation to evidence reversal. We set out to understand how the phenomenon had
been explored thus far, both inside and outside of the academic literature, and based on
our findings we propose that there are four essential facets to the evidence reversal
discussion and meta-research.
The first facet is research about the phenomenon itself: research surrounding the
event of new evidence contradicting what was previously found and believed about a
given practice or theory. The second facet is research around the processes and
consequences of evidence reversal: the difficulties inherent in, and methods by which
practices are de-implemented. The third facet of studying evidence reversal is identifying
and declaring the targets for evidence reversal: the practices, health-care, and services
that are known or suspected to be of low value. The fourth facet of this area of metaresearch is studying the potential predictors of future reversal: the characteristics of
research that may lead to reversal of a practice in the future.
In order to reduce the impact of evidence reversals, the two most important areas
of research are the latter two facets: identifying the targets of ER for removal and the
potential predictors of ER for prevention. These areas of meta-research will take time and
a concerted effort on behalf of the meta-research community. The first step to reduce the
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impact is to bring cohesion to the first two facets of ER: studying the phenomenon of ER
as well as the processes and consequences of ER.
The 26 unique sets of terms describing the phenomenon and consequences of ER
suggest that there is currently no cohesion in this field of meta-research. While terms
such as “Medical Reversal” and “De-implementation” are used most often, there are
many other terms that have similar definitions but have slight contextual differences. For
example: “Unfavourable or favourable shifts over time,” defined as “Changes in whether
results become less or more favourable for the experimental intervention over time”

53

;

“Change in Evidence,” defined as “Quantitative changes include differences of statistical
significance or ≥50% effect change in magnitude for important outcomes. Qualitative
changes include differences in definition of effectiveness, new data on harm, and caveats
about previous evidence”

57

; or “Translation Failure,” defined as “When the results of

preclinical, observational and/or early phase studies fail to predict the results of well-done
(i.e. appropriately controlled, adequately powered, and properly conducted) phase III or
randomised clinical trials.”118 This variety of terms causes unnecessary confusion and
increases the difficulty for those who wish to understand the processes involved. This
difficulty was evident while designing database specific search strategies as there are no
subject headings that are specific to evidence reversal.
In 2015, Niven et al. proposed the term “De-adoption” as a unifying term for the
process of removing a practice from use. We agree that this would be a good term to
describe the consequences of reversal in an all-encompassing context, as opposed to the
most frequently cited term for the process – disinvestment – which was more often used
in a monetary/economical context. In adopting the term “de-adoption” for the process and
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consequences of evidence reversal, there is still the confusion created by the many terms
for the phenomenon. Although it has not been used before in the literature, we propose
the term Evidence Reversal as a unifying term because it represents finding contradictory
evidence for any established practices or beliefs in both medical and non-medical fields,
unlike the current most commonly used term, “Medical Reversal,” which is restricted to
the field of medicine and clinical practice.
2.3.1

Significance and future directions

The significance of this review for the field and for this thesis lies in the proposed
unity that the term Evidence Reversal would bring to this area of meta-research. Previous
research in the field of reversals has been focused on the medical literature and clinical
practices. As a term for the phenomenon, “medical reversal” is clinically oriented and
carries an implication of cessation of practice. This systematic overview review expands
the definition from “medical reversal” to “evidence reversal,” thereby encompassing both
medical and non-medical practices, and providing an appropriate term for when the
evidence has been reversed, but the practice continues to be used.
The next step for resolving the large collection of terms and definitions would be
to form a common language framework using input from content experts in medical
reversal, disinvestment, and meta-research through the Delphi Method to reach consensus
on subject headings and how they should be defined. Once created, the framework will
promote consistent use of terms and concepts to maximize comparability, repeatability,
and quality of evidence, which will allow universal discussion and higher quality reviews
in the future, thus advancing the field of evidence reversal in a more structured way.
This review will inform the development of such a framework because it has
revealed that although exploration of reversals as a field of research has only recently
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begun, there are many different terms that have similar definitions. This discrepancy
suggests that the best way to approach ER may be through a simplified definition such as:
“when newer and stronger evidence contradicts a previously held belief that was based on
older or weaker evidence.”
2.3.2

Strengths and limitations

This review was very thorough and the search strategies and methodologies
employed gave the results a very high sensitivity to capture all of the relevant material.
As the purpose of this review was to explore the literature and capture the different ways
that reversal has been described, our broadly defined inclusion criteria allowed us to
capture what should be the vast majority of relevant articles related to evidence reversal.
The high sensitivity of our search is also one of its weaknesses. This review was
very labour intensive and thus, screening was not conducted in duplicate and inclusion
may have been more subjective than is typically desirable for a systematic review. While
there was a six-month period of overlap between the original searches and this update
(from January 2014 until July 2014), agreement was not calculated for any of the
screening levels (i.e. title, abstract, full-text). However, the articles for final inclusion
were agreed upon between authors (RQ and DS), with all disagreements resolved through
discussion.
The quality of articles included in this review was very low and the focus was
largely on collections of studies instead of systematic reviews. The median AMSTAR
rating was 2/9, which would suggest very low confidence in the conclusions and
recommendations of this review. However, as the purpose of this review was to explore
the terminology and definitions of the field, and not the conclusions or findings made by
any particular articles, this poor quality of included studies should not have an effect on
Chapter II

Unlocking Evidence Reversal

Riaz Qureshi

49

the quality of this review. Rather, such consistently low quality of research into the field
should instead suggest that more high-quality research be conducted to verify or disprove
the phenomenon of evidence reversal.
While the quality of included studies may not necessarily affect the quality of the
conclusions that this review makes, one limitation that must be considered lies with the
definitions of some of the included terms. Many of the included reviews used multiple
terms but did not provide all of the corresponding definitions. As a result, our table of
terms and definitions has much overlap between the definitions given for different terms
from the same article (e.g. Niven et al. only provided a definition for “de-adoption,”
though they found over 40 terms related to the process, many of which we considered to
be unique and were separated into different term sets).97 This limits the strength of our
results because some of the sets of terms that we found do not have distinct definitions,
despite the terms themselves being unique – even to the point of having different
relationships to reversal (e.g. “Re-appraisal” and “Contradict*” which are respectively
terms for a consequence and the phenomenon of reversal, were both found in the review
article by Niven et al., but neither was defined in its own right, so both are assigned the
only relevant definition provided by the article: the definition for de-adoption “The
discontinuation of a clinical practice after it was previously adopted” 97).

2.4

CONCLUSION
Evidence reversal, though not a new phenomenon, has only recently been named.

There are many different terms for the phenomenon of reversal as well as the
consequences and process that follow identifying practices that are targeted for reversal.
Given the similarities between definitions for the various terms, the best way to proceed
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with discussion of evidence reversal is under a simplified and all-encompassing
definition. Consensus should be reached on which terms are most appropriate so that
subject headings can be developed and cohesion can be brought to this emerging field of
meta-research. Once there is unity in the theoretical aspects of ER, then researchers can
start to investigate more tangible aspects including identifying the targets of reversal and
characteristics of initial evidence that may be potential predictors of future reversal.
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CHAPTER 3

An exploration of characteristics associated with Evidence
Reversal: Methods – Part I
Rationale & Methods of Database Generation

Riaz Qureshi

Chapter Summary: This chapter presents the methods used to construct the database upon
which we conduct all of our exploratory analyses. The rationale for our
approach is presented first, followed by explanations of our screening and dataextraction methods. More detailed protocols with exact descriptions of the
decision-making processes at each stage are presented in Appendices D and E.
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CHAPTER 3
3.0

A QUANTITATIVE APPROACH TO REVERSAL
Evidence reversal is the phenomenon whereby new and better evidence

contradicts a previously held belief about an established practice or standard of care that
was based on weaker evidence. In its current state, the meta-research surrounding the
field of medical reversals and evidence reversals remains disorganized and unnecessarily
complicated. Since the field is new, there are many different terms and areas of research
being explored. In our systematic overview of the literature, we found 87 articles that
could be characterized into four broader categories of research surrounding reversal:
research about the instance of reversal or contradictory findings, research about the
consequences or recommendations for practice change after something has been reversed,
research about the practices that are low value and should be targeted as reversal, and
research about the characteristics of practices and early research that increases the
likelihood of later reversal.122
Between these four facets of reversal research we found 50 unique sets of terms
that have been used in the literature. The phenomenon of reversal was most often denoted
as “medical reversal” and “contradicted / contradict* / refute / contradictory result” while
“disinvestment” and “overtreatment, medical overuse, ‘too much medicine,’ overuse, or
misuse” were primarily used to describe the consequences of reversal.122 We found that
the practices targeted as reversals were most often referred to as “low-value [practices /
healthcare / services / interventions]” or “[research updates most / trials / POEMS] likely
to change clinical practice,” and that discussion of potential predictors of future reversal
included research characteristics such as “discrepancy,” “inconsistency,” “uncertainty,”
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“known uncertainty,” “false positive or inflated results,” “initially stronger effects,” and
“non-replication.”122
Despite being a quickly expanding field, the vast majority of research pertaining
to evidence reversal has been qualitative: we found that the most common type of review
article discussing an aspect of reversal was “collection of studies,” which were primarily
narrative and included letters to the editor, editorials, and recommendations for clinical
practice.122

3.1

THE CAUSES AND CHARACTERISTICS OF REVERSAL
The phenomenon of evidence reversal is complex and there are two different

directions from which the problems posed by unnecessary reversals can be approached.
One approach is an analysis of the characteristics of original research that leads to the
premature adoption of practices that will later be reversed. Such an analysis would
provide insight into the causes of reversal and could lead to the generation of a predictive
model for the likelihood of reversal in the future. The other approach would be an
analysis of the characteristics of trials that find contradictory evidence against established
practices and beliefs. Such an analysis would not provide a predictive model, but could
elucidate the characteristics of research that are associated with reversing previous
evidence.
In his paper about the high prevalence of research findings that are false or
inaccurate, Ioannidis touched on several important characteristics of research that could
contribute to future reversal – in relation to the first approach – including: increased
financial interests or prejudices, the non-declaration of conflicts of interest, and the
novelty of a research field.23,39 Beyond these contributing factors, other characteristics of
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research that may be associated with risk of reversal include: the use and support of
traditional practices that have never been tested using randomized controlled trials, the
overgeneralization of pathophysiological models to untested indications and populations,
and implementing interventions and practices based on their effects on surrogate
outcomes.1,22,30,33,35,36 Furthermore are the common problems with study design and
conduct that can affect the validity and fragility of research findings which include,
among others: small sample size, low numbers of events, use of restricted populations,
biased data collection and assessment, as well as the validity of measures used to assess
an outcome. All of these characteristics may be applicable to evidence reversal in
assessing the risk of future reversal based on initial studies.
The second approach is also important as the analysis and understanding of the
characteristics of contradictory evidence is critical for the development of a framework of
reversibility. By ‘framework of reversibility,’ we mean a conceptual framework of study
characteristics that are associated with the contradiction of beliefs about current medical
practices that can be used to guide future research and practice. In particular, a
framework outlining the prevalence of study characteristics and degrees of association
that trials may have with evidence reversal would be valuable to researchers and policy
makers in guiding trial design to test current standards of care and the adoption or deadoption of practices.

3.2

A DATABASE OF “REVERSALS” AND “CONFIRMATIONS”
Prasad et al.’s 2013 study, ‘A decade of reversal,’ was a review of all original

articles published in the New England Journal of Medicine between 2001 and 2010.4
After screening 2044 articles, they determined that approximately 65% (1344/2044)
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concerned a medical practice, 27% (363/1344) of which tested an established practice,
and of those, 40% (146/363) were declared medical reversals: finding the practice no
better or worse than originally believed.4
While this was the first systematic attempt to quantify reversal, the study had
several limitations, particularly with respect to how reversals were characterized. One
element that was not included was the quality of studies. A study was classified as a
medical reversal if the original study authors declared that their findings contradicted
current practice, and all original research articles, regardless of the study design, were
included in their review. However, the element of study quality is inherent to the
definition of reversal (i.e. a study must be better quality than its predecessor to reverse
that previously established practice). We sought to improve upon this limitation by
including only randomized controlled trials, which are assumed to represent higher
quality of evidence than other study designs for testing interventions.123 However, our
classification of reversal or reaffirmation was still largely based on what was presented
by the authors of each respective RCT included in our database.
Another limitation of ‘A decade of reversal’ was that the statistical analyses were
primarily descriptive of the sample of studies that they had collected: percentages of trials
that examined new versus existing medical practices, the distribution of study designs,
the percentages of trials that had conclusions that were positive versus negative or no
difference between comparators, and the prevalence of studies that were classified as:
‘reversal,’ ‘confirmation,’ ‘replacement,’ or ‘back to the drawing board’.4 Prasad et al.
also qualitatively described each study that they considered to be reversals. However, no
analyses of association of characteristics with reversals were conducted.
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Table 3.1 outlines the features of ‘A decade of reversal’ and directly compares
them to the approach taken in this thesis.
Table 3.1 Comparing our approach to Prasad et al.’s ‘A decade of reversal’
‘A decade of reversal’
• NEJM (2001-2010)
• All original research studies
• Includes studies of both new and
established standards
• Descriptive statistics (study design)
• Qualitative descriptions of ‘reversals’

Expanded study outlined in this thesis
• NEJM (2000-2016)
• Randomized Controlled Trials (subset of all original
research studies)
• Includes only trials testing established practices
• Descriptive statistics (study design)
• Descriptive statistics (study results, methodology, and
quality)
• Exploratory analyses of association of trial
characteristics with reversal of evidence using 3
logistic regression approaches
• Univariable
• Multi-variable
• Backwards-stepwise model selection

To construct our database of reversals and reaffirmations, we first collected all of
the same characteristics assessed by Prasad et al. To expand upon their analyses and to
further explore the characteristics of study design that may be associated with reversal,
we also conducted an extensive quality assessment for each included trial using several
different approaches. The inclusion of each of the individual components of these
assessments, as well as their overall judgements allows us to quantitatively explore the
characteristics of reversal to a greater degree than possible in ‘A decade of reversal.’

3.3

SCREENING
We collected and screened all articles published as original research studies in the

New England Journal of Medicine (NEJM) from January 2000 until December 2016. The
NEJM was selected because it was the most cited journal in the medical sciences at the
time: based on the 5-year Hirsch Index for Medical Journals.124 The use of a single
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journal was also necessary to restrict the project to a manageable size, given the time
constraints of a two-year program.
Collected articles were screened in three consecutive stages on the basis of
published abstracts and full-text articles. The first two levels of screening were not
conducted in duplicate, but the third level was screened in duplicate (RQ, DS).
In order to be included in this review, articles must have met three criteria: 1) they
must evaluate a medical practice; 2) they must be a randomized controlled trial; and 3)
they must evaluate an established practice or current standard of care.
As we planned to analyse the characteristics of studies that are likely to be
associated with reversal, it necessitated two further inclusion criteria beyond the
collection of all studies of medical practices: that of RCT study design – the established
gold standard for testing the effect of interventions and consequently assumed higher
quality than observational study designs – and that of established practices so as to create
a dichotomous outcome upon which to build a logistic regression: contradiction (i.e.
reversal) or confirmation (i.e. reaffirmation) of the current practice.
There were no restrictions placed on medical field or setting: all articles that met
the above three criteria were included, regardless of their domain. For full descriptions of
how decisions were made for each of the three inclusion criteria, including article
excerpts to support the description of methods, please see APPENDIX D.
3.3.1

Medical practice

As per the methods described by Prasad et al., articles that tested a medical
practice were defined as “any investigation that assesses a screening, stratifying, or
diagnostic test, a medication, a procedure or surgery, or any change in health care
provision systems”.4
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Besides medical practices, there were several other subject areas that appeared in
the NEJM including research articles pertaining to molecular basis of disease,
pathophysiology of disease, and animal studies. Articles addressing these subjects were
excluded as they did not fit the pre-specified definition of medical practice.
3.3.2

Randomized controlled trial

On the basis of their abstracts and methods, the study design of an article was
classified as randomized controlled trial (RCT), prospective controlled (but nonrandomized) intervention study, observational study (prospective or retrospective), casecontrol study, or other methods (including reviews, case series, and case studies). Only
RCTs were included in this review; all other study designs were excluded in an effort to
create a database of higher quality studies.
3.3.3

Current standard of care or existing practice

The classification of whether or not a trial tested an existing practice was made on
the basis of the abstract, introduction, and discussion sections of the papers. While no
literature searches were conducted to verify each practice as being currently in use, as this
would have been infeasible given the number and extent of searches that would have
been necessary, this inclusion criterion was screened by two authors (RQ, DS) who had
access to practicing health care providers, and all disagreements were resolved through
consensus, and when necessary by consultation with a health care provider. We believe
this to be a fair replication of Prasad et al.’s methods for determining whether a practice
was new or existing, though they were not explicit in describing the criteria used to
determine whether a practice was new or existing.
Some trial authors were clear in their description of a practice’s prior use, while
some chose to downplay or overemphasize the use of a practice. As such, while we felt
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that the majority of trials were correctly designated as testing new or existing practices,
there were some trials that were contentious and required discussion between RQ, DS,
and JM.

3.4

DATA EXTRACTION
As we sought to explore the characteristics of studies that may be associated with

reversal, our extraction included any characteristics that we believed may have some
relevance to the phenomenon. Thus, the extraction for each RCT included: general
identifying information, study design and methodology, study results, overall
conclusions, conflicts of interest, PICOTS assessment, Risk of Bias assessment, and
overall GRADE rating. Table 3.2 presents each of the characteristics included in the
database.
Table 3.2 Database characteristics extracted and automatically completed for each
included trial
Extraction Section

Characteristics Extracted

General information

•
•
•
•
•
•
•
•
•
•
•
•
•
•

Study design and
methodology

•
•
•
•
•
•
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Authors
Title
DOI
Date of publication
Registered/protocol published
Registration number/protocol citation
Year of trial initiation
Year of trial registration
Year of trial completion
Population
Intervention
Comparison
Primary outcome
Primary outcome:
favourable/unfavourable?
Secondary outcomes
Duration of follow up
Sample size
Required sample size
Delta used to calculate sample size
Whether each of the above elements
matches the protocol

Automated Characteristics
• Year of publication
• Years between start and
registration
• Years between registration and
publication
• Years between completion and
publication
• Years since publication
None

An Exploration of Trial Characteristics: Methods I

Riaz Qureshi
Study results

60
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Overall conclusions

•
•
•
•
•
•
•
•
•

Conflicts of interest
PICOTS assessment
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•
•
•

Total loss to follow up
Loss to follow up in intervention group
Loss to follow up in comparison group
P-value for primary outcome
Statistical significance of P-value
Point estimate for effect measure
Confidence interval around point
estimate
Measure of effect
Type of outcome
Events in intervention group
(dichotomous)
Number of subjects in intervention
group
Events in comparison group
(dichotomous)
Number of subjects in comparison
group
Intervention group mean (continuous)
Intervention group standard deviation
(continuous)
Comparison group mean (continuous)
Comparison group standard deviation
(continuous)
End point conclusions
Justification for conclusion
Does the article contradict current
medical practice?
Justification for contradiction or
confirmation
Primary outcome reported in abstract
conclusion
Abstract conclusion based on subgroup
analyses
Abstract conclusion based on
secondary outcomes
If reversal: what category?
Personal judgement on whether trial is
a reversal
Funding designation
Sources of funding
Sufficiency or Insufficiency of each of
the following characteristics
o Population
o Sample size
o Intervention
o Comparison
o Outcomes
o Type of outcome (hard, surrogate,
composite)
o Follow up
o Study design
o Study purpose/question

• Percent of sample size lost to
follow up
• Intervention group rate and
confidence interval
(dichotomous)
• Control group rate and confidence
interval (dichotomous)
• Absolute risk difference and
confidence interval
(dichotomous)
• Number needed to treat and
confidence interval
(dichotomous)
• Total number of events
(dichotomous)
• Relative risk reduction
(dichotomous)
• Fragility index (dichotomous)
• Standardized effect size and
confidence interval (continuous
and dichotomous)
• Adequacy of power (continuous
and dichotomous)
• Is the article a reversal or a
reaffirmation?

None
None
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• Justification for the designation
applied to each of the above
characteristics
• Overall sufficiency of PICOTS
• The likelihood of risk of bias in each
of the following characteristics
o Sequence generation
o Allocation concealment
o Blinding
o Incomplete outcome data
o Selective outcome reporting
o Other design areas
• Justification for the designation
applied to each of the above
characteristics
• Overall likelihood of risk of bias
None

None

• General risk of bias (Overall
likelihood of risk of bias)
• Directness and applicability
(Overall sufficiency of PICOTS)
• Imprecision of results (Adequacy
of power)
• Modified risk of publication bias
(Selective outcome reporting
bias)
• Total number of downgrades
• Overall quality of evidence

Data extraction was completed by three extractors: RQ (years: 2000, 2001, 2002,
2003, 2004, 2006, 2008, 2010, 2012, 2014, 2016), DS (years: 2005, 2007, 2009, 2011,
2013, 2015), and Dr. Leonardo Guizzetti, who was also trained and contributed to data
extraction for 2006.
To guide the data extraction process, a protocol for this review, outlined by Sutton
et al. was followed.45 This protocol outlined the components and processes followed for
each characteristic in the database. The use of the protocol and a random test-set of trials
before completing extraction minimized potential differences between extractors. The full
table of data-extraction and analysis elements for the database can be found in
APPENDIX E.
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General information

General information collected from each study was primarily used for
identification, although characteristics such as the dates of publication, trial registration,
initiation, and completion were also used to inform the PICOTS assessment.
3.4.2

Study design and methodology

Characteristics of the study design and methodology that were extracted include:
population, intervention, comparison, primary outcome, secondary outcomes, duration of
follow-up in weeks, actual sample size, and the required sample size to meet author
specified power level, significance level, and specified differences between point
estimates of measures of effect. Furthermore, each of these characteristics was compared
with the trial protocol or registration (if available) to inform the PICOTS assessment.
It is important to address the selection of intervention, comparison, and primary
outcome because they formed the basis for the characteristics of the study results. All
three of these characteristics were attributed based on the authors’ designation. In some
cases, the designation was not explicit or multiple options were available, in which case
pre-specified rules were followed, as outlined in the data extraction protocol
(APPENDIX E).
3.4.3

Study results and overall conclusions

Characteristics of the study results that were extracted include: loss to follow up,
significance, point estimate and confidence intervals of measures of effect for the primary
outcome (if provided), as well as the raw findings pertaining to the primary outcome:
numbers of subjects in each group and numbers of events, for dichotomous outcomes,
and means/medians and standard deviations/interquartile ranges for continuous outcomes.
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In addition to the extracted characteristics, the Excel database was encoded to
automatically calculate clinical measures including: point estimates and confidence
intervals for the absolute risk difference (ARD), number needed to treat (NNT), the
relative risk reduction (RRR), and a standardized effect size for dichotomous and
continuous outcomes. The Fragility Index and reverse Fragility Index were respectively
calculated for each eligible trial using a web application and the R – 3.3.3 ‘Fragility
Index’ package.
The overall conclusions of the included trials were taken from the discussion or
the conclusion of the abstract and pertain to the main finding for the primary outcome.
Similarly, the classification of the trial as contradicting current medical practice was
taken from the authors’ conclusions, recommendations, and background in describing the
current beliefs surrounding the practice in question.
If a trial was determined to contradict a previously established and currently used
practice, the type of reversal was specified as one of several predetermined categories
including when the practice was found to be harmful; not effective; less effective than
currently believed, but still beneficial; or beneficial if thought to be harmful/not
effective/inferior to a different practice.
3.4.4

Conflicts of interest

The conflicts of interest included all sources of funding reported by the authors. If
sources of funding or other potential conflicts of interest were stated, they were classified
as non-industry or industry. If any of the sources of funding were from an industry
company (e.g. pharmaceutical makers), then the conflicts were classified as industry.
However, if a company provided only the intervention and this was declared in the paper
(i.e. the authors explicitly stated that the company only provided drugs/devices and not
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any funding or further support), then the designation was based on the other sources of
funding and potential conflicts.
3.4.5

PICOTS assessment

A PICOTS (population, intervention, comparison, outcome, timing, study design)
assessment was conducted to determine the sufficiency of the study methodology that
was extracted previously. Each component of trial methodology was classified as
sufficient or insufficient with regards to its adequacy for reaching an answer for the
primary outcome and overall study question, as well as its similarity to the trial
protocol/registration (if available). The general guideline that was followed led to a
designation of sufficient as being appropriate if the relevant information was itemized or
stated in the article or its protocol. If the information was not present or was
inappropriately different from the protocol (when available) then the component was
designated as insufficient. An overall assessment of the PICOTS was generated on the
basis of the sufficiency of the individual components. APPENDIX E contains detailed
instructions to guide the designation of each component as sufficient or insufficient.
3.4.6

Risk of Bias assessment

A risk of bias (ROB) assessment was conducted to determine the overall risk of
bias for each trial. The ROB tool was developed from the Cochrane Handbook, Chapter 8
and each item is given a designation on a 4-point scale: ‘definitely low risk of bias,’
‘probably low risk of bias,’ ‘probably high risk of bias,’ or ‘definitely high risk of
bias.’125 The ROB assessment is similar to a PICOTS in that it requires one to judge a
study’s design, however it covers different aspects of methodology where biases may be
introduced including: treatment sequence generation, allocation concealment, blinding to
intervention groups, handling of incomplete outcome data, whether outcomes were
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selected and switched or pre-specified, and other general issues with study design (e.g.
early termination, industry influence, extreme baseline imbalance).
The general guideline that was followed for the ROB assessment was that if direct
evidence to inform the decision was provided in the article, then ratings of “definitely low
risk of bias” or “definitely high risk of bias” were appropriate options. However, if the
relevant information was not explicitly reported in the article but could be inferred, or
there was insufficient information to permit judgement, then ratings of “probably low risk
of bias” or “probably high risk of bias” were appropriate options. A rating of “definitely
high risk of bias” was assigned to a domain when there was direct evidence that bias
could have been introduced in that design element. An overall assessment of the ROB
was generated on the basis of the individual domains. APPENDIX E contains detailed
instructions to guide the rating of each component’s risk of bias.
3.4.7

GRADE assessment

Grading of Recommendations Assessment, Development and Evaluation
(GRADE) is a well-established tool to help determine the overall quality of evidence that
a study provides.126 There are five domains including general risk of bias, directness and
applicability, imprecision, risk of publication bias, and inconsistency of findings.126 All
studies included in our review had an initial GRADE rating of ‘high quality evidence’
because under the GRADE framework, trials are considered to start at the highest level of
evidence as opposed to observational studies, which begin at a low level of evidence.123
The GRADE assessment in the database was coded to automatically complete for
each trial based on the previously extracted characteristics. The GRADE ‘risk of bias’
was taken from the overall ROB assessment. ‘Directness and applicability’ was
autocompleted with the overall PICOTS assessment. ‘Imprecision’ was automatically
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characterized as ‘sufficient’ or ‘insufficient’ based on the adequacy of the trial’s power.
A modified ‘risk of publication bias’ was based on the risk of bias for outcomes selection
(within the ROB assessment) using reporting bias as a proxy for publication bias.
We did not include the GRADE domain of ‘inconsistency’ in our assessment
because it is specifically used for describing the heterogeneity of results across multiple
trials on the same topic. As we collected all original RCTs of medical practices, with no
restriction on type or field of practice, it was impossible to describe the degree of
consistency across the evidence. Therefore, we made the simplifying decision to not
assess the inconsistency of included trials.
Another simplifying assumption that we made in our GRADE assessment was the
inability to increase quality of evidence rating through inflating factors. The GRADE
framework allows studies to increase their quality rating if they exhibit: a large or very
large effect size, a dose-response relationship, or if the presence of residual confounding
would reduce the demonstrated effect or suggest a spurious effect if no effect was
observed.127 However, this upgrading of the evidence is primarily only applied to
observational studies and though it is theoretically possible to upgrade the quality rating
of RCTs, the GRADE Working Group remark that they “have yet to find a compelling
example of such an instance.”127 Also, by including only RCTs, each article was
automatically categorized as the highest quality of evidence initially. For these reason, we
decided that for our GRADE assessment, trials – and consequently all included studies in
this review – would not be able to receive any upgrading of evidence as proposed within
standard GRADE methodology.
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CONCLUSIONS
Prasad et al.’s review from 2013 provided a starting point from which we sought

to further explore the characteristics of research that may be associated with reversal. To
this end, we independently replicated and also further expanded their methodology to
allow for more in-depth analyses of quality, methodology, and the findings of RCTs that
test established practices and may lead to evidence reversal.
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CHAPTER 4

An exploration of characteristics associated with Evidence
Reversal: Methods – Part II
Data Analysis Plan

Riaz Qureshi

Chapter Summary: This chapter presents the methods used for all of our planned analyses
and additionally serves as a protocol to guide the analyses as it was written
before the analyses were conducted. The planned reproduction and expansion
of ‘A decade of reversal’ is presented first, followed by an explanation of our
exploratory logistic regression analyses. The Stata do-files for setting up the
database and conducting the analyses are presented in Appendices F and G.
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CHAPTER 4
4.0

STATISTICAL ANALYSES PLAN
The ‘Decade of Reversal’ study by Prasad et al. was a landmark review in the

field of medical and evidence reversal as it was the largest and most comprehensive study
to specifically address the phenomenon.4 Given its importance, and their focus on the
years 2001 to 2010, an independent replication of the study, together with a further
expansion to include more recent articles (2000 to 2016), is needed to assess
reproducibility and to add power. Furthermore, reproducing the review provides an
opportunity to expand the breadth of analyses to identify trial characteristics that may be
associated with reversal, potentially providing the necessary data to create an evidenceinformed framework of reversibility to guide future research.
After screening all articles published in the New England Journal of Medicine
between January 2000 and December 2016, the characteristics of included articles were
extracted into an excel database as described in Chapter 3 and APPENDICES D and E.
All descriptive statistics were calculated using Stata 13, as were all regression analyses.
The Stata do-files for importing and setting up the excel database and then conducting the
analyses described in this chapter can be found in APPENDIX F and APPENDIX G,
respectively.

4.1

ANALYSES IN ‘A DECADE OF REVERSAL’
The 2013 review was conducted to identify medical practices that offer no net

benefits. The authors reviewed all articles published in the NEJM between 2001 and
2010, and classified them according to whether they addressed a clinical practice,
whether they tested a new therapy or an existing therapy, whether the final results and
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conclusions were positive versus negative or no difference (i.e. whether they found a
significant effect favouring their intervention or control group, or found the groups were
not statistically different), and whether the results constituted evidence “replacement,”
“back-to-the-drawing-board,” “reaffirmation,” or “reversal.”4
The analyses that Prasad et al. conducted in ‘A decade of reversal’ were primarily
descriptive. In their results they described: the proportion of articles addressing a medical
practice (65.8%); the proportion of medical practices that were new versus existing (73%
and 27%, respectively); the proportions of different study designs (67.7% RCTs, 16.4%
prospective controlled but non-randomized studies, 8.7% observational studies, 3.2%
case-control studies, and 3.9% studies with other methods); the proportions of studies
reaching conclusions that were positive (significant difference in favour of intervention)
versus negative (significant difference in favour of control or non-significant difference)
between comparators (70.5% and 29.5%, respectively); as well as the overall proportions
with conclusions that constituted replacement, back to the drawing board, reaffirmation,
or reversal (56.3%, 12.3%, 10.9%, and 10.3%, respectively).4
In addition to the above descriptive statistics, Prasad et al. specified the most
common study type, the proportions of reaffirmations and reversals among studies that
tested existing medical practices, the proportions of study types among articles that
constituted reversals, and the statistical likelihood that articles testing new or existing
practices would find the practice to be beneficial or ineffective. The remainder of the
results presented in the review were qualitative descriptions of selected reversals and a
limited exploration of their trends; namely the narrative shared by many reversals, which
entails the acceptance of a practice or standard – despite a weak evidence base – due to
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support from prominent members of the medical community and a faith in the
pathophysiologic mechanism, which is subsequently undermined when adequately tested
by properly conducted randomized controlled trials.4

4.2

INDEPENDENTLY REPRODUCING AND EXPANDING
ANALYSES OF ‘A DECADE OF REVERSAL’
In an effort to independently reproduce, expand, and update ‘A decade of

reversal,’ we attempted to classify articles into the same categories over the same years as
in Prasad et al., with an additional 7 years of trials. We replicated their methodology as
accurately as we could from the description provided in the article. However, we also
wanted to improve upon their methods by assessing the characteristics of studies that may
be associated with reversal. To this end, we only extracted data for articles that were
classified as randomized controlled trials (RCTs) as they are assumed to provide a higher
quality of evidence than observational studies, and generally provide conclusions that are
more robust.
The baseline analyses of our database of RCTs will include independent
reproduction of all descriptive statistics presented in ‘A decade of reversal.’ This will
include: the proportion of articles that address a medical practice, the proportion of
medical practices that were new versus existing, the proportions of different study
designs testing medical practices, the proportions of article conclusions being positive
(significant) versus negative (non-significant difference) between comparators, and the
proportions of reaffirmations and reversals among trials that tested established practices.
There are several descriptive statistics that were not conducted because articles
that were classified as testing “new” practices were excluded from our study and have no
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further data extracted beyond that collected to inform the first two levels of screening
(outlined in Chapter 3, Section 3.3). Further, the “study type” of all included articles for
our study is “RCT,” and thus descriptive statistics relevant to other study designs do not
apply to our study sample. We will not describe: the overall proportions of studies
designated as “replacement” or “back to the drawing board,” the most common study
type, the proportions of study types among articles that constituted reversals, and the
statistical likelihood that a trial testing new practices would find the practice to be
beneficial or ineffective.

4.3

EXPANDED ANALYSES: DESCRIPTIVE STATISTICS
Prasad et al. explored the presence of reversal within the NEJM and described

several characteristics of the articles that they found. Our goal was to expand the analyses
conducted in ‘A decade of reversal.’ Consequently, we collected additional
characteristics about the included trials, which allowed us to provide improved
description of the sample of trials and characteristics that may be associated with
reversal. In addition to independently reproducing the descriptive statistics presented by
Prasad et al., as outlined above in section 4.2, we also report other descriptive statistics
for our sample as would be found in an observational study or trial. These will be
reported for the overall sample and according to whether the trial contradicted or
supported the practice that it was examining (i.e. reversal vs. reaffirmation).
In our tables of sample characteristics, we will report: proportion of trials that
were registered; proportion of those registered that had an accessible protocol or
registration; mean number of years between trial start and registration of those where the
protocols/registrations were accessible; the proportion of trials that had a primary
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outcome that was focused on harm; mean duration of follow up; mean sample size
achieved; mean required sample size; mean percentage lost to follow up; proportion that
had significant primary outcomes (with a P-value ≤ 0.05); proportions of studies using
different measures of effect; proportion with a primary outcome that was dichotomous;
proportions of studies with primary outcomes that are based on hard, composite, or
surrogate outcomes; proportions of studies that reported abstract conclusions based on
their primary outcome, subgroup analyses, or secondary outcomes; proportions of studies
belonging to each category of ‘reason for reversal;’ proportions of studies with each
overall PICOTS designation; proportions of studies with each overall ROB designation;
and proportions of studies with each overall GRADE level of evidence.

4.4

EXPANDED ANALYSES: LOGISTIC REGRESSION
While descriptive statistics are valuable in characterizing a sample of studies that

may lead to evidence reversal, the conclusions that can be drawn from such analyses are
limited. A multivariable logistic regression of the characteristics of these studies would
provide a greater understanding of the degree to which they are associated with reversal.
Logistic regression will be used for this analysis because it is the most widely used model
for binary outcomes in clinical and epidemiological applications.128 This quantitative
approach to assessing the characteristics of trials will contribute to the generation of a
framework of reversibility to help guide future research in the field.
The multivariable logistic regression model assumes that multiple covariates are
related to the outcome in an additive fashion on the log scale.128 Other assumptions about
the covariates and outcome include: the model is fitted correctly; the outcome follows a
binomial distribution; the mean expected outcome for a given set of covariates (E[y|x] =
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P(x)) is given by the logistic function; values of the outcome are statistically independent
(i.e. truly binary); all observations are independent; and the requirement of large sample
sizes.
To ensure the model has appropriate fit, Pearson and Hosmer-Lemeshow (HL)
goodness-of-fit tests will be performed. If either goodness-of-fit test suggests that the
model is not appropriate (P-value ≤ 0.05) then the least non-significant covariate will be
removed and the goodness-of-fit retested, until the model is appropriate. The outcome of
the model (reversal versus reaffirmation) is binary and the requirement of large sample
sizes will be assumed met for all univariable analyses, as there will be more than 10
reversals (cases) per covariate given the sample size of 611 trials. However, there will be
reduced power for the overall multivariable regression as controlling for several
categorical covariates will lower the number of trials with each specific designation. An
assumption that may not be met is the independence of all observations, as some trials
included in the database are related. As all RCTs from 2000-2016 that met the inclusion
criteria are in the database, some included trials are secondary analyses of earlier trials
(which may also be included), or multiple publications on different outcomes of the same
trial (e.g. publication of intermediary analyses and final outcome data). However, the
simplifying assumption of independence between observations will be applied as only a
small proportion of the 611 included trials are not independent.
This project presents a comprehensive study of RCTs published in the NEJM, but
it is neither a meta-analysis, nor a meta-regression. Rather, the sample of trials that have
been collected will be treated as ‘individuals’ in assessing the relation of their
characteristics to a known outcome. In this sense, an analogous study design to the
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overall approach could be described as a repeated cross-sectional study. A case-control
design would not be an appropriate analogue, as a sample of reversals and reaffirmations
was not selected at the start of the trial based on their outcome. Neither would a cohort
design be an appropriate analogue because there are different ‘subjects’ each year and
there are no repeated measures of the same ‘individuals.’ A repeated cross-sectional study
design is the most appropriate as the database is a sample of trials each year for the past
17 years – selected on the basis of inclusion criteria that were designed to refine the
sample to one most likely to have the outcome of interest – and extracted relevant
characteristics for which the relation to the outcome of interest (determined after
inclusion in the study) will be described. The implication of this ‘approach’ is that we
cannot infer causality or influence of the characteristics on the outcome, only the degree
to which they are associated, because all of the data for the characteristics and the
outcome is collected at the same time.
4.4.1

Overall logistic regression

In order to assess the strengths of associations that the characteristics of trials may
have with reversal, potentially important characteristics will be included as covariates in a
multivariable logistic regression on the outcome of reversal (contradiction of established
practice) or reaffirmation (confirmation of established practice). Table 4.1 presents the
covariates that will be included in the overall logistic regression model, as well as their
possible values. Section 4.5 describes the rationale for inclusion of each covariate in the
model as well as the methods for describing and assessing their distribution and validity
of inclusion in the model.
In the logistic regression analyses of these characteristics, the associations of all
individual covariates were first tested in univariable analyses. An overall logistic
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regression model was then fitted with all potential predictors in a simple exploratory
analysis, which was followed by a backwards-stepwise model selection. As an additional
approach to assessing the covariates, we assessed the correlation of each covariate with
the others.
Table 4.1 The 15 covariates included in overall logistic regression
Type of
Covariate

Covariate name

Possible values

Continuous

1. Percentage of participants lost to follow up
2. Length of follow up
3. P-value
4. Sample size
5. Standardized effect size
6. Year of publication
7. Protocol registered

0.0 to 100
0 to (+ ∞)
0.0 to 1.0
0.0 to (+ ∞)
0.0 to (+ ∞)
2000 to 2016
• Yes
• No
• Yes
• No
• Yes
• No
• Yes
• No
• Sufficient
• Somewhat insufficient
• Clearly insufficient
• Definitely low risk of bias
• Probably low risk of bias
• Probably high risk of bias
• Definitely high risk of bias
• High
• Moderate
• Low
• Very low
• Non-industry
• Industry
• None reported
• Hard
• Composite
• Surrogate

Binary

8. Abstract conclusions based on primary outcome

Categorical
(Ordinal)

9. Abstract conclusions based on secondary
outcome
10. Abstract conclusions based on subgroup
hypotheses
11. Overall PICOTS assessment

12. Overall ROB assessment

13. Overall GRADE assessment

Categorical
(Nominal)

14. Conflicts of interest

15. Type of outcome

The logistic backwards-stepwise regression fits all explanatory variables to a
model and then sequentially removes the covariates that are non-significant by a pre-
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specified level for removal.129 The model iteratively checks the significance of the least
significant included covariate to see if it is less than the pre-specified level for exclusion
from the model and re-estimates the fit after each removal until all include covariates are
significant at the pre-specified level.129 This method theoretically produces the best fitting
model from a set of potential predictors, but only when there is no prior subject matter
knowledge to enable pre-specification of important covariates.130
There are limitations to the use of backwards-stepwise model building –
particularly with regards to the stability of the selection process in the presence of
collinearity – such as over-fitting the model to the data, yielding highly biased R2 values
and models that are not generalizable.130,131 However, as this analysis is exploratory, and
we wished to determine if any of our pre-determined covariates have relationships with
reversal – whether significant or not – and not necessarily to build the most appropriate
predictive model, we deemed the backwards-stepwise approach acceptable. Our model
selection criteria were lenient and we used a significance level of ‘0.5’ for dropping
covariates from the model.130 Thus, if a covariate has a p-value > 0.5 it may be excluded
from the model.131 The Hosmer-Lemeshow goodness of fit for the original model was
compared to the final model generated with the backwards-stepwise method.
The results of the individual covariate analyses and overall logistic regression are
presented as a table of the odds ratios, confidence intervals, and p-values for the
relationship that each covariate has with the outcome of reversal. These associations
between each covariate and the outcome were interpreted from the perspective of trial
methodologists to inform the development of a framework which attempts to incorporate
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the relationships discovered into a unified decision aid for directing future research and
assessing generalizability for detecting past reversals or predicting future reversals.
4.4.2

Logistic regression of multidimensional summary scores

After the general logistic regression had been conducted with all of the covariates
of interest, it was possible that one or more of the multidimensional summary
components may have been found significantly associated with reversal. The overall
GRADE, PICOTS, and ROB assessments are summary scores that are comprised of
individual components – covering different aspects of study design and methodology. If
any of these summary measures were found to be significantly associated with the
contradiction of established practices, we planned to conduct multivariable logistic
regressions of the component domains on the outcome to determine which of the
components drives the significance of the overall measure.
Table 4.2 outlines each of the three smaller logistic regressions that would have
been conducted to assess the individual components of the multidimensional summary
scores, if any of them had been significantly associated with the outcome in the overall
logistic regression. These models also would have been assessed with Pearson and HL
goodness of fit tests.
Table 4.2 Model covariates for each of three separate summary score regressions
Significant summary score

Covariates

PICOTS (8 components)

•
•
•
•
•
•
•
•
•
•
•

ROB (6 components)

CHAPTER IV

Population
Sample size
Intervention
Comparison
Outcomes
Follow up
Study design
Study purpose/question
Sequence generation
Allocation concealment
Blinding

Possible values
• Sufficient
• Insufficient

• Definitely low risk of bias
• Probably low risk of bias
• Probably high risk of bias
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•
•
•
•

Incomplete outcome data
Selective outcome reporting
Other design areas
General risk of bias

• Directness and applicability

• Imprecision of results
• Modified risk of publication
bias

4.5

• Definitely high risk of bias

•
•
•
•
•
•
•
•
•
•
•
•
•

Definitely low risk of bias
Probably low risk of bias
Probably high risk of bias
Definitely high risk of bias
Sufficient
Somewhat insufficient
Clearly insufficient
Sufficient
Insufficient
Definitely low risk of bias
Probably low risk of bias
Probably high risk of bias
Definitely high risk of bias

RATIONALE FOR COVARIATE INCLUSION
The initial set of explanatory variables that were selected for inclusion in the

model included a mix of continuous, binary, ordinal, and nominal categorical. There were
15 covariates that we believed might be associated with the outcome of reversal or
confirmation of practice because they have been previously identified as indicators of
study quality and strength of evidence. Given that a common trend for many reversals
involves high quality randomized controlled trials that contradict a practice implemented
on a weak evidence base, we assumed that these common markers of study quality may
represent good candidate markers with plausible mechanism for relationship with reversal
or reaffirmation of established practices.
When there is a high degree of loss-to-follow up within a trial, it can be difficult
to interpret the effect of the intervention.132 Differential or non-random loss to follow up
– in terms of numbers and reasons between comparison groups – is particularly
challenging as it may affect the validity of trial conclusions, while a low loss-to-follow
up can be indicative of good trial design and conduct.132
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As experience in clinical research has developed, it has become apparent that
interventions that were believed to have short-term effects will continue to elicit effects
and impact patient outcomes in the long term (e.g. excess mortality among patients with
sepsis admitted to the hospital, compared to the general population, remains for several
years, yet most interventional sepsis studies use end-points of mortality at 28-days).133,134
As a consequence, the study of clinical outcomes almost always requires longer lengths
of follow up to find the true net effects of an intervention. Thus, duration of follow up is
included as a continuous covariate because theoretically, the longer patients are followed,
the more likely it is that the true net effect of a practice will be found and potentially
reversed.
While sample size is a predictor of significance, both the P-value and sample size
were included in the overall model because practices that are established based on small
studies may be overturned by large, adequately powered, trials, and thus these
characteristics may have some relation to evidence reversal. Similarly, a standardized
effect size was included in the model to allow comparison between the various measures
of effect, both dichotomous and continuous, used by different trials.
We investigated the year of publication as a potential predictor for two reasons.
Firstly, Prasad et al. tested if there was a significant relationship between the percent of
reversals over time using a linear regression. Even though they found that the percentage
of reversals among articles that tested a standard was consistent across the decade (P =
0.51), we still included year as a covariate because, theoretically, the risk of reversals
may change as time progresses, and our study has increased the number of years from 10
to 17. This assumption is logical because the longer that a practice has been implemented,
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the more opportunities arise where it may be reversed and consequently practices may be
significantly more likely to be reversed as time progresses.
The sources for abstract conclusions (primary outcome, secondary outcomes, or
subgroup hypothesis) were included in the overall model as dichotomous markers for
potential reporting bias. The conclusions of the abstract should report the general
interpretation of results and be consistent with the primary outcome reported in the
abstract.135 Publications that make abstract conclusions based on subgroup analyses or
secondary outcomes (i.e. selective reporting) may be trying to draw attention away from
an unfavourable or insignificant primary outcome.136
The overall PICOTS, ROB, and GRADE assessments were also tested in the
model because they are summary measures of several multidimensional characteristics
concerning study quality. We believe that designations of higher study quality may be
associated with reversal because for a practice to be reversed there must be sufficient
evidence to support the decision and poor quality studies are less likely to constitute
sufficient evidence. This rationale is further supported by the definitions of medical and
evidence reversal, which include the qualification that the new evidence claiming to
reverse an established practice be superior to that which preceded it.1
The designation of potential conflicts of interest and sources of funding were
included in the model as trials with industry influence may be more likely to lead to
confirmation. This is because all trials in our database test established practices. While
industry trials of new practices are more likely to find significant differences, when
testing interventions that are already adopted – particularly those created by their own
company – they may be more likely to confirm what is believed than contradict it.137,138

CHAPTER IV

An Exploration of Trial Characteristics: Methods II

Riaz Qureshi

82

Outcome type was the final covariate included in the overall model as its
relationship with reversal is one of the trends seen among many reversals: practices
implemented based on intervention effects on surrogate outcomes are subsequently
reversed when the relevant ‘hard’ (clinically-relevant; patient-important) outcomes are
tested.2,77 We included this characteristic because we expected that trials using surrogate
outcomes or composite outcomes may be more likely to confirm the practices that they
are testing, while trials investigating an intervention’s effect on hard, patient-important,
outcomes may be more likely to lead to reversal.139
In addition to the 15 included in the overall model, there are five covariates for
which the relationship with reversal was only examined in univariable analyses. These
are ‘years between trial start and registration,’ ‘years between trial end and publication,’
‘Fragility Index,’ ‘Total Number of Events,’ and ‘Adequacy of Power.’ These covariates
are of interest because they are related to the confidence that can be expressed in a trial’s
results, but must be assessed on their own because all but the Adequacy of Power have
high degrees of missing data that cannot be meaningfully imputed, and the Adequacy of
Power is an indicator variable of our devising that we do not feel comfortable influencing
the potential relationships of other covariates.
The two continuous covariates that measure the years between start and
registration, and completion and publication, are indicators of reporting and publication
biases as trials with large positive values indicate retroactive registration and long periods
of non-publication. These two covariates were not included in the overall model because
they only had numerical values when a registered protocol is accessible and have a
designation of ‘N/A’ when there is no registration available. Consideration was given to
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including them in the model with a binary indicator variable (the availability of a protocol
or registration), but after deliberation with committee members, the decision was made to
explore them on their own. The Fragility Index is an indication of how many events
would be required to change the significance of a trial’s results.140 A lower Fragility
Index suggests that a trial’s conclusions may have been different with a few more events
in one group or the other and, consequently, that the results may be ‘fragile’ and more
easily reversed.140 A Fragility Index value of ‘0’ may arise because of a difference in the
statistical test used to determine significance, as the Fragility Index calculates p-values
using the Fischer’s Exact Test.140 The total number of events is closely linked to the
Fragility Index as it is calculated using the number of events and subjects in each group.
However, investigating the relationship of total number of events is also of interest
because it is a more familiar metric to the medical community and an established
contributing factor to the power of a trial in making conclusions. The adequacy of power
is a dichotomous indicator of whether or not a trial had sufficient power based on its
actual sample size, its reported necessary sample size, and the desired delta between
comparators (if reported).

4.6

MISSING DATA
The NEJM was selected as the journal upon which to conduct this review based

on its 5-year impact factor (Hirsch-index).4 The NEJM is widely regarded as being one of
the highest quality medical journals in the world and as such, maintains a high standard in
the reporting and writing of the articles it publishes. However, even within this high
impact journal, some elements of trial design and results were missing from the
descriptions provided in the publication (as well as provided appendices and protocols).
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In an effort to account for missing data, simple mean imputation was used for
characteristics where appropriate. Each imputed characteristic underwent sensitivity
analyses to test whether use of the imputed data significantly affected the resulting
relationship. The amount of missing data for each covariate – before and after imputation
– will be presented in Chapter 5 as the number of observations contributing to the result
for each characteristic.
Table 4.3 outlines the methods used for imputation of missing data for each of the
covariates in the general model. There are several covariates for which there was no
missing data, including: year of publication, whether the trial was registered, the end
point conclusions, overall PICOTS assessment, overall ROB assessment, overall GRADE
assessment, the reason for reversal, the designation of conflicts of interest, and the type of
primary outcome. These are mostly covariates that were our judgements and
interpretations of aspects of the trial – based on what the author had presented in their
paper – and therefore cannot be missing because they are not directly taken from the
publication.
Table 4.3 The 15 covariates and proposed imputation methods for missing data
Covariate

Proposed method of imputation

% Subjects lost to follow up
P-value

Mean imputation with average % subjects lost to follow up
If raw data or effect measure for primary outcome is provided, the
missing p-value will be imputed with a mean significant p-value for
significant trials with a significant outcome confidence interval, and
the mean non-significant p-value for trials with non-significant
confidence intervals for their primary outcome
Standardized effect size is calculated using the raw trial data. For
trials with dichotomous outcomes, the number of subjects and
number of events for each group are used to calculate an absolute risk
difference, which is used to generate a standard effect size. For trials
with continuous outcomes, the mean and standard deviations for each
group are used to generate a standard effect size.

Standardized effect size

Length of follow up
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Year of publication
Abstract conclusion primary
Abstract conclusion secondary
Abstract conclusion subgroup
Protocol registered
End point conclusions
Overall PICOTS assessment
Overall ROB assessment
Overall GRADE assessment
Conflicts of interest
Type of outcome
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No missing data
No missing data
No missing data
No missing data
No missing data
No missing data
No missing data
No missing data
No missing data
No missing data
No missing data

DEVELOPING A FRAMEWORK OF REVERSIBILITY
An initial framework of reversibility has been proposed by Sutton and Martin that

focuses on specific components of the design, execution, and analysis of evidence by
using indicators derived from trial design, methodology, and reporting.45 The framework
– which includes the individual domains of a PICOTS, ROB, and modified GRADE
assessment, as well as modified optimum information size, fragility index, duration from
trial start to registration and from completion to publication, and sources of abstract
conclusions – is proposed as a tool to inform the likelihood that a trial reverses an
established practice.45 This framework may aid healthcare decision-makers in delaying
the adoption of new practices or disinvesting established practices until the evidence has
matured. Our expanded analyses will further the development of this framework as we
explore the relationship that these characteristics and others have with the declaration of
reversal.
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The characteristics of Reversal: Results
Descriptive Statistics and Logistic Regression Analyses

Riaz Qureshi

Chapter Summary: This chapter presents the results of both descriptive analyses (the
reproduction and expansion of those conducted in ‘A decade of reversal’) and
the exploratory logistic regression analyses.
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CHAPTER 5
5.0

SCREENING
Three thousand five hundred and sixty original research studies published in the

New England Journal of Medicine (NEJM) between January 1st, 2000 and December 31st,
2016 were collected by two authors (RQ and DS). These articles were screened at three
levels for inclusion criteria using the abstract and full texts, leading to exclusions of: 834
for not studying a medical practice, 964 for not being randomized controlled trials, and
1147 for testing new practices.

Figure 5.1 PRISMA flow diagram for inclusion of trials
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Screening for the first two levels was not conducted in duplicate, but the third tier
– existing versus new practices – was duplicated and had an initial Kappa of 69%
between the two authors (RQ and DS). After screening for exclusion criteria, 615 trials
were included in the database. However, during data extraction, four trials were excluded
for reasons that were not accounted for in the initial exclusion criteria. These trials were
excluded primarily due to the lack of useable outcome data. One publication was an
ICER (Incremental Cost-Effectiveness Ratio) analysis of a previously published trial.
One trial was of a screening test, but provided no summary outcome data that could be
used. One publication was an interim analysis of the participant’s baseline data and had
no outcome data for either group. One trial did not present outcome data for each
intervention group, but as summary data for the entire study group. Therefore, the
database includes 611 randomized controlled trials of established medical practices.

5.1

DESCRIPTIVE STATISTICS FOR INCLUDED TRIALS
Between 2000 and 2016, 3560 original research studies were published in the

NEJM. The majority of studies (2726 [77%]) addressed a medical practice. Of the studies
concerning a medical practice during these 17 years, we identified 1762 (65%)
randomized controlled trials, 725 (27%) observational studies, 118 (4%) prospective
controlled but non-randomized studies, 88 (3%) case control studies, and 33 (1%) studies
of other design. Of the randomized controlled trials, 615 (35%) were determined to
address an existing practice. Characteristics of the 611 included trials were extracted and
the descriptive statistics for the sample, presented in Tables 5.1 through 5.4, were
calculated using Stata 13.
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Table 5.1 Classifying characteristics of studies screened
Screened Studies (2010 – 2017) (n = 3560)
Articles that addressed a medical practice
Articles with study design of:
Randomized Controlled Trial
Observational (prospective or retrospective)
Prospective (non-randomized) Controlled Trial
Case-Control
Other (meta-analysis, case-study, case-series)
RCTs that addressed an existing practice

# of Studies (%)

# of
Observations

2726 (77%)

3560

1762 (65%)
725 (27%)
118 (4%)
88 (3%)
33 (1%)
615 (35%)

2726

1762

Based on authors’ conclusions and the information presented within their
backgrounds and discussion, 331 (54%) were reversals – contradicting the established
practice being tested – while 280 (46%) confirmed what was believed or upheld the
standard of care over a lesser or prior standard (reaffirmation). With regard to the trial
results, 256 (42%) reached positive conclusions while 355 (58%) reached negative
conclusions or found no statistically significant difference between their comparators.
Among trials that contradicted the established practice being tested, there were
several different possible reasons for reversal including: the practice was found to be
harmful if it was thought beneficial (19%); the practice was found to be ineffective to the
comparator if it was believed to be effective (46%); the practice was found to be less
effective or equivalent to a comparator if it was believed to be superior (19%); or the
practice was found to be beneficial if it was originally believed to be harmful, noteffective, or inferior to another practice (16%).
Table 5.2 Primary descriptive statistics characterizing evidence reversal
Characteristics of included Randomized Controlled Trials
(n = 611)
Authors declarations regarding the tested practice:
Contradiction (evidence reversal)
Confirmation (evidence reaffirmation)
Trial conclusions regarding primary outcome:
Positive
Negative or no difference
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# of
Observations

331 (54%)
280 (46%)

611

256 (42%)
355 (58%)
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Reason for contradiction of established practice:
Not effective if thought effective
Less effective if thought beneficial
Harmful if thought beneficial
Beneficial if thought harmful/not-effective/inferior

152 (46%)
64 (19%)
63 (19%)
52 (16%)

331

Additional characteristics describing the methodology, findings are described in
Table 5.3. Concerning registration, 89% of trials were registered, and of those, 86% were
accessible and the average duration between trial start and registration was 1.20 years.
Four hundred forty four (73%) trials had a primary outcome that was oriented around
harm and 276 (45%) trials had a primary outcome that was significant with a P-value ≤
0.05. Among included trials: the mean duration of follow up was 115.34 weeks; the mean
percentage of subjects lost to follow up was 7%; the mean sample size was 3305; and, if
provided by the authors, the mean required sample size was 2184.
The majority of trials had a primary outcome that was dichotomous (474 [78%]),
and the results for primary outcomes were presented with a variety of different measures
of effect including: Hazard Ratio (27%), Relative Risk (19%), Absolute Risk (17%),
Odds Ratio (8%), Effect Size / Mean Difference (11%), Relative Risk Reduction (1%),
and 18% where no measure nor magnitude of effect was provided (i.e. Not Applicable).
The primary outcomes of trials were most often (45%) based on hard, patient-important,
response variables – such as all-cause or cause-specific mortality, risk of stroke, or
myocardial infarction – but some studies used composite outcomes (i.e. combinations of
outcomes) (31%) or surrogate outcomes (e.g. physiological measures or laboratory
values) (23%) as their primary outcome. The abstract conclusions of most trials (520
[85%]) were based on the primary outcome, but 232 (38%) abstracts were based on
secondary outcomes and 52 (9%) were based on subgroup analyses. The reason why the
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proportions of abstract conclusions do not sum to 100% is because they are not mutually
exclusive and may have been derived from the primary outcome, and/or the secondary
outcomes, and/or the subgroup analyses.
Table 5.3 Secondary descriptive statistics characterizing included trials
Characteristics of included Randomized Controlled Trials
(n = 611)

# of Trials (%) or
Mean (Std. Err.)

# of
Observations

Trials registered
542 (89%)
611
Protocol / registration accessible
464 (86%)
542
Mean duration between trial start and registration (years)
1.20 (0.13)
412
Trials with an unfavourable primary outcome
443 (73%)
611
Mean duration of follow up (weeks)
115.34 (6.77)
600
Mean sample size
3305 (467.50)
611
Mean required sample size (where provided)
2184 (226.14)
477
Mean loss to follow up as proportion of total sample size
0.07 (0.004)
598
Trials with significant primary outcomes (P ≤ 0.05)
276 (45%)
611
Trials with a primary outcome measure of effect:
HR (Hazard Ratio)
166 (27.2%)
RR (Relative Risk)
115 (18.8%)
AR (Absolute Risk)
103 (16.9%)
ES / MD (Effect Size / Mean Difference)
65 (10.6%)
611
OR (Odds Ratio)
49 (8%)
RRR (Relative Risk Reduction)
5 (0.8%)
NNT / NNH (Number Needed to Treat / Harm)
0 (0%)
N/A (Not Available)
108 (17.7%)
Trials with a dichotomous primary outcome
474 (78%)
611
Trials with a primary outcome that is:
Hard (i.e. clinical / patient-important)
277 (45%)
611
Composite
192 (31%)
Surrogate
142 (23%)
Trials reporting abstract conclusions based on:
Primary outcome *
520 (85%)
611
Secondary outcome *
232 (38%)
Subgroup analyses *
52 (9%)
* Proportions of sources for abstract conclusions do not sum to 100% because abstract conclusions could be
derived from none or all three of the sources

In comparing descriptive statistics between trials that were classified as reversals
versus reaffirmations (APPENDIX H: Table 6), the two are largely comparable. The most
notable difference between the two groups is the proportion of trials having significant
findings with regard to their primary outcomes, which was 58% among trials that
confirmed the tested practice, but only 34% among trials that contradicted the practice.
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The general quality of the trials included in this review was low, as can been seen
in Table 5.4 as the greatest proportions of studies had PICOTS, ROB, and GRADE
designations of ‘Somewhat Insufficient’ (48%), ‘Probably Low Risk of Bias,’ (35%),
and ‘Very Low Quality’ (31%).
Table 5.4 Descriptive statistics for quality assessments of included trials
Quality assessments for included Randomized Controlled
Trials (n = 611)
Trials with overall PICOTS designation:
Sufficient
Somewhat insufficient
Clearly insufficient
Trials with overall ROB designation:
Definitely low risk of bias
Probably low risk of bias
Probably high risk of bias
Definitely high risk of bias
Trials with overall GRADE level of evidence:
High
Moderate
Low
Very low

# of Trials (%)
243 (40%)
294 (48%)
74 (12%)
165 (27%)
212 (35%)
167 (27%)
67 (11%)
124 (20%)
168 (28%)
128 (21%)
191 (31%)

# of
Observations
611

611

611

Figures 5.2, 5.3, and 5.4 depict the distribution of the individual components for
the PICOTS, ROB, and GRADE assessments for the whole sample. The distributions of
overall assessments for PICOTS were: 40% ‘Sufficient,’ 48% ‘Somewhat insufficient,’
and 12% ‘Clearly insufficient.’ The distributions of overall assessments for ROB were:
27% ‘Definitely low,’ 35% ‘Probably low,’ 27% ‘Probably high,’ and 11% ‘Definitely
high.’ The distributions of overall GRADE quality of evidence scores were: 20% ‘High,’
27% ‘Moderate,’ 21% ‘Low,’ and 31% ‘Very low.’
The PICOTS component that contributed the most to decreasing the sufficiency
was the ‘Sample size:’ 42% of trials had either a sample smaller than required by their
reported power calculation or failed to report a required sample size. The ROB
component that contributed the most to increasing the likelihood of bias in a trial was
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‘Other:’ 20% of trials had some element of trial design or conduct that implied a high risk
of

bias

and

was

not

captured

in

the

other

components

(e.g.

industry

design/conduct/analysis, stopping early for statistical reasons, extreme baseline
imbalance, or bias related to the study design/conduct/analysis/reporting). The GRADE
component that contributed most to downgrading of evidence was ‘Directness and
applicability:’ 48% of trials were downgraded by -1 for having overall PICOTS of
‘Somewhat insufficient.’

Figure 5.2 PICOTS components for all 611 included trials
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Figure 5.3 ROB components for all 611 included trials

Figure 5.4 GRADE components for all 611 included trials
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UNIVARIABLE AND OVERALL LOGISTIC REGRESSIONS
The relationship with reversal for each potential predictor was tested twice:

individually and controlling for all others. In the univariable analyses – the results of
which are presented in Table 5.2 – five of the 20 potential predictors were statistically
significant at an alpha level of 0.05, and 11 had p-values less than 0.5, suggesting a
relationship that did not reach significance. Imputing the missing data for four of the
variables that are to be included in the overall model does not change the magnitude, or
the significance, of their relationship with reversal. The beta-coefficients for each
predictor in each of the regression analyses are presented in APPENDIX H. These are
used to calculate the odds ratios of relevant unit differences for continuous covariates.
Table 5.5 Univariable analyses of potential predictors on “reversal vs. reaffirmation”
Covariate

(# trials / 611)

Percent participants lost to follow up (+10%)
Percent participants lost to follow up (imputed) (+10%)
Duration of follow up in weeks (+52)
Duration of follow up in weeks (+52) (imputed)
P-value (+0.10)
P-value (imputed) (+0.10)
Sample size (+100)
Total number of events (+50)
Fragility Index (+5)
Sufficient Adequacy of Power
Standardized effect size (+1)
Standardized effect size (imputed) (+1)
Year of publication (+5)
Years between trial start and trial registration (+5)
Years between trial completion and publication (+5)
Protocol registered
Abstract conclusion based on primary outcome
Abstract conclusion based on subgroup analyses
Abstract conclusion based on secondary outcome
Conflicts of interest
Non-industry vs. Industry
None-reported vs. Industry
Type of outcome
Hard vs. Surrogate
Composite vs. Surrogate
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(598)
(611)
(600)
(611)
(535)
(611)
(611)
(473)
(367)
(611)
(523)
(611)
(611)
(412)
(343)
(611)
(611)
(611)
(611)
(611)

OR

95% CI

P-value

0.83
0.83
0.99
0.99
1.18
1.19
1.00
1.00
1.01
1.04
0.89
0.89
1.06
0.81
1.07
0.96
1.02
0.50
0.85

0.69 to 0.99
0.69 to 0.99
0.94 to 1.04
0.94 to 1.04
1.11 to 1.26
1.12 to 1.26
1.00 to 1.00
1.00 to 1.00
0.93 to 1.09
0.74 to 1.46
0.83 to 0.96
0.83 to 0.96
0.89 to 1.25
0.55 to 1.19
0.57 to 2.02
0.58 to 1.59
0.65 to 1.59
0.28 to 0.89
0.62 to 1.18

0.036
0.036
0.592
0.592
< 0.001
< 0.001
0.771
0.252
0.866
0.826
0.002
0.002
0.521
0.279
0.835
0.874
0.946
0.019
0.342
0.812

1.10
1.26

0.80 to 1.52
0.39 to 4.06

1.49
1.51

0.99 to 2.23
0.98 to 2.34

(611)

0.111
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Overall PICOTS
Sufficient vs. Clearly insufficient
Somewhat insufficient vs. Clearly insufficient
Overall ROB
Definitely low ROB vs. Definitely high ROB
Probably low ROB vs. Definitely high ROB
Probably high ROB vs. Definitely high ROB
Overall GRADE
High vs. Very low
Moderate vs. Very low
Low vs. Very low

96
(611)

0.900
1.03
1.10

0.61 to 1.74
0.66 to 1.84

2.38
1.62
1.44

1.33 to 4.24
0.93 to 2.82
0.82 to 2.56

1.27
1.38
1.22

0.81 to 2.00
0.91 to 2.10
0.78 to 1.91

(611)

0.019

(611)

0.477

The covariates that we investigated were a mix of continuous, binary, and
categorical. Unmodified regression results for continuous covariates are the effect of a 1unit increase, which is not meaningful for some covariates. The effect of continuous
predictors is more appropriately presented as that for a relevant unit increase. The
calculations for these specific unit-difference odds ratios and their respective confidence
intervals can be found in APPENDIX H.
There were two continuous covariates for which the effect was so small that a
relevant unit increase failed to show an effect. For every additional 50 events in a trial,
the odds of reversal, on average, do not change (OR = 1.00, 95% CI: 1.00 to 1.00 [p =
0.252]). Nor do the odds of reversal change with an additional 100 subjects (OR = 1.00,
95% CI: 1.00 to 1.00 [p = 0.771]).
Five of the potential predictors were found to be significantly associated with the
outcome at an alpha of 0.05: overall risk of bias, p-value, proportion lost to follow up,
standardized effect size, and abstract conclusions based on subgroup hypotheses. As the
overall Risk of Bias decreases, the odds of reversal increase with each lower designation:
on average, trials with an overall ROB of ‘definitely low,’ ‘probably low,’ or ‘probably
high,’ had odds of reversal that were respectively 2.38 [95% CI: 1.33 to 4.24], 1.62 [95%
CI: 0.93 to 2.82], and 1.44 [95% CI: 0.82 to 2.56] times the odds of trials with an overall
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ROB that is ‘definitely high’ (p = 0.019). For every increase of 0.1 in the p-value for a
trial’s primary outcome, the odds of reversal increased by 19% (OR = 1.19, 95% CI: 1.12
to 1.26 [p < 0.001]). On average, an increase in the percentage of participants lost to
follow up of 10% decreases the odds of reversal by 17% (OR = 0.83, 95% CI: 0.69 to
0.99 [p = 0.036]). The odds of reversal are on average 11% less (OR = 0.89, 95% CI:
0.83 to 0.96 [p = 0.002]) for every single unit increase in the standardized effect size for a
trial’s primary outcome. And trials with abstract conclusions based on subgroup analyses,
had odds of reversal that were on average 50% less (OR = 0.50, 95% CI: 0.28 to 0.89 [p
= 0.019]) than the odds of reversal compared with trials for which the abstract conclusion
was not based on subgroup analyses.
Four potential predictors had p-values that were less than 0.5 suggesting a
potential relationship that did not reach significance: ‘years between trial start and
registration,’ type of primary outcome, overall GRADE, and abstract conclusion based on
secondary outcomes. We describe the relationships of these covariates with reversal as
“associations,” based on the direction of their Odds Ratios. A 5-year increase in ‘years
between trial start and registration’ was associated with an average decrease the odds of
reversal of 19% (OR = 0.81, 95% CI: 0.55 to 1.19 [p = 0.279]). The type of primary
outcome used for a comparison (p = 0.181) was associated with reversal. On average,
when compared with trials using surrogate outcomes for their primary comparison, the
odds of reversal were 49% (OR = 1.49, 95% CI: 0.95 to 2.34) higher for trials using hard
outcomes and 47% (OR = 1.47, 95% CI: 0.91 to 2.38) higher for trials using composite
outcomes. The overall GRADE quality of evidence (p = 0.477) may be associated with
the outcome, as the odds of reversal, when compared trials of ‘very low quality,’ were
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27% (OR = 1.27, 95% CI: 0.81 to 2.00) higher for ‘high quality’ trials, 38% (OR = 1.38,
95% CI: 0.91 to 2.10) higher for ‘moderate quality’ trials, and 22% (OR = 1.22, 95% CI:
0.78 to 1.91) higher for ‘low quality trials.’ Trials with an abstract conclusion based on
secondary outcomes was, on average, associated with odds of reversal that were 0.85
(95% CI: 0.62 to 1.18 [p = 0.342]) times those of trials with abstract conclusions that
were not based on secondary outcomes.
When assessed on their own, six of the potential predictors did not appear to have
an association with reversal of evidence, having p-values greater than 0.50: ‘years
between trial end and publication,’ duration of follow up, Fragility Index, Adequacy of
Power, year of publication, abstract conclusion based on primary outcome, sources of
potential conflicts of interest, overall PICOTS, and trial registration. We describe the
relationships of these covariates with reversal as “trends,” based on the direction of their
Odds Ratios. On average, a 5-year increase in ‘years between trial end and publication’
trended towards increasing the odds of reversal by 7% (OR = 1.07, 95% CI: 0.57 to 2.02
[p = 0.835]). Every additional 52 weeks of follow up, trended to an average decrease in
the odds of reversal by 1% (OR = 0.99, 95% CI: 0.94 to 1.04 [p = 0.592]). And an
additional 5-unit difference in Fragility Index trended to increase the odds of reversal by
1% on average (OR = 1.01, 95% CI: 0.93 to 1.09 [p = 0.866]). On average, the trend of
trials for which the Adequacy of Power was sufficient had odds of reversal that were 4%
(OR = 1.04, 95% CI: 0.74 to 1.46 [p = 0.826]) higher than trials for which the Adequacy
of Power was insufficient. As compared with trials published any year between 2000 and
2016, trials published an additional 5-years later trended towards reversal, with odds that
were on average 6% greater (OR = 1.06, 95% CI: 0.89 to 1.25 [p = 0.521]) times greater.
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For trials that based their abstract conclusion on primary outcomes, the trend was to
increase the odds of reversal by 2% (OR = 1.02, 95% CI: 0.65 to 1.59 [p = 0.946])
compared with trials that did not. The sources of potential conflicts of interest (p = 0.812)
trended towards influencing reversibility as the odds of reversal for trials with nonindustry funding or no-conflicts reported were respectively 1.10 (95% CI: 0.80 to 1.52)
and 1.26 (95% CI: 0.39 to 4.06) times that of trials with reported industry conflicts. The
overall PICOTS (p = 0.900) had a similar trend as the odds of reversal were 1.03 (95%
CI: 0.61 to 1.74) times higher for trials having ‘sufficient’ PICOTS and 1.10 (95% CI:
0.66 to 1.84) times higher for trials having ‘somewhat insufficient’ PICOTS, compared to
trials with PICOTS designated ‘clearly insufficient.’ And lastly, trial registration, on
average, trended away from reversal, with registered trials having odds of reversal that
were 4% (OR = 0.96, 95% CI: 0.58 to 1.59 [p = 0.874]) less than trials that were not.
Before conducting the overall logistic regression, the correlation of the potential
predictors with each other was checked (APPENDIX H: Table 7). As there were no
highly correlated covariates – the greatest magnitude of correlation was -0.27 between
‘Standardized effect size’ and ‘P-value’ – all pre-specified predictors were included in the
model. Out of the 15 potential predictors, two were significant at an alpha level of 0.05
and six had p-values less than 0.50, suggesting a potential relationship with reversal after
controlling for all other predictors. All regression beta-coefficients for univariable,
overall, and backwards-stepwise logistic analyses can be found in APPENDIX H: Table
8. This provides a direct comparison of the changes in covariate relationships with
reversal across all analyses.
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Table 5.6 Overall multivariable logistic regression (611 trials)
Covariate

OR

95% CI

P-value

Percent participants lost to follow up (imputed) (+10%)
Duration of follow up in weeks (imputed) (+52)
P-value (imputed) (+0.10)
Sample size (+100)
Standardized effect size (imputed) (+1)
Year of publication (+5)
Protocol registered
Abstract conclusion based on primary outcome
Abstract conclusion based on subgroup analyses
Abstract conclusion based on secondary outcome
Conflicts of interest
Non-industry vs. Industry
None-reported vs. Industry
Type of outcome
Hard vs. Surrogate
Composite vs. Surrogate
Overall PICOTS
Sufficient vs. Clearly insufficient
Somewhat insufficient vs. Clearly insufficient
Overall ROB
Definitely low ROB vs. Definitely high ROB
Probably low ROB vs. Definitely high ROB
Probably high ROB vs. Definitely high ROB
Overall GRADE
High vs. Very low
Moderate vs. Very low
Low vs. Very low

0.91
0.99
1.16
1.00
0.93
1.04
0.86
1.14
0.55
0.93

0.75 to 1.09
0.93 to 1.04
1.09 to 1.24
1.00 to 1.00
0.86 to 1.00
0.85 to 1.28
0.47 to 1.56
0.70 to 1.85
0.30 to 1.02
0.66 to 1.32

0.296
0.620
< 0.001
0.803
0.049
0.716
0.616
0.601
0.058
0.696
0.758

0.87
0.98

0.59 to 1.27
0.28 to 3.42

1.47
1.45

0.94 to 2.30
0.90 to 2.35

0.70
0.79

0.33 to 1.48
0.43 to 1.44

2.38
1.62
1.35

1.00 to 5.64
0.75 to 3.49
0.72 to 2.52

0.85
1.00
1.03

0.34 to 2.12
0.49 to 2.04
0.57 to 1.86

0.196
0.640
0.206

0.951

Controlling for all other covariates in the overall model, eight covariates retained
the same relationship as when they were assessed on their own in that their association
with prediction or protection of reversal had similar magnitude and significance. As
compared with trials published any year between 2000 and 2016, trials published five
years later trended to increasing odds of reversal by 4% on average (OR = 1.04, 95% CI:
0.85 to 1.28 [p = 0.716]). As the p-value for the trial’s primary outcome increases by 0.1,
the odds of reversal increase by 16% on average (OR = 1.16, 95% CI: 1.09 to 1.24 [p <
0.001]). A 1-unit increase in standardized effect size for a trial’s primary comparison
decreases the odds of reversal by 7% on average (OR = 0.93, 95% CI: 0.86 to 1.00 [p =
0.049]). Trials for which the abstract conclusion is based on subgroup analyses are
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associated with an odds of reversal that are, on average, 45% lower than trials that do not
(OR = 0.55, 95% CI: 0.30 to 1.02 [p = 0.058]). The type of outcome used for a trial’s
primary comparison (p = 0.196) may be associated with the outcome as the odds of
reversal for trials with hard and composite outcomes were respectively 47% (OR = 1.47,
95% CI: 0.94 to 2.30) and 45% (OR = 1.45, 95% CI: 0.90 to 2.35) greater than for trials
using a surrogate outcome. Controlling for other covariates, an additional 52 weeks of
follow up trended towards decreasing the odds of reversal by 1% on average (OR = 0.99,
95% CI: 0.94 to 1.04 [p = 0.620]). The trend among trials that had an abstract conclusion
based on the primary outcome compared to those that did not, was an average increase in
odds of reversal of 14% (OR = 1.14, 95% CI: 0.70 to 1.85 [p = 0.601]). Sample size
retained a lack of association as an additional 100 subjects neither increased nor
decreased the odds of reversal (OR = 1.00, 95% CI: 1.00 to 1.00 [p = 0.803]).
After adjusting for other covariates, five had relationships in the same direction as
they did on their own, but with different levels of significance. On average, trials with an
overall ROB of ‘definitely low,’ ‘probably low,’ or ‘probably high,’ had odds of reversal
that were respectively 2.38 [95% CI: 1.00 to 5.64], 1.62 [95% CI: 0.75 to 3.49], and 1.35
[95% CI: 0.72 to 2.52] times those of trials with an overall ROB that is ‘definitely high’
(p = 0.206). An additional 10% of participants lost to follow up was associated with a
decrease in odds of reversal by 9% on average (OR = 0.91, 95% CI: 0.75 to 1.09 [p =
0.296]). Trials with registration or protocols, on average, trended towards odds of
reversal that were 24% less than those that did not (OR = 0.86, 95% CI: 0.47 to 1.56 [p =
0.616]). Trials with abstract conclusions based on secondary outcomes, on average,
trended towards odds of reversal that were 7% less than trials for which the abstract
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conclusions were not based on secondary outcomes (OR = 0.93, 95% CI: 0.66 to 1.32 [p
= 0.696]). On average, trials with an overall GRADE quality of evidence rating of ‘high,’
‘moderate,’ or ‘low’ quality trended to having odds of reversal that were respectively
0.85 (95% CI: 0.34 to 2.12), 1.00 (95% CI: 0.49 to 2.04), and 1.03 (95% CI: 0.57 to 1.86)
times those of trials with overall GRADE ratings of ‘very low’ (p = 0.951).
When all potential predictors were included in the overall model, two covariates
changed their apparent relationship with reversal. As compared with trials reporting
industry conflicts of interest, trials that reported ‘non-industry’ or ‘no conflicts’ trended
towards odds of reversal that were on average lower by 13% (OR = 0.87, 95% CI: 0.59 to
1.27) and 2% (OR = 0.98, 95% CI: 0.28 to 3.42) respectively (p = 0.758). Furthermore,
after controlling for all other covariates, the overall PICOTS trended towards decreasing
the odds of reversal: compared with trials that had an overall PICOTS designation of
‘clearly insufficient,’ trials with designations of ‘sufficient’ and ‘somewhat insufficient’
were respectively lower by 30% (OR = 0.70, 95% CI: 0.33 to 1.48) and 21% (OR = 0.79,
95% CI: 0.43 to 1.44) (p = 0.640).
Testing the overall model using the Pearson and Hosmer-Lemeshow Goodnessof-Fit tests produces p-values of 0.210 and 0.824 respectively, suggesting that the model
adequately describes the database. The overall model has 22 degrees of freedom (15
covariates and 611 trials) and consequently 15 cases (i.e. reversals) per degree of
freedom.

5.3

BACKWARDS STEP-WISE MODEL
The overall logistic model was fit using all potential predictors and demonstrated

that some covariates may have a significant effect on whether the results of a trial
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contradict (i.e. reverse) or confirm (i.e. reaffirm) previous beliefs about the tested
practice, while some may have no effect. Backwards-stepwise regression is generally not
recommended for model building, but as these are exploratory analyses with no prior
evidence base from which to construct a model, and with covariates that may have
varying effects on the outcome, the stepwise approach was deemed suitable. All
covariates from the overall model were included at the start and a dropping significance
level of 0.50 was set, based on Harrell’s recommendation.130
Table 5.7 Covariates included in the final model generated by backwards-stepwise
selection
Covariate

OR

95% CI

P-value

Percent participants lost to follow up (imputed) (+10%)
P-value (imputed) (+0.10)
Standardized effect size (imputed) (+1)
Abstract conclusion based on subgroup analyses
Overall PICOTS
Sufficient vs. Clearly insufficient
Somewhat insufficient vs. Clearly insufficient
Overall ROB
Definitely low ROB vs. Definitely high ROB
Probably low ROB vs. Definitely high ROB
Probably high ROB vs. Definitely high ROB

0.88
1.16
0.93
0.53

0.73 to 1.05
1.09 to 1.24
0.87 to 1.00
0.29 to 0.98

0.152
< 0.001
0.054
0.044
0.435

0.69
0.81

0.39 to 1.24
0.47 to 1.41

2.10
1.52
1.36

1.10 to 3.99
0.83 to 2.77
0.74 to 2.48

0.115

The final model produced by the backwards-stepwise selection included six
covariates, all of which had similar relationships to reversal as found in the overall
model. Two of the covariates were associated with increased odds of reversal, while four
decreased the odds of reversal, thereby increasing the odds of reaffirmation.
A 0.10 increase in the p-value of a trial increased the odds of reversal of 16% on
average (OR = 1.16, 95% CI: 1.09 to 1.24 [p < 0.001]). As compared with trials that had
‘definitely high’ overall ROB assessments, trials that had ‘definitely low,’ ‘probably
low,’ or ‘probably high’ overall ROB were associated with increased odds of reversal of
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respectively 110% (OR = 2.10, 95% CI: 1.10 to 3.99), 52% (OR = 1.52, 95% CI: 0.83 to
2.77), and 36% (1.36, 95% CI: 0.74 to 2.48) (p = 0.115).
On average, increasing the percent of participants lost to follow up by 10% was
associated with decreased odds of reversal of 12% (OR = 0.88, 95% CI: 0.73 to 1.05 [p =
0.152]). A 1-unit increase in the standardized effect size for a trial’s primary comparison
was on average associated with a 7% decrease in the odds of reversal (OR = 0.93, 95%
CI: 0.87 to 1.00 [p = 0.054]). Trials for which the abstract conclusions were based on
subgroup analyses had odds of reversal that were 47% less than trials that did not (OR =
0.53, 95% CI: 0.29 to 0.98 [p = 0.044]). And on average, compared with trials for which
the overall PICOTS assessment was ‘clearly insufficient,’ trials that were designated
‘sufficient’ or ‘somewhat insufficient’ were associated with 31% (OR = 0.69, 95% CI:
0.39 to 1.24) and 19% (OR = 0.81, 95% CI: 0.47 to 1.41) reductions in the odds of
reversal (p = 0.435).
Testing the final model produced by the backwards-stepwise regression with
Pearson and Hosmer-Lemeshow Goodness-of-Fit tests produce respective p-values of
0.345 and 0.660, suggesting that the model is adequate to describe the database. The
model generated by backwards-stepwise regression has 9 degrees of freedom (6
covariates and 611 trials) and consequently 36 cases (i.e. reversals) per degree of
freedom.
Figure 5.5 presents the odds ratios for all covariates across all regression analyses
to show their relative magnitude, direction, and significance. The first six characteristics
(overall ROB, overall PICOTS, abstract conclusion based on subgroup hypotheses,
standard effect size, p-value, and proportion of participants lost to follow up) are those
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from the model produced by backwards-stepwise selection and consequently have odds
ratios from all three logistic regressions. The next nine characteristics (overall GRADE,
outcome type, conflicts of interest, abstract conclusion based on secondary outcome,
abstract conclusion based on primary outcome, protocol registered, year of publication,
sample size, and duration of follow up) were excluded in the backwards-stepwise
selection, but were included in the overall model and consequently have odds ratios from
the univariable and multivariable logistic regressions. The last five characteristics (years
between trial start and registration, years between trial end and publication, total number
of events, Adequacy of Power, and Fragility Index) were those assessed only in
univariable analyses and consequently only have a single odds ratio. Statistical
significance (p ≤ 0.05) of the odds ratios for each characteristic is noted on the graph as
follows: * = univariable analysis, ** = multivariable analysis, *** = backwards-stepwise
analysis.
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Logistic Regression Odds Ratios (Univariable, Multivariable, Backwards-Stepwise)
Backwards OR

Multivariable OR

Univariable OR

Overall ROB (probably high vs. definitely high) *

Overall ROB (probably low vs. definitely high) *

Overall ROB (definitely low vs. definitely high) *

Overall PICOTS (somewhat insufficient vs. clearly insufficient)

Overall PICOTS (sufficient vs. clearly insufficient)

Abs. conclusion based on subgroup analyses * ***

Standardized effect size (+1) * **

P-value (+0.1) * ** ***
% subjects lost to follow up (+10%) *

Trial characteristics assessed with logistic regression on Reversal vs. Reaffirmation

Overall GRADE (low vs. very low)

Overall GRADE (moderate vs. very low)

Overall GRADE (high vs. very low)

Type of outcome (composite vs. surrogate)

Type of outcome (hard vs. surrogate)

Conflicts of interest (none declared vs. industry)

Conflicts of interest (non-industry vs. industry)

Abs. conclusion based on secondary

Abs. conclusion based on primary

Protocol registered

Year of pub (+5)

Sample size (+100)

Duration of follow up (+52)

Years between trial end and publication (+5)

Years between trial start and registration (+5)

Total number of events (+50)

Sufficient adequacy of power

Fragilty index (+5)
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Odds Ratios and 95% Confidence Intervals (OR > 1 favours "reversal;" OR < 1 favours "reaffirmation")

Figure 5.5 Odds Ratios of covariates across all logistic regression analyses
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CHAPTER 6

A framework of reversibility
Discussion of findings and limitations

Riaz Qureshi

Chapter Summary: This chapter presents a discussion of the results of our exploratory
analyses of the characteristics of reversal. A comparison is first made between
our reproduction of ‘A decade of reversal,’ followed by a detailed discussion
of the results from the logistic regressions – both expected and unexpected –
and how the relationships influence the development of a framework of
reversibility. The limitations of the study design and methods are presented at
the end of this chapter.
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CHAPTER 6
6.0

COMPARISON TO ‘A DECADE OF REVERSAL’
‘A decade of reversal’ by Prasad et al. was the first major step towards

understanding the phenomenon of evidence reversal. Their analyses provided
rudimentary explorations of the characteristics of the phenomenon that prepared the field
for more advanced study.
The trial conclusions regarding their primary outcome were based on the results,
discussion, and conclusions, and incorporated statistical significance, direction of effect,
and the manner in which authors described their findings. Thus, trials with statistically
significant effects in favour of the intervention or in line with the hypotheses or primary
question were deemed positive, trials that found statistically significant evidence contrary
to their hypotheses or against their intervention were deemed negative, and trials that did
not find a significant effect favouring either comparator were designated as showing no
difference. We found that 42% of trials had positive conclusions, whereas 58% had
conclusions that were negative or showed no difference between comparators. Prasad et
al. found proportions of 38% and 62% respectively for trials that found the practice
beneficial and trials that were inconclusive or found the intervention to be no better or
worse than the comparator.4
With regard to the determination of trial results that contradict or confirm the use
of an established standard and the consequent declaration of reversal or reaffirmation, our
study showed that 54% of RCTs that tested an established medical practice represented
reversal, and 46% represented reaffirmation. Prasad et al. concluded that 40% of studies
that tested an existing practice ended in reversal, 38% in reaffirmation, and 22% were
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inconclusive. This difference between our reproduction and the original likely arose
because we reached a decision on all trials to force a binary outcome, whereas Prasad et
al. deemed 22% of trials to be inconclusive.

6.1

INTERPRETATION OF REGRESSION RESULTS
In this thesis, we have performed a comprehensive analysis that is the first of its

kind in the field of reversals and deepens the understanding of the phenomenon of
reversal within high-quality medical literature. This thesis is the first exploration of
characteristics that may be associated with reversal of established practices and as such,
we have no literature upon which to base the accuracy, nor credibility of our findings.
However, we know that reversals require high-quality evidence as the nature of reversal
is contradicting what was previously believed, based on lower quality evidence.1,2
Consideration of this is what led to the development of Sutton and Martin’s Framework
of Reversibility and the rationale for investigating our potential predictors.45
The Framework of Reversibility included nine characteristics of studies to
consider in assessing a study’s conclusions with regard to their primary comparison:
PICOTS, ROB, modified GRADE, modified optimum information size, fragility index,
years between trial start and registration, years between trial completion and publication,
whether abstract conclusions were based on secondary outcomes, and whether abstract
conclusions were based on subgroup analyses.45 In seeking to inform the development of
this framework, we assessed these characteristics and 12 others, including: proportion of
participants lost to follow up, duration of follow up, p-value for primary outcome, sample
size, total number of events, standardized effect size, year of publication, registration of
the trial or a protocol, whether abstract conclusions were based on the primary outcome,
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potential sources of conflicts of interest, and the type of outcome used for primary
comparison of intervention and control groups.
The overall amount of missing data among the potential predictors was low as can
be seen in Table 5.3 (Chapter 5) and the mean imputation of missing values did not affect
the covariate’s relationship to reversal in univariable analyses. As the imputation did not
statistically change the relationships of variables with missing data, the imputed data
were used in the overall model to allow the use of all observations in the database.
In describing the relationships that we found, we are aware that the majority were
non-significant and the strength and validity of the relationships may be questioned as a
consequence. In exploring these characteristics and their influence on finding
contradictory evidence for established practices, we are aware of the low power that we
have with regards to conclusions and make no claims as to declaring definitive results.
Our aims were exploratory and we have been consistent in expressing the relationships
that we have found as presented (i.e. significant associations, non-significant
associations, or highly non-significant trends), based on the magnitude and directions of
the odds ratios.
Among all of the characteristics that we investigated as potential predictors of
reversal or reaffirmation, most of the relationships were as expected with a few surprising
results. The expected relationships coincided with our rationale for exploring them and
how we thought they might influence the likelihood of a trial reversing the established
practices being tested. Some relationships were unexpected by having no impact on
reversal, having an influence in the opposite direction as expected, or changing their
direction of influence after controlling for other covariates. However, in controlling for
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multiple covariates, we have reduced power and expect unstable estimates around the null
hypothesis, which is what we see in several categorical covariates.
6.1.1

Expected relationships

The relationships that were expected included characteristics from the
methodology, results, and quality of the trials. In univariable and overall analyses, trials
that used hard or composite outcomes were more likely to find contradictory results than
trials using surrogate outcomes. Although non-significant, the trend conforms to the
expectation that using outcomes that are non-subjective is important when seeking the
true effect of an intervention, as opposed to outcomes that may confirm a
pathophysiological pathway, but fail to influence an aspect of health that is tangible to the
patient.
We did not expect the year of publication to have an influence on reversal as there
was no association found in ‘A decade of reversal.’ During a trial’s conduct, greater
proportions of participants lost to follow up lowered the odds of the trial finding a
contradictory result (significantly when assessed alone and non-significantly in
multivariable analyses), which is directly related to the study quality and confidence that
is held in the findings. When trials have a high degree of loss to follow up, it can be
difficult to differentiate between a true effect and one that is an artefact of the data that
remains. Similarly, having a high value for Fragility Index and sufficient Adequacy of
Power – respectively symbolizing results that are non-fragile and appropriately powered
to make conclusions – are other markers for confidence in a trial’s results and both
characteristics trended towards increasing the likelihood of reversal. However, the
relationships of Fragility Index and Adequacy of Power were only assessed in univariable
analyses: Fragility Index due to a high degree of missing data and inability to impute the
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missing data, and the Adequacy of Power because it was an experimental indicator that
we developed. Further, as they were both highly non-significant with p-values of 0.866
and 0.826 for FI and sufficient AP respectively, we cannot draw conclusions as to their
effect on a trial’s reversibility.
The results of the primary comparison made in a trial also directly influenced the
odds of reversal. We found the greater the p-value and the smaller the standardized effect
size for a difference between comparators, the greater the odds that a trial would
contradict what was previously believed about the established practice being tested. Both
of these relationships were significant in all analyses and were expected, as a common
trend of many reversals is high quality trials failing to replicate the results of lowerquality studies that may have found large and significant effects. These relationships
with reversal have also been explored by Ioannidis as The Proteus Phenomenon:
describing when early extreme results are later contradicted when attempts to replicate
findings are made.54,56 It is an established publication bias that extreme results are more
likely to be published than non-significant or modest effects, which may consequently
lead to early studies of practices presenting findings that are disproportionate or
exaggerated from the true effect.54
Interestingly, in our exploration of descriptive statistics we classified the reasons
for reversal and while the most common reasons fit the trend shown in the data (i.e.
finding a practice ‘not effective if thought to be’ (46%) or ‘less effective if thought
beneficial/superior’ (19%)), there were two others: the finding of practices to be ‘harmful
if thought beneficial’ (19%) or ‘beneficial if thought harmful/not-effective/inferior
(16%).’ This last reason for reversal is particularly interesting as it demonstrates the
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complexity of the phenomenon and necessitates a change in the way people think of
reversal. Evidence reversal does not only occur when new evidence shows a currently
used practice does not work; rather, it occurs when the current belief about a practice is
contradicted. Thus, a practice that is not recommended, or is recommended against, may
be reversed if it is found to have a positive effect when tested, leading to its
recommendation.
Many of the characteristics that we assessed were related to the quality of trials
and most had the expected effect on reversal. A greater number of years between a trial’s
start and registration was associated with increased odds of reaffirmation. This direction
of this relationship was expected as an indicator of publication biases since trials that are
higher quality would be expected to have a shorter duration, with negative values
indicating pre-registration and positive values indicating retroactive registration. The
various sources of abstract conclusions were consistent as checks of reporting bias as
trials that reported their primary outcome in the abstract trended towards being reversals,
and trials for which the reported conclusions were based on subgroup analyses or
secondary outcomes were associated with increased odds of reaffirmation. The size of
these associations became stronger when controlling for all covariates in the overall
analyses.
The relationship of the overall Risk of Bias with reversal was expected as each
increasing quality level (i.e. decreasing risk of bias) had a greater effect on the odds of
reversal when compared to trials with the greatest risk of bias. This monotonic
relationship is significant in two regards. First, when assessed on its own, the overall
categorical predictor was significantly associated with reversal. Although this statistical
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significance disappeared when controlling for other covariates, the strength of all
categorical associations was expected to decrease in multivariable analyses because of the
reduced number of cases in each category upon which to base an estimate of effect.
Second, the monotonic relationship remained throughout all analyses and, despite a loss
of statistical significance, retained a similar magnitude of effect. Due to the statistical
non-significance of this covariate in the overall analyses, we did not conduct a
multivariable regression on the individual components of the measure. However, the
apparent relationship indicates that investigating the elements of this measure in future
study would be warranted and may provide insight into future applications of this
assessment.
6.1.2

Unexpected relationships

While most of the relationships between trial characteristics and reversal were
expected, there were some characteristics which had unexpected relationships in that they
were associated with the alternative outcome than we rationalized, or their association
changed direction after controlling for the effects of other characteristics.
The association of trial registration and/or use of a protocol with a greater
likelihood of reaffirmation and a greater number of years between trial completion and
publication with reversal were both unexpected as we believed registration and fewer
years between end and publication to be integral to low risk of reporting bias.
Furthermore, the relationships of other characteristics that were related to reporting and
publication biases (i.e. duration between start and registration, and the sources of abstract
conclusions) were as expected. The effect of registration that we found could be due to
the fact that the majority of trials published before 2006 were not registered because it
was not yet a standard requirement of clinical trials. Consequently, the proportion of
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reversals and reaffirmations that would have been registered may be skewed and the true
effect obfuscated. However, by including the year of publication in the overall analyses,
the effect of changing requirements over time should have been accounted for, yet in the
overall analyses the strength of the relationship grows (albeit remaining a non-significant
trend) instead of diminishing or reversing. Similarly, the duration between trial end and
publication was only available for some trials that were registered and consequently had a
high proportion of missing data (44%).
We believed that a greater duration of follow up would be associated with a
greater likelihood of reversal as most interventions require a long period of follow up to
determine their true effect. However, we found that the greater the duration of follow up,
the odds trended towards reaffirmation – though this effect was small and nonsignificant: an increase in follow up of 52 weeks increased the odds of reaffirmation by
1% in both the univariable and overall analyses. Also unexpected, for the same reasons,
were the effects of sample size and total number of events. For each additional 100
subjects or 50 events in a trial, there were no trends in changing in the odds of reversal
(OR = 1.00). Both of these characteristics are classically portrayed as being paramount to
quality trials as they decrease the variability in average outcomes and present more
accurate portrayals of interventions effects. It is possible that no association was found
for these characteristics due to the population from which they came. In looking at the
difference in mean duration of follow up and sample size among reversals and
reaffirmations (APPENDIX H: Table 6), reaffirmations are 7.28 weeks longer and
reversals are 273 subjects larger, which may not be a large enough to establish an effect
on the outcome. It is possible that this similarity could derive from publication in a high-
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quality medical journal, which may accept trials that are of similar size and conduct,
thereby rendering some characteristics uniform across all trials, regardless of results and
conclusions.
Among the unexpected results were three potential predictors that exhibited the
expected relationships when analyzed on their own (increasing the odds of reversal), but
changed to increase the odds of reaffirmation when controlling for other covariates in the
overall analyses. These included: potential conflicts of interest, the overall PICOTS
assessment, and the overall GRADE quality of evidence.
While none of the above characteristics were significantly associated with
reversal or reaffirmation in any of the analyses, they all trended towards increasing the
odds of reversal on their own, and increasing the odds of reaffirmation when adjusting for
all covariates. While the change in direction of these relationships in the multivariable
analyses was interesting, it was unsurprising as they are all categorical covariates and we
expected low power and unstable estimates around the null for these covariates when
controlling for other predictors, as the numbers of trials in each category upon which to
base an estimate are reduced. We expected the declaration of potential conflicts of
interest as ‘industry’ would lead to greater odds of reaffirmation compared with ‘nonindustry’ or ‘none to declare/reported,’ which is the trend we saw when analyzed as a
single predictor. We did not expect a monotonic relationship in this covariate as the
categories were nominal, not ordinal. It is likely that the change in effect was due to the
instability of estimates around the mean, but it is also possible that there may be other
characteristics that are influenced by the presence of conflicts of interest (e.g. sources of
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abstract conclusions, type of outcome used, standardized effect size, or overall PICOTS
or ROB) that consequently confound the effect in multivariable analyses.
The overall PICOTS and GRADE assessments are multidimensional summary
scores for trials that each account for several elements of a trial’s design and conduct.
Consequently, while higher quality levels of both, on their own, are associated with
increasing the odds of reversal, it is possible that when controlling for all other covariates
– some of which may influence the components that make up the summary scores – the
expected effect is lost. Furthermore, neither summary score had a consistent monotonic
relationship with reversal as found with the Risk of Bias assessment. In univariable
analyses, the highest quality PICOTS and GRADE assessment both trended towards
increasing the odds of reversal to a lesser degree than assessments of moderate quality.
While the non-significance of these trends is important in knowing the limitations for
how we draw conclusions regarding the effects of covariates, the fact that we did not find
a clear effect for GRADE in even the univariable analysis is interesting. Since we
modified GRADE for application with a single trial – from its validated use in assessing
aggregate evidence – its relationship to contradictory results may be less appropriate than
that of a measure designed for a single trial (such as ROB). However, as GRADE is
considered to be the gold-standard for assessment of evidence, the lack of an apparent
relationship with reversal demonstrates a need for further exploration on more
appropriate and larger datasets.

6.2

UPDATING THE FRAMEWORK OF REVERSIBILITY
The framework developed by Sutton and Martin, based on assumptions about the

nature of trials that lead to reversal, was comprised of eight components: PICOTS, ROB,
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and modified GRADE assessments, modified optimum information size, fragility index,
duration from trial start to registration and from completion to publication, and abstract
conclusions.45
In extracting these characteristics for testing, the optimum information size was
amended to Adequacy of Power. The difference being that optimum information size is a
concept from meta-analyses that was difficult to apply to individual trials – in essence: a
means of assessing whether or not a meta-analytic database had sufficient power, based
on the assumption that the overall sample size was equivalent to a trial of the same size –
but the Adequacy of Power was more applicable to single trials and derived more simply
from whether the trial met its pre-specified sample size and whether the confidence limits
of the effect met the trial’s pre-specified delta.
From our univariable analyses, the fragility index, sufficient Adequacy of Power,
and duration from trial completion to publication do not appear to influence the
likelihood of reversal in a meaningful way, so we can remove these from the framework.
While a measure of the fragility of a trial’s findings is an interesting concept, and
deserves further study on its own, it may not contribute meaningfully to our framework
of reversibility given its overlap with other concepts inherent to the framework.
Additionally, providing context for the FI (e.g. as a percent of loss to follow up or the
sample size), could increase the meaningfulness of this measure.
The overall GRADE assessment was highly non-significant and did not
demonstrate a coherent relationship with reversal across the analyses. For this reason, we
also remove the modified GRADE assessment from our framework.
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Both the overall ROB and PICOTS assessments were demonstrably associated
with reversal and reaffirmation respectively, such that they were included in the final
model created by the backwards-stepwise regression. It is possible that these two
characteristics – themselves being two of the components that contributed to the final
GRADE score – are sufficient measures of study quality and bias and that GRADE is not
additionally needed in considering the likelihood of reversibility. As such, both of these
summary scores remain in our framework.
The years from trial start to registration was only assessed in univariable analyses
but was found to have a potential association with reaffirmation as the p-value was 0.279
and the corresponding OR for reversal was 0.81 for an increase of five-years. While nonsignificant, the trend is expected and Harrell suggests that a model built on theory is more
purposeful than one based solely on the data and that the exclusion of all non-significant
predictors is often inappropriate.130 As such, this covariate remains in our framework.
Similar justification applies to the retention of the sources of abstract conclusions
from the original framework to the updated. Although only one source (subgroup
analyses) had a significant relationship with whether or not the trial found contradictory
evidence, the other two (primary or secondary outcomes) trended towards the outcome
that we expected when controlling for other covariates to a greater degree than when they
were assessed on their own, and together they provide a complete picture of the source of
a trial’s abstract conclusion.
After conducting our exploratory analyses of trial characteristics, we found
several covariates that are strongly associated with reversal or reaffirmation of
established practices and we are consequently adding them to the framework. The
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relationships of the p-value and standardized effect size for a trial’s primary comparison
were both significant in univariable and multivariable analyses. The larger the effect
found by a trial, and the more significant the result, the more likely that trial was to
confirm an established practice. The same association with reaffirmation was found for
increased proportions of subjects lost to follow up. Although it was only significantly
associated when it was assessed on its own, it was one of the final covariates included in
the model created by the backwards stepwise regression. The final characteristic that we
explored and are adding to the updated framework is the type of outcome used for a
trial’s primary comparison. This covariate was not statistically significant in either the
univariable or the multivariable regressions, but the association with reversal remained
almost unchanged both in magnitude and significance between its baseline effect and
after controlling for other covariates. Furthermore, this is one of the only predictors for
which an evidence base existed to support its association with evidence reversal as it is
known that surrogate outcomes do not necessarily correlate with patient important
outcomes. Because of this, trials that test established practices with hard and definitive
outcomes may contradict what was believed about practices that were prematurely
adopted based on results from studies using surrogate outcomes.
Our updated, proposed framework of reversibility is presented in Table 6.1 and
includes eight components that are supported by our results as being associated with the
outcome of contradictory results among randomized controlled trials that test established
medical practices. These components can separately be placed into five of the domains of
a randomized controlled trial: design, conduct, results, quality, and reporting.
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Table 6.1 Updated proposed framework of reversibility
Component

Purpose in the Framework

Overall PICOTS

Multidimensional summary score of the appropriateness of a trial’s question
and design

Overall ROB

Multidimensional summary score of a trial’s quality

Years between trial start
and registration

Measure of reporting bias as trials should be registered before they begin (i.e.
have negative values)

Sources of abstract
conclusions

Measure of reporting bias as trials should base abstract conclusions on
primary outcome, not secondary outcome or subgroup hypotheses

P-value

Measure of significance of a trial’s findings for primary comparison

Standardized effect size

Measure of the magnitude of effect for primary comparison

Proportion of subjects
lost to follow up

Indicator for the confidence that can be held in a trial’s results

Type of outcome

Indication of the use of an appropriate outcome for finding the clinical effect
of intervention

6.3

STRENGTHS AND LIMITATIONS
There are many strengths in our study design and conduct, the most prominent

being that this is the first quantitative assessment of study design elements and their
relation to evidence reversal in this newly emerging field of meta-research. This study is
also the largest and most comprehensive examination of the phenomenon to date. The
similarity of results that we found in the reproduction of ‘A decade of reversal’ is another
strength that lends validity to our methods. The thoroughness and care that was taken in
ensuring accurate and consistent data extraction is a major strength of our study.
Similarly, our high degree of transparency is a major strength as we have provided all
methods used for data extraction with the intention of increasing the reproducibility of
our findings for future researchers. However, there are still limitations in the design and
conduct of our study. The limitations that could be addressed were, to the best of our
ability, but there were still some that could not be addressed because of time constraints,
a lack of resources, or necessitated assumptions based on practicality and feasibility.
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Limitations in the creation of the database of reversals

A critical limitation is the use of a single journal (NEJM) as a source of trials and
potential reversals. An ideal search would have collected RCTs from several
different journals or databases. However, given the aims of this study and limited
resources for conducting the study, a single-journal was deemed most feasible and
appropriate. It does however limit the generalizability of our findings to other
medical literature where the majority of studies are published, and upon which
many health-care decisions are made.

•

The lack of time and resources led to several other limitations including the first
two levels of screening and the data extraction not being done in duplicate. It also
contributed to a difficulty in reaching decisions with regard to the established use
of practices, as the reviewers do not have clinical experience and did not have the
time to conduct literature searches to verify the existence or novelty of every
practice. While a decision was reached for each trial’s intervention being new or
existing, and with regards to the outcome being reversal or reaffirmation of
evidence, the decision was not always clear. Despite the discussion of
discrepancies and reaching agreement as to what was believed to be the correct
designation, some readers may disagree with how articles were categorized. We
tried to be as objective as possible in our determination and to guide the decisions
by what was provided by the publication authors. Thus, despite this limitation, we
are confident in our results and feel that a few disagreements from other metaresearchers would not likely change our conclusions.
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Another limitation that is related to our objective judgment of articles is the
extraction and assessment of PICOTS and ROB. We attempted to prevent
potential bias and ensure uniformity across extractions in two ways: firstly, by
extracting a test-set of trials in duplicate and comparing extraction to verify the
similarity of results; and secondly, by having a protocol with clearly defined
guidelines for how to extract all elements in the database. However, these
measures are subjective and even trained assessors may apply different ratings of
overall sufficiency and likelihood of risk of bias.

•

This same limitation also applies to GRADE because even though the rating
consistency was mediated slightly by the automatic completion of components
based on other extracted characteristics, the automatic completion of its individual
domains were taken from other subjective characteristics (i.e. overall PICOTS,
overall ROB, ROB for selective outcome reporting, and the adequacy of power.).

•

A further limitation of the GRADE assessment was that it was incomplete. We
used a modified GRADE that did not include the domain of inconsistency because
it would not have been feasible to examine the relevant literature for each
intervention to assess inconsistency of results within that field, nor appropriate to
compare the inconsistency of results across the many different types of
interventions that we included in our review. The GRADE component for
publication bias was also modified to be determined by the likelihood of selective
outcome reporting because we did not have time to explore the relevant literature
for each trial’s comparators.
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A less consequential limitation of our study conduct was the use of an Excel file
for our screening and the creation of our database. As a general rule for any study
involving large amounts of data collection, this practice should be avoided
because of the potential for transposition errors and incorrectly encoding
automatic columns. However, the ease of use, availability and access to the
program, and versatility for analyses across multiple types of quantitative and
qualitative information made it ideal for this project.
6.3.2

•

Limitations of statistical analyses

A major limitation of our analysis is the designation of reversal or reaffirmation of
evidence based on the author’s declaration and description of how their findings
align with current beliefs about the practice (i.e. whether their findings are
incongruent or congruent with practitioners’ use). Ideally, cumulative metaanalyses or a similar measure of sufficiency and stability of the evidence for a
practice would be used to indicate reversal or reaffirmation. As currently
designated, these author’s conclusions may yet again be contradicted with time
and we do not know how the practices and standards have changed since the trials
that we have used were published. However, populating our database with RCTs
and not meta-analyses or other standards for decision-making is another
consequential limitation. Prasad et al. examined all original studies and so we too
looked at original studies, but chose to examine RCTs because they are the gold
standard for investigating the effects of interventions and should provide a higher
level of evidence for decision-making than other original research designs.
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Another limitation related to the outcome used in our regression is that all
reversals, partial and full, were categorized the same. It would have added an
extra layer of complexity that would have made the project infeasible to try and
distinguish between complete reversals (e.g. findings that indicate direct harm and
a recommendation for immediate cessation of use) and partial reversals (e.g.
findings that a practice does not work as well as was believed, but it still has use
and a recommendation for further study). Similarly, when a trial tested two
established practices where there was no consensus about which is better (as was
often the case), and one was found to be superior, then it was classified as a
reversal because it contradicted the belief that they were equal, even though in
doing so they also confirmed the use of the superior practice.

•

This difficulty in classifying reversals and reaffirmations of evidence introduces a
further limitation by necessitating an assumption for our logistic regressions:
namely that the outcome follows a binary distribution. We reached a decision on
all included trials, but Prasad et al. deemed 22% of studies that test established
practices to be inconclusive – neither reversing, nor reaffirming a practice. While
the differentiation between reversal and reaffirmation of evidence is not black and
white, we consider the assumption valid for the purposes of exploring the
phenomenon of reversals given that most of the decisions for reversals will never
be without some uncertainty, and most of the decisions could be adequately
inferred from the original studies’ details.

•

Within the analyses – both descriptive and regression – there are also several
other assumptions that are limiting but were necessary to allow the analyses to
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occur. The most prominent of these is that any error in data extraction is random
and not systematically biased. It was assumed that the judgments made by data
extractors (RQ and DS) were comparable with respect to PICOTS, ROB, and
consequently GRADE. As explained in section 6.3.1, we attempted to mitigate
differences in extraction by comparing responses across a random test-set of
articles before completing the extraction and by using a pre-specified protocol
(APPENDIX E) to guide the extraction.
•

Another important limitation in the analysis and extraction arose from the
inclusion of trials with multiple interventions including multi-arm studies and
factorial designs. Within our study sample, there were 98 trials with these designs,
comparing multiple practices against each other and control groups. For these
trials, we extracted only a single intervention and control group for our summary
of study results. This simplifying assumption was necessary for project feasibility
as extraction of every pair of comparisons from the multi-arm and factorial trials
would have increased the number of “trials” to unmanageable levels. The decision
to include only a single comparison from each trial publication also acts to
simplify the analysis as the number of “subjects” that are related is greatly
diminished and the independence of our observations can be assumed.

•

An assumption made in the overall logistic regression analyses included that all
measures of effect were directly comparable through the use of a standardized
effect size. Not all event data is directly comparable when accounting for the
primary question (e.g. if a trial intended to find an intervention’s effect on timeto-event, then comparing the overall event rates between groups may not be a
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valid indicator of the effect in question). Despite this limitation, an assumption
was made that comparability through the use of a standardized effect size – based
on the Absolute Risk Difference for dichotomous outcomes, calculated using raw
data, and based on the mean difference for continuous outcomes – would be
appropriate to convey the relative magnitude and direction of effect, seen across
all trials.
•

Calculating the Fragility Index for all trials with dichotomous outcomes that
compared two interventions in 1:1 allocation involved an assumption that all
dichotomous event data were comparable, as it is calculated using the numbers of
events and subjects in each group. This is a limitation as the applicability of the
Fragility Index to hazard data and trials with long periods of follow-up has been
questioned due to the tendency of both types of trials to reach similar overall
event rates in groups with increasing time.

•

Another assumption of the regression analyses was the interpretation of “Not
Available” as missing data for covariates, and that the overall amount missing
does not affect the outcome of the analyses. As a result of this interpretation, the
amount missing for some covariates was exaggerated. ‘N/A’ was used in the
database for information that could not be found within a trial (e.g. some trials did
not report a p-value for their primary outcome), and it was also used to denote
when a response was not possible for a particular covariate (e.g. the Fragility
Index cannot be calculated for trials that have continuous outcomes, compare
more than two interventions, or have allocation ratios other than 1:1).
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A major limitation with our analyses lies in our choice of backwards-stepwise
model selection for our exploration of characteristics that may be associated with
reversal. Stepwise model selection procedures are generally not recommended for
building predictive models because they are unreliable in the presence of
collinearity, lead to high-biased R2 values, generate standard errors for the
parameter estimates that are too small and consequently parameter confidence
intervals that are too narrow, create parameter estimates that are biased high in
absolute value, and generate p-values that are biased low.130 Stepwise selection
procedures can be appropriate for exploratory analyses when there is no prior
information to guide variable selection. However, while traditional significance
criteria for exclusion from a model tend to be stringent (e.g. α = 0.05 or 0.10), an
alpha of 0.5 is more reasonable in allowing for the deletion of some variables that
may be irrelevant to the outcome, but the retention of most variables that may
help to predict the outcome, despite insignificance.130 Given that our purposes
were exploratory and there is no literature to guide variable pre-specification in
relation to reversal, we believe a backwards-stepwise model selection to be
appropriate for informing the development of our framework of reversibility.

•

A final limitation in our interpretation of results is the reporting of relationships
on the basis of the directionality and magnitude of covariate odds ratios. We are
aware that the majority of potential predictors were not statistically significantly
associated with our outcome, but as these analyses were exploratory, we felt that
it was best to describe and interpret the relationships that we found in terms of
whether they trended towards influencing the outcome in the way that we
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expected, whether or not they were significant. In doing so, we referred to
covariates that were highly non-significant (p > 0.5) as trending relationships,
covariates that were moderately non-significant (0.5 > p > 0.05) as associated, and
covariates that were significantly associated as such. This is a limitation in that we
make no claims to these covariates being definitive predictors of contradictory
findings for established practices, but we present the magnitude and degree of
associations as we found them and make recommendations for which
relationships we believe further study or consideration in use is warranted.
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CHAPTER 7

The future of reversibility research
Impact, Applications, Future Directions, and Conclusions

Riaz Qureshi

Chapter Summary: This chapter presents further discussion of the overall results of this
study, particularly with regards to the impact and applications of this research
and the future directions that should be explored in the field of reversals. The
chapter ends by presenting an overall summary of the thesis and its
conclusions.

Riaz Qureshi

131

CHAPTER 7
7.0

IMPACT AND IMPORTANCE
Our framework of reversibility consists of eight components of randomized

controlled trials that have relationships with the likelihood of reversal and cover multiple
domains from design to reporting. The development of a framework of characteristics
that should be considered in assessing trials that contradict current standards and
established practices has important implications for the field of reversals and to our
knowledge has not previously been attempted. Not only is this the largest review of the
phenomenon of reversal – updating the previous largest review with an additional seven
years of studies – but also significantly expands analyses of associations between study
variables and reversal. This is the most comprehensive, and the first quantitative,
exploration of trial characteristics that may lead to evidence reversal. This framework can
serve as a tool to be used by researchers and health policy-makers in guiding the
decisions around adoption, de-adoption, and dis-investment of practices.

7.1

APPLICATIONS OF THE FRAMEWORK
The responsibility of identifying evidence reversals lies primarily with the

researchers and developers of interventions and standards, and also with agencies that
grant approval for research and implementation.2,26,36 In knowing where the burden of
proof lies, consideration must be given to the methods and tools that are currently
employed for identifying and reducing the impact of evidence reversals and medical
reversals. While standards of practice exist in all scientific disciplines, and new findings
always require dissemination before they can be implemented, there currently exist
several methods by which the effect of reversals are mitigated and which may benefit
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from incorporating our framework of reversibility. These are clinical guidelines,
knowledge translation, and various other tools for de-implementation of practices.
7.1.1

Clinical guidelines

Evidence Based Medicine is a common goal for decision-makers in literature, yet
practice does not always follow the best available evidence. Physicians report that the
proportion of their practices that are evidence based are as low as 50% of their
practices.141 This proportion is unsurprising given the overwhelming amount of literature
available to physicians and the difficulty that exists in finding clinically important
literature that is relevant to practice and has enough evidence to inform a decision.142 A
major systematic review of the publication of clinically important and relevant articles in
primary healthcare journals suggests that clinicians would need to read an average of 1314 articles to obtain one that is directly clinically relevant.143
As a consequence of this information overload, many clinicians rely on clinical
guidelines in medical practice.141 However, the quality of clinical guidelines varies
significantly based on the methods and processes used to select and apply evidence to
guide recommendations. As a result, the benefit of clinical guidelines is somewhat
contested and they are not guaranteed to reduce the impact of medical reversals.144
Despite their necessity for efficient and consistent practice, there remain several inherent
difficulties in generation and dissemination of effective and unbiased guidelines.144 These
challenges may be especially powerful barriers against effectively mitigating the impact
of evidence reversals.
The first difficulty in establishing a clinical guideline is creating an impartial team
where there is no conflict of interest. A survey from 2012 found that 71% of chairs of
clinical policy committees and 90.5% of co-chairs had financial conflicts of interest and
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that these conflicts could have a substantial effect on the conclusions and
recommendations of the guideline.145
The second major difficulty with guideline creation is missing data as a direct
result of poor knowledge translation practices (i.e. publication bias) and proprietary rights
of those who own data.38,146 One of the outcomes of poor knowledge translation that
contributes to the difficulty in establishing clinical guidelines is a general lack of
confidence in conclusions of efficacy.147 An evaluation of the quality and sufficiency of
evidence for clinical practices by The Cochrane Collaboration in 2011 found that as many
as 45% of Cochrane reviews conclude that there is insufficient evidence to endorse the
intervention.147 Due to insufficiency of evidence, an analysis of clinical care in Australia
found that patients only received appropriate care (i.e. based on expert recommendations
and clinical guidelines) between 54% and 57% of the time.148 Increasing the amount of
open data and transparency in research findings would be the first step to improving
clinical guideline development and reducing unnecessary medical reversals.38,149
Beyond the difficulties associated with conflicts of interest and knowledge
translation, clinical guidelines are also controversial because they can become out of date
very quickly, they often require incredible resources to assimilate all the relevant
information, there are often overlapping guidelines to consider, they are often written for
a general population but must be applied to patient-specific needs, and they are often not
sensitive to local needs or circumstances wherein the decision maker might otherwise
have used the available evidence and their clinical expertise to devise a more appropriate
therapy.150,151
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Our application could be used as a tool in the development of clinical guidelines,
in conjunction with other methods, when considering new evidence that contradicts
established practices. In order to declare a reversal of evidence and recommend the deadoption or adoption of a practice, the totality of evidence in support of it must be
considered. Our framework suggests a set of characteristics of RCTs that may be
associated with evidence reversal and should be considered when assessing trials for
informing changes in recommendations for practice. Furthermore, as the ‘evidence base’
for evidence reversals matures to define predictors, future guideline developers should
consider risk of reversibility of the evidence before they recommend implementation of a
new intervention.
7.1.2

Improved knowledge translation

Poor knowledge translation (especially premature translation) is directly related to
evidence reversal.118 According to Prasad, “translation failure occurs when the results of
preclinical, observational and/or early phase studies fail to predict the results of well done
(i.e. appropriately controlled, adequately powered, and properly conducted) phase III or
randomized clinical trials.”118 While knowledge translation and de-implementation go
hand in hand with medical reversals, there are barriers to knowledge translation and
reasons why good evidence is not readily adopted into clinical practice.152 Barriers may
include characteristics of the evidence itself, features of the practice environment (e.g.
financial disincentives, organizational constraints, perception of liability, patient
expectations), the prevailing opinions and social contexts for treatment (e.g. standards of
practice, beliefs held by opinion leaders, out-dated medical training, advocacy groups), or
knowledge and attitudes about interventions in the professional context (e.g. clinical
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uncertainty, physician’s sense of competence, compulsion to act, information
overload).153,154
If knowledge translation could be improved and clinicians made more aware of
which treatments had proven efficacy and which did not, it logically follows that there
should be a decrease in the use of harmful or unnecessary practices. However, there are a
number of reasons why physicians may continue to use treatments that are harmful or do
not work, including: clinical experience, over-reliance on a surrogate outcome, natural
history of the illness, strong belief in the pathophysiological model, ritual or mystique
(i.e. medical tradition), a need to do something and take action, patients’ expectations, or
even because the correct questions about the treatment have not yet been asked.52 The
continued use of practices that should have been phased out is common as evidence
suggests that up to 25% of patients receive treatments that are harmful and as many as
40% receive treatments for which the effectiveness is not known or inconclusive.155,156
The assumption that improved knowledge translation may decrease the premature
adoption of practices may be questioned with the argument that publication bias leads to
an incomplete understanding of any given research topic, with preferential publication of
significant and positive findings.39,157 This argument would infer that improving the
translation of research findings would not necessarily be commensurate with a decrease
in the impact of unnecessary reversals if the research that is being translated is being
published with bias or ‘false’ due to other reasons, such as p-hacking, outcome switching,
or newness of a field.
In application to knowledge translation, our framework comprises elements of
high quality studies at all stages – from conception to publication – that we found to have
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potential relationships with the conclusions of RCTs that test established practices and
should be considered by investigators in designing trials of established practices.
7.1.3

De-implementation tools

Without knowledge translation, the development of evidence-based clinical
guidelines would be impossible. These tools for EBM are primarily thought of as
“positive re-enforcers” (i.e. guidance on what to do in practice), useful for the
implementation of practices and standards. However, both knowledge translation and
practice guidelines can also be negative and serve as tools for de-implementation (i.e.
guidance on what not to do in practice).
A number of campaigns have been proposed to aid in the de-implementation of
practices that have been, or are likely to be, reversed. Practices that are the target of deimplementation are often low value or not supported by the evidence. These tools exist to
provide summary recommendations for the cessation or continuation of practices based
on the best available evidence. They include: the United Kingdom’s (UK) National
Institute for Clinical Excellence (NICE) “do-not-do” lists and Database of Uncertainties
about the Effects of Treatments (DUETs) 116,158; Canadian, American, and UK “Choosing
Wisely” Campaigns
78

70,95,106

; the British Medical Journal’s (BMJ) “Too Much Medicine”

; and Australia’s “Low-value lists.”66
Similarly to the development of guidelines, our framework may have use in

helping inform the de-implementation of practices that are harmful or of low value. It
provides a set of characteristics that should be considered when assessing trials that test
established practices.
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A TOOLBOX FOR FUTURE REVERSAL RESEARCH
In the pursuit of reducing the burden and harms associated with unnecessary

medical and evidence reversal, there are two important characteristics to consider. The
first is the identification of practices or paradigms that are to be tested. There are many
global initiatives that list contradicted, unproven, or new interventions and claims. These
categories provide potential targets for reversal and de-implementation and promote
awareness to practitioners regarding the maturity of interventions that they use in daily
practice, as many have been adopted prematurely based on inadequate evidence.44 The
second characteristic is whether or not enough evidence has been accrued to confidently
make a decision regarding the tested paradigm. One method that has been utilized for
public health interventions, and which we propose would be appropriate for describing
the evidence base for reversals, is the calculation of evidence sufficiency and stability.159
At their core, the characteristics of sufficiency and stability provide a means of
determining the point at which an intervention has been studied enough that conducting
another test no longer provides any information of added value for decision-making.159
When interventions are studied in humans, it is ethically irresponsible to conduct research
beyond this point as participants will be unnecessarily randomized to receive no benefit
(or harm if the intervention is determined to be dangerous), the implementation of
effective risk-reduction interventions will be delayed, and there may be unnecessary
waste of health care resources.159
Evidence sufficiency refers to whether or not a meta-analytic database
demonstrates that an intervention does or does not work to an adequate degree.159
However, evidence sufficiency is a term that requires further exploration, especially with
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respect to its relationship to tracking evidence cumulation and ultimately indicating when
“enough evidence” has accrued, because it has been inadequately discussed in the
literature and formal definitions still need to be derived. Some have suggested that
sufficiency refers to whether or not cumulation such as through meta-analysis
demonstrates that an intervention works, or does not work, with sufficient margin of
difference and with sufficient precision (narrow CI) to suggest further evidence is
unlikely to change this conclusion. Sufficiency may be related to the number of
hypothesis tests (i.e. studies) and the power within those studies.159,160
Evidence stability refers to the shifts in direction over time for support of the
intervention being studied.159 Stability derives from the flow of the running estimate
generated over the sequential meta-analyses: if the evidence all tends to point in one
direction then the database is stable.159,160
These definitions represent initial attempts at defining the concept of when there
is ‘enough evidence’, and should be further defined and tested to determine whether they
can be better used to inform the concept of evidence reversibility. There are several
different meta-research methods that have been proposed to describe evidence sufficiency
or make use of the maturity of evidence in medical decision-making, including Value of
Information Analysis, Trial Sequential Analysis, and Bayesian analysis. We propose that
these methods, which we describe in APPENDIX I, be explored as tools for use in future
research about reversals, particularly with regards to determining the sufficiency and
stability of the evidence base for practices that should be de-adopted, or those for which
the evidence is mature enough to warrant a recommendation of adoption into practice.
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NEXT STEPS AND FUTURE DIRECTIONS
With this thesis, we have provided a comprehensive overview and study of a

phenomenon that is rapidly gaining attention in the medical community and beyond.
Through literature reviews and detailed exploratory analyses, we have presented the first
quantitative examination of characteristics that may be associated with reversibility
within high quality medical literature. However, this thesis is only one step of the many
required before understanding the phenomenon and being able to reduce the impact of
reversals on population health.
Unnecessary reversal implies several harms to the medical industry and the
patients who are administered treatments including decreased trust in the medical
community, the possibility of receiving unnecessary or ineffective treatments, and an
increased risk of unnecessary harm.26 The most efficient way to minimize these harms
would be to reduce the impact of evidence reversal and medical reversal that occurs as a
consequence of practices being prematurely adopted: before the evidence has sufficiently
demonstrated the true effect. If practices were adopted only after the evidence for their
use had matured, then the rate of unnecessary reversal would be lower.
This thesis has been a comprehensive analysis of the contradiction of evidence by
individual trials, and builds upon the foundation of the first area of research in the field
(identified in our Chapter 2 literature review): research about the phenomenon itself.
There are already many initiatives worldwide that pursue the second major area of
research (i.e. the practices that are low value or harmful and should be targeted for deadoption and reversal), and our proposed toolbox for reversal includes several methods
that we believe should be further explored for use in determining the sufficiency and
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stability of an evidence base to declare a practice as being reversed or a confirmed
standard of care. One of the next steps for reversal research should be the exploration of
de-adoption and de-implementation strategies for practices that should not be in use. This
will be challenging as some practices will have evidence mature enough to support or
refute their use, but many will have immature evidence to adequately support their use,
which will require judgement calls about whether likely benefits outweigh the risks and
costs of continued use. Another major next step for research in reversal will be to explore
the potential predictors of future reversal – the characteristics of original research that
lead to practices being prematurely adopted – and to create a predictive model for the
likelihood that a newly adopted developed practice may be reversed in the future.

7.4

CONCLUSIONS
Evidence reversal can be defined as “when new evidence that is stronger than

preceding evidence arises to contradict previously established evidence.” In our analysis
of 17 years of original studies from the NEJM, a total of 54% of randomized controlled
trials that tested established practices met the definition of evidence reversals. Within
these trials, a total of 8 characteristics were associated with reversal including: overall
PICOTS and ROB assessment, number of years between a trial initiation and registration,
sources of abstract conclusions, p-value and standardized effect size for the primary
comparison, proportion of subjects lost to follow up, and use of surrogate versus
clinically-relevant outcomes. Using these characteristics, we propose an Evidence
Reversal framework which may be useful for tracking and detecting evidence reversals,
and for informing design of future robust RCTs that challenge established practices.
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These results provide a research agenda to better inform related research for the
rate and predictors of reversal and for identification of low-value practices as targets for
de-adoption. Perhaps more importantly, this research may help to better inform next steps
towards preventing premature adoption of new treatments, which represents a significant
driver of inefficiency and waste in healthcare.
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APPENDIX A
SYSTEMATIC REVIEW METHODOLOGY
DATABASE SEARCH STRATEGIES & PRISMA FLOW DIAGRAM
Table 1: Database Search Strategies and Results A
PUBMED Database Search Strategy and Results
(July 6th, 2016)
Search

Search Terms

1

("Evidence-based practice"[MeSH Major Topic] OR "Patient care
management"[MeSH Major Topic]) OR "guidelines as topic"[MeSH Major
Topic]
((((“clinical practice”[All Fields] OR “practice guideline*”[All Fields]) OR
“physician's practice pattern”[All Fields]) OR “evidence-based”[All Fields]) OR
“evidence based”[All Fields])
1 or 2
((((((((((((publication) OR publish*) OR evidence) OR practice) OR guideline*)
OR medical) OR clinical) OR standard) OR standards) OR unexpected) OR
surprising) N3 ((((((revers*) OR change) OR contradict*) OR divest*) OR deimplement*))[All Fields] OR disinvest*[All Fields]
3 and 4
prasad v[Author] OR ioannidis j[Author] OR ioannidis jp[Author] OR cifu
a[Author] OR elshaug a[Author]
5 or 6
Limit 7 to yr=“2014-Current”

2
3
4*

5
6
7
FINAL

Articles

MEDLINE (EMBASE) Database Search Strategy and Results
Search Terms

1

exp Evidence-Based Practice/ OR exp Patient Care Management/ OR exp
Guidelines as Topic/
(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence-based OR evidence based)
1 or 2
((publication OR publish* OR evidence OR practice OR guideline* OR medical
OR clinical OR standard OR standards OR unexpected OR surprising) adj3
(revers* OR change OR contradict* OR divest* OR de-implement*)).mp. OR
disinvest*.mp.
3 and 4
(prasad v OR ioannidis j OR ioannidis jp OR cifu a OR elshaug a).au.
5 or 6
Limit 7 to yr=“2014-Current”

3
4*

5
6
7
FINAL

Search Terms

1

exp Evidence-Based Practice/ OR exp Patient Care Management/ OR exp
Guidelines as Topic/
(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence-based OR evidence based)
1 or 2
((publication OR publish* OR evidence OR practice OR guideline* OR medical
OR clinical OR standard OR standards OR unexpected OR surprising) adj3
(revers* OR change OR contradict* OR divest* OR de-implement*)).mp. OR
disinvest*.mp.
3 and 4

5

55
1,804
1,844
443

777,823
331,623
937,017
19,891

4,577
1,421
4,577
957

(July 22nd, 2014)

Search

3
4*

626,571
351

Articles

MEDLINE (OVID) Database Search Strategy and Results

2

259,320

(July 1st, 2016)

Search
2

417,307

Articles

I

669,457
273,895
794,592
16,538

3,676

6
FINAL

(prasad v OR ioannidis j OR ioannidis jp OR cifu a OR elshaug a).au.
5 or 6

1,152
4,811

* For search #4, the original search strategy was missing a space between “disinvest*”
and “OR,” thus the final search string lacked results generated from “OR disinvest* OR
result*”. The updated search strategy includes “disinest*” but excludes “result*” due to
an extraneous number of results.
TOTAL ARTICLES RETRIEVED FROM MEDLINE

EMBASE (EMBASE) Database Search Strategy and Results

6,201

(July 1st, 2016)

Search

Search Terms

Articles

1

exp Evidence-Based Practice/ OR exp Patient Care Management/ OR exp
Guidelines as Topic/
(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence-based OR evidence based)
1 or 2
((publication OR publish* OR evidence OR practice OR guideline* OR medical
OR clinical OR standard OR standards OR unexpected OR surprising) adj3
(revers* OR change OR contradict* OR divest* OR de-implement*)).mp. OR
disinvest*.mp.
3 and 4
(prasad v OR ioannidis j OR ioannidis jp OR cifu a OR elshaug a).au.
5 or 6
Limit 7 to yr=“2014-Current”

1,704,315

2
3
4*

5
6
7
FINAL

EMBASE (OVID) Database Search Strategy and Results

680,007
1,935,989
27,833

7,960
859
7,960
1,902

(July 22nd, 2014)

Search

Search Terms

Articles

1

exp Evidence-Based Practice/ OR exp Patient Care Management/ OR exp
Guidelines as Topic/
(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence-based OR evidence based)
1 or 2
((publication OR publish* OR evidence OR practice OR guideline* OR medical
OR clinical OR standard OR standards OR unexpected OR surprising) adj3
(revers* OR change OR contradict* OR divest* OR de-implement*)).mp. OR
disinvest*.mp.
3 and 4
(prasad v OR ioannidis j OR ioannidis jp OR cifu a OR elshaug a).au.
5 or 6

1,407,119

2
3
4*

5
6
FINAL

566,343
1,598,004
24,119

6,262
637
6,894

* For search #4, the original search strategy was missing a space between “disinvest*”
and “OR,” thus the final search string lacked results generated from “OR disinvest* OR
result*”. The updated search strategy includes “disinest*” but excludes “result*” due to
an extraneous number of results.
TOTAL ARTICLES RETRIEVED FROM EMBASE

II

8,796

CINAHL Database Search Strategy and Results

(July 1st, 2016)

Search

Search Terms

1

(MH "Professional Practice, Evidence-Based") OR (MH "Evidence- Based
Dental Practice") OR (MH "Medical Practice, Evidence- Based") OR (MH
"Nursing Practice, Evidence-Based") OR (MH "Occupational Therapy Practice,
Evidence-Based") OR (MH "Physical Therapy Practice, Evidence-Based") OR
(MH "Professional Practice, Research- Based") OR (MH "Physical Therapy
Practice, Research-Based") OR (MH "Occupational Therapy Practice, ResearchBased") OR (MH "Practice Guidelines") OR (MH "Nursing Practice, ResearchBased") OR (MH "Medical Practice, Research- Based") OR (MH "Practice
Patterns") OR (MH "Medical Practice") OR (MH "Nursing Care Plans")
( clinical practice OR practice guideline* OR physician's practice pattern OR
evidence- based OR evidence based )
1 or 2
((publication OR publish* OR evidence OR practice OR guideline* OR medical
OR clinical OR standard OR standards OR surprising OR unexpected) N3
(revers* OR change OR contradict* OR divest* OR de-implement* OR
disinvest* OR result*))
3 and 4
AU (prasad v OR ioannidis j OR ioannidis jp OR ioannidis jpa OR cifu a OR
elshaug a)
5 or 6
Limiters – Published date: 20140101-20161231

2
3
4

5
6
7
FINAL

Articles

CINAHL Database Search Strategy and Results

76,539

126,752
139,840
40,459

7,653
190
7,839
1,250

(July 22nd, 2014)

Search

Search Terms

1

(MH "Professional Practice, Evidence-Based") OR (MH "Evidence-Based Dental
Practice") OR (MH "Medical Practice, Evidence-Based") OR (MH "Nursing
Practice, Evidence-Based") OR (MH "Occupational Therapy Practice, EvidenceBased") OR (MH "Physical Therapy Practice, Evidence-Based") OR (MH
"Professional Practice, Research- Based") OR (MH "Physical Therapy Practice,
Research-Based") OR (MH "Occupational Therapy Practice, Research-Based")
OR (MH "Practice Guidelines") OR (MH "Nursing Practice, Research-Based")
OR (MH "Medical Practice, Research-Based") OR (MH "Practice Patterns") OR
(MH "Medical Practice") OR (MH "Nursing Care Plans")
( clinical practice OR practice guideline* OR physician's practice pattern OR
evidence- based OR evidence based )
1 or 2
((publication OR publish* OR evidence OR practice OR guideline* OR medical
OR clinical OR standard OR standards OR surprising OR unexpected) N3
(revers* OR change OR contradict* OR divest* OR de-implement* OR
disinvest* OR result*))
3 and 4
AU (prasad v OR ioannidis j OR ioannidis jp OR ioannidis jpa OR cifu a OR
elshaug a)
5 or 6

106,511

TOTAL ARTICLES RETRIEVED FROM CINAHL

7,827

2
3
4

5
6
FINAL

Articles

III

137,475
156,054
36,042

6,313
268
6,577

Web of Science Database Search Strategy and Results

(July 3rd, 2016)

Search

Search Terms

1
2

TS=(Evidence-Based Practice OR Patient Care Management OR Guidelines)
TI=(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence- based OR evidence based)
1 or 2
TI=((publication OR publish* OR evidence OR practice OR guideline* OR
medical OR clinical OR standard OR standards OR surprising OR unexpected)
NEAR/3 (revers* OR change OR contradict* OR divest* OR de-implement* OR
disinvest* OR result*))
3 and 4
AU=(Prasad V OR Ioannidis J OR Ioannidis JP OR Ioannidis JPA OR Cifu A OR
Elshaug A)
5 or 6
#7 From 2014-2016

3
4

5
6
7
FINAL

Articles

Web of Science Database Search Strategy and Results

447,145
61,470
487,183
30,851

2,937
3,502
6,435
1,215

(July 22nd, 2014)

Search

Search Terms

1
2

TS=(Evidence-Based Practice OR Patient Care Management OR Guidelines)
TI=(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence- based OR evidence based)
1 or 2
TI=((publication OR publish* OR evidence OR practice OR guideline* OR
medical OR clinical OR standard OR standards OR surprising OR unexpected)
NEAR/3 (revers* OR change OR contradict* OR divest* OR de-implement* OR
disinvest* OR result*))
3 and 4
AU=(Prasad V OR Ioannidis J OR Ioannidis JP OR Ioannidis JPA OR Cifu A OR
Elshaug A)
5 or 6

354,556
51,412

TOTAL ARTICLES RETRIEVED FROM WEB OF SCIENCE

6,599

3
4

5
6
FINAL

Articles

Dissertations and Theses Database Search Strategy and Results
Search Terms

1
2

su(Evidence-Based Practice OR Patient Care Management OR Guidelines)
all(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence- based OR evidence based)
1 or 2
all((publication OR publish* OR evidence OR practice OR guideline* OR
medical OR clinical OR standard OR standards OR surprising OR unexpected)
NEAR/3 (revers* OR change OR contradict* OR divest* OR de-implement* OR
disinvest* OR result*))
3 and 4
Limit to 2014-2016

5
FINAL

2,398
2,990
5,384

(July 3rd, 2016)

Search

3
4

388,323
27,607

Articles

IV

1,816
88,179
89,262
42,744

6,607
893

Dissertations and Theses Database Search Strategy and Results

(July 22nd, 2014)

Search

Search Terms

1
2

su(Evidence-Based Practice OR Patient Care Management OR Guidelines)
all(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence- based OR evidence based)
1 or 2
all((publication OR publish* OR evidence OR practice OR guideline* OR
medical OR clinical OR standard OR standards OR surprising OR unexpected)
NEAR/3 (revers* OR change OR contradict* OR divest* OR de-implement* OR
disinvest* OR result*))
3 and 4

1,245
73,768

TOTAL ARTICLES RETRIEVED FROM DISSERTATIONS AND THESES

2,242

3
4

FINAL

Articles

74,504
9,517

1,349

Canadian Health Research Collection (CHRC) Database Search Strategy and Results
(July 5th, 2016)
Search

Search Terms

1

((Evidence-Based Practice OR Patient Care Management OR Guidelines) OR
(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence-based OR evidence based)) AND ((publication OR publish* OR
evidence OR practice OR guideline* OR medical OR clinical OR standard OR
standards) WITHIN-3 (revers* OR change OR contradict* OR divest* OR deimplement* OR disinvest* OR surprising result*))
Limit to 2014-2016

FINAL

Articles
13,268

1,900

Canadian Health Research Collection (CHRC) Database Search Strategy and Results
(July 22nd, 2014)
Search

Search Terms

1
2

All:(Evidence-Based Practice OR Patient Care Management OR Guidelines)
All:(clinical practice OR practice guideline* OR physician's practice pattern OR
evidence- based OR evidence based)
1 or 2
All:((publication OR publish* OR evidence OR practice OR guideline* OR
medical OR clinical OR standard OR standards) WITHIN-3 (revers* OR change
OR contradict* OR divest* OR de-implement* OR disinvest* OR surprising
result*))
3 and 4

3
4

FINAL

Articles

TOTAL ARTICLES RETRIEVED FROM CHRC

V

10,902
10,734
11,316
11,553

11,225
13,125

Google Scholar Database Search Strategy and Results

(July 22nd, 2014)

Search

Search Terms

FINAL
FINAL
FINAL
FINAL
FINAL

Author Profile for “Vinay Prasad” [Custom Range: 2014-2016]
Author Profile for “Adam Cifu” [Custom Range: 2014-2016]
Author Profile for “John P. A. Ioannidis” [Custom Range: 2014-2016]
Author Profile for “Dr Adam Elshaug” [Custom Range: 2014-2016]
(“evidence reversal” OR “clinical reversal” OR “medical reversal” OR
“divestment” OR “de-implement” OR “disinvestment” OR “surprising result”)
AND (“evidence based” OR “evidence-based”) [Custom Range: 2014-2016]
Total

Articles

Google Scholar Database Search Strategy and Results

86
32
203
16
1,000
1,337

(July 22nd, 2014)

Search

Search Terms

FINAL
FINAL
FINAL
FINAL
FINAL

Author Profile for “Vinay Prasad” [Custom Range: 2014-2016]
Author Profile for “Adam Cifu” [Custom Range: 2014-2016]
Author Profile for “John P. A. Ioannidis” [Custom Range: 2014-2016]
Author Profile for “Dr Adam Elshaug” [Custom Range: 2014-2016]
(“evidence reversal” OR “clinical reversal” OR “medical reversal” OR
“divestment” OR “de-implement” OR “disinvestment” OR “surprising result”)
AND (“evidence based” OR “evidence-based”) [Custom Range: 2014-2016]
Total

Articles

TOTAL ARTICLES RETRIEVED FROM GOOGLE SCHOLAR

VI

93
32
1,132
90
969
2,316
3,653

Identification

Records Identified Through
Database Searching
(n=22,836)

Records Identified Through
Grey Literature Searching
(n=26,077)

Records Identified Through
Hand Searching
(n=22)

Total (n=48,935)
Duplicates (n=5,342)

Title Screening

Number of Records after Duplicates Removed (n=43,593)

Abstract Screening

Number of Records after Title Screening (n=280)

Full-Text Screening

Excluded (n=43,313)

Number of Records after Abstract Screening (n=160)

Excluded (n=120)
Does not fit definition (n=75)
Not a review (n=45)

Additional Records Identified Though
Snowball Screening of Bibliographies,
Cited Works, and Related Articles
(n=54,396)

Excluded (n=89)
Does not fit definition (n=32)
Not a review (n=57)

Excluded
(n=54,376)

Duplicates (n=5)

Included

Number of Records after
Screening (n=21)

Included after Full-Text Screening (n=87)
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.
doi:10.1371/journal.pmed1000097
For more information, visit www.prisma‐statement.org.

aFigure 1: PRISMA Flow Diagram
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APPENDIX B
DATA EXTRACTION FOR 87 INCLUDED ARTICLES
Table 2: Complete data extraction of 87 included articles
Author(s) or
Organization

Title

Year

Study Type

Term(s) Used

Relationship
to Reversal

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Advancing
Medical
Professionalism to
Improve Health
Care Foundation1

The American Board of
Internal Medicine (ABIM)
Foundation Initiative
Choosing Wisely

2012

Systematic
Review

Things providers and
patients should
question
Unnecessary medical
tests, treatments and
procedures
Wasteful medical tests,
treatments and
procedures
Recommendations for
practice

Target

1

Very Low
Quality

Target

4

Low Quality

Australia
Comprehensive
Management
Framework for
Medicare Benefits
Schedule2
Brien et al3

British Medical
Journal4
Bryson5

Target
Target

Australian Government
Department of Health and
Ageing, Medicare
‘Comprehensive
Management Framework’
environmental scan
(Australia)
A scoping review of
appropriateness of care
research activity in Canada
from a health system-level
perspective

2011

Collection of
Studies

2014

Systematic
Scoping
Review

Inappropriate care

Target

5

Low Quality

BMJ's Too Much
Medicine
Back to the future:
Medical reversals and
perioperative medicine

2013

Systematic
Review
Collection of
Studies

Overdiagnosis
Too Much Medicine
Medical reversal

Phenomenon
Consequence
Phenomenon

1

Very Low
Quality
Very Low
Quality

2014

VIII

1

Author(s) or
Organization

Title

Year

Study Type

Term(s) Used

Relationship
to Reversal

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Choosing Wisely
Canada6

The Canadian Medical
Association (CMA)
Campaign Choosing
Wisely
Medical debates and
medical reversal
On the undiffusion of
established medical
practices
Why do doctors use
treatments that do not
work?
Stereostatic body
radiotherapy for
oligometastatic breast
cancer: A new standard of
care, or a medical reversal
in waiting?
Identifying and acting on
potentially inappropriate
care
Top 20 research studies of
2011 for primary care
physicians
Top 20 research studies of
2012 for primary care
physicians
Top 20 research studies of
2013 for primary care
physicians
Top 20 research studies of
2014 for primary care
physicians

2014

Systematic
Review

Unnecessary tests,
treatments and
procedures

Target

1

Very Low
Quality

2015

Collection of
Studies
Collection of
Studies

Medical reversal

Phenomenon

0

Undiffusion

Consequence

1

Very Low
Quality
Very Low
Quality

2004

Collection of
Studies

Ineffective or harmful
interventions

Target

1

Very Low
Quality

2016

Systematic
Review

Medical reversal

Phenomenon

1

Very Low
Quality

2015

Secondary
Data Analysis
and Review
Collection of
Studies

Inappropriate care

Target

2

Very Low
Quality

POEMs likely to
change practice

Target

2

Very Low
Quality

2013

Collection of
Studies

POEMs likely to
change practice

Target

3

Low Quality

2014

Collection of
Studies

POEMs likely to
change practice

Target

3

Low Quality

2015

Collection of
Studies

POEMs likely to
change practice

Target

4

Low Quality

Cifu and Prasad7
Davidoff 8
Doust and Del
Mar9
Drazer et al10

Duckett et al11
Ebell and Grad12
Ebell and Grad13
Ebell and Grad14
Ebell and Grad15

2015

2012

IX

Author(s) or
Organization

Title

Year

Study Type

Term(s) Used

Relationship
to Reversal

Ebell and Grad16

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Top 20 research studies of
2015 for primary care
physicians
Building the evidence base
for disinvestment from
ineffective health care
practices: a case study in
obstructive sleep apnoea
syndrome
Identifying existing health
care services that do not
provide value for money

2016

Collection of
Studies

POEMs likely to
change practice

Target

5

Low Quality

2007

Collection of
Studies

Disinvestment

Consequence

2

Very Low
Quality

2009

Collection of
Studies

Assess new
interventions –
displace old
Ineffective, harmful, or
non-cost-effective
interventions
Legacy items
Technology
development
Low value care

Consequence

1

Very Low
Quality

Target

5

Low Quality
Very Low
Quality
Very Low
Quality

Elshaug et al17

Elshaug et al18

Elshaug et al19
Elshaug et al20
Fatovich21
Finn and
Greenwald22

Over 150 potentially lowvalue health care practices:
an Australian study
The value of low-value
lists
Medical reversal: what are
you doing wrong for your
patient today?
Update in hospital
medicine: evidence you
should know

Target
Target
Target

2012

Systematic
Review

2013

Collection of
Studies
Collection of
Studies

Low value care
Waste
Medical reversal
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Phenomenon

1

Collection of
Studies

Recommendations for
practice

Consequence

4

2013
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1

Low Quality
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Organization
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Garner et al23

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Reducing ineffective
practice: challenges in
identifying low-value
health care using Cochrane
Systematic Reviews
De-adoption and its 43
related terms: harmonizing
low-value care
terminology

2013

Collection of
Studies

Low-value health care

Target

2

Very Low
Quality

2015

Collection of
Studies

Very Low
Quality

2012

Collection of
Studies

Consequence
Phenomenon
Consequence
Consequence
Consequence
Consequence
Consequence
Target
Target
Phenomenon
Phenomenon
Consequence
Consequence
Consequence
Phenomenon
Target
Consequence
Target
Target
Target

2

Breaking up is hard to do:
why disinvestment in
medical technology is
harder than investment

Abandon*
Contradict
De-adoption
Decrease use
Decline in use
Discontinu*
Disinvestment
Ineffective
Obsole*
Opportunity cost
Overdiagnosis
Overtreatment
Re-assessment
Resource re-allocation
Reversal
Waste
Disinvestment
Improper use
Negative list
Obsolete / outmoded /
abandoned
technologies
Services not medically
necessary
Change in treatment
guidelines

1

Very Low
Quality

1

Very Low
Quality

Gnjidic and
Elshaug24

Haas et al25

Hampton26

Clinical trial results may
lead to changes in
cardiovascular care

2014

Collection of
Studies
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Organization
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Year

Study Type

Term(s) Used

Relationship
to Reversal

Hanrahan et al27

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Sacred cow gone to
pasture: a systematic
evaluation and integration
of evidence-based practice
Contradicted and initially
stronger effects in highly
cited clinical research
Evolution and translation
of research findings: from
bench to where?
Molecular bias

2015

Collection of
Studies

Sacred cows

Target

2

Very Low
Quality

2005

Systematic
Review

Very Low
Quality

Collection of
Studies

Phenomenon
Potential
Predictor
Phenomenon
Phenomenon

2

2006

Contradicted
Initially stronger
effects
Contradictory results
Proteus phenomenon

1

Very Low
Quality

2005

Proteus phenomenon

Phenomenon

1

Non-replication and
inconsistency in the
genome-wide association
setting
Evolution of treatment
effects over time:
empirical insight from
recursive cumulative
metaanalyses
Comparison of effect sizes
associated with biomarkers
reported in highly cited
individual articles and in
subsequent meta-analyses
Early extreme
contradictory estimates
may appear in published
research: the Proteus
phenomenon in molecular
genetics research and
randomized trials

2007

Collection of
Studies
Systematic
Review

Inconsistent results

Potential
Predictor
Potential
Predictor
Potential
Predictor

1

Very Low
Quality
Very Low
Quality

3

Low Quality

Potential
Predictor
Potential
Predictor

4

Low Quality

Phenomenon

2

Very Low
Quality

Ioannidis28
Ioannidis29
Ioannidis30
Ioannidis31

Ioannidis and
Lau32

Ioannidis and
Panagiotou33

Ioannidis and
Trikalinos34

Non-replication
2001

Recursive
Cumulative
Meta-Analysis

Uncertainty
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Systematic
Review

False positive
Inflated results

2005

Systematic
Review

Proteus phenomenon
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Ioannidis et al35

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Genetic associations in
large versus small studies:
an empirical assessment
Adding value to health
care through
discontinuation of lowvalue practices:
ESSENCIAL Project in
Catalonia
The pace of change in
medical practice and
health policy: collision or
coexistence
Choosing wisely in
headache medicine: the
American Headache
Society's list of five things
physicians and patients
should question
Biomedical research:
increasing value, reducing
waste
Evidence-based practice
habits: putting more sacred
cows out to pasture
Examining the evidence to
guide practice: challenging
practice habits
Putting evidence into
nursing practice: four
traditional practices not
supported by the evidence
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Systematic
Review

Discrepancies of effect
over time

Potential
Predictor

1

Very Low
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2013

Collection of
Studies

Low value practices

Target

1

Very Low
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2015

Collection of
Studies

Medical reversal
Change in guideline
recommendation

Phenomenon
Consequence

1

Very Low
Quality

2013

Collection of
Studies

Overused or misused
tests and treatments

Target

2

Very Low
Quality

2014

Collection of
Studies

Research Waste

Target
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Quality
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Collection of
Studies

Sacred cows

Target

1

Very Low
Quality

2014

Collection of
Studies
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Studies

Practices not supported
by the evidence
Sacred cows
Sacred cows

Target
Target

2
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Kotzeva et al36

Laiteerapong and
Huang37
Loder et al38

Macleod et al39
Makic et al40
Makic et al41
Makic et al42
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Malhotra et al43

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Choosing wisely in the
UK: The Academy of
Medical Royal Colleges'
initiative to reduce the
harms of too much
medicine
Disinvesting from
ineffective technologies:
lessons learned from
current programs
Snake oil version 2

2015

Collection of
Studies

Overtreatment

Consequence

0

Very Low
Quality

2015

Systematic
Review

Disinvestment
Ineffective technology
Obsolete technology

Consequence
Target
Target

3

Low Quality

2014

Snake oil

Target

2

Snake oil superfoods?

2013

Snake oil

Target

2

Snake oil supplements?
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Snake oil

Target

1

2015

Low-value practices
Harmful practices
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Target

2
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Quality
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Quality
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Quality
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Morgan et al49

Choosing Wisely Canada
cancer list: ten low-value
or harmful practices that
should be avoided in
cancer care
Update on medical overuse
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Studies
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Studies
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Studies
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Studies

2015

Systematic
Review

Low Quality

National Institute for
Health and Care
Excellence (NICE) “Do
not do” list
UK Database of
Uncertainties about the
Effects of Treatments (UK
DUETs)

Current

Systematic
Review

Consequence
Phenomenon
Consequence
Target
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National Institute
for Health and
Care Excellence
(NICE)50
National Institute
for Health and
Care Excellence
(NICE)51

Medical overuse
Overdiagnosis
Overtreatment
Do not do
recommendations
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Quality

Current

Overview
Systematic
Review

Known uncertainty

Potential
Predictor

2
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Quality

Mayer and
Nachtnebel44
McCandless et
al45
McCandless et
al46
McCandless et
al47
Mitera et al48
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Niven et al52

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Towards understanding the
de-adoption of low-value
clinical practices: a
scoping review

2015

Systematic
Review

Abandon*
Contradict
Change in practice
Change in use
Clinical redesign
De-adopt*
Decline in use
De-commission
Decrease use
Defunding
De-implement*
De-list
Disadoption
Discontinu*
Disinvest*
Do not do
Drop in use
Evidence-based
reassessment
Health technology
reassessment
Inappropriate use
Ineffective
Low value practice /
intervention
Medical reversal
Misuse
Obsole*
Over use
Reallocation
Re-appraisal
Reassess*
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Consequence
Consequence
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Consequence
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Consequence
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Paprica et al53

From talk to action: policy
stakeholders,
appropriateness, and
selective disinvestment

2015

Collection of
Studies

Polisena et al54

Case studies that illustrate
disinvestment and resource
allocation decision-making
processes in health care: a
Systematic Review
Translation failure and
medical reversal: two sides
of the same coin
A medical burden of
proof: towards a new ethic

2013

Systematic
Review

Prasad55
Prasad and Cifu56

Term(s) Used

Relationship
to Reversal

Redeploy
Reduc*
Refute
Re-invest
Relinquish*
Remov*

Consequence
Consequence
Phenomenon
Consequence
Consequence
Consequence

Replace
Re-prioritization
Resource release
Reversal
Stop*
Substitutional reinvestment
Withdraw*
Withdrawing from a
service and redeploying
resources
De-implementation
Disinvestment
Harmful practices
Inappropriate care
Low-value services
Disinvestment
Ineffective
technologies
Obsolete technologies

Consequence
Consequence
Consequence
Phenomenon
Consequence
Consequence

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

1

Very Low
Quality
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Quality

Consequence
Consequence
Consequence
Consequence
Target
Target
Target
Consequence
Target
Target
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Collection of
Studies

Medical reversal
Translation failure

Phenomenon
Phenomenon

1

Very Low
Quality
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Studies

Medical reversal

Phenomenon

2

Very Low
Quality

XVI

Author(s) or
Organization

Title

Year

Study Type

Term(s) Used

Relationship
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Prasad and Cifu57

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Medical reversal: why we
must raise the bar before
adopting new technologies
The reversal of cardiology
practices: interventions
that were tried in vain
Evidence-based deimplementation for
contradicted, unproven,
and aspiring healthcare
practices

2011

Collection of
Studies

Medical reversal

Phenomenon

1

Very Low
Quality

2013

Systematic
Review

Medical reversal

Phenomenon

2

Very Low
Quality

2014

Collection of
Studies

Phenomenon

1

Very Low
Quality

A decade of reversal: an
analysis of 146
contradicted medical
practices
Reversals of established
medical practices:
evidence to abandon ship
The frequency of medical
reversal
Seven evidence-based
practice habits: putting
some sacred cows out to
pasture
Advancing evidence-based
practice - a quarterly
compilation of research
updates most likely to
change clinical practice.
Fall 2012

2013

Systematic
Review

Contradicted
established medical
practices
De-implementation
Unproven medical
practices
Medical reversal

Phenomenon

3

Low Quality

2012

Collection of
Studies

Medical reversal

Phenomenon

1

Very Low
Quality

2011

Systematic
Review
Collection of
Studies

Medical reversal

Phenomenon

2

Sacred cows

Target

1

Very Low
Quality
Very Low
Quality

Collection of
Studies

Research updates most
likely to change
clinical practice

Target

2

Prasad and Cifu58
Prasad and
Ioannidis59

Prasad et al60

Prasad et al61
Prasad et al62
Rauen et al63

Ray64
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Consequence
Target

Very Low
Quality

Author(s) or
Organization
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Year

Study Type

Term(s) Used

Relationship
to Reversal

Ray65

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Advancing evidence-based
practice - a quarterly
compilation of research
updates most likely to
change clinical practice.
Fall 2013
Advancing evidence-based
practice - a quarterly
compilation of research
updates most likely to
change clinical practice.
Spring 2013
Advancing evidence-based
practice - a quarterly
compilation of research
updates most likely to
change clinical practice.
Spring 2014
Advancing evidence-based
practice - a quarterly
compilation of research
updates most likely to
change clinical practice.
Summer 2013
Advancing evidence-based
practice - a quarterly
compilation of research
updates most likely to
change clinical practice.
Summer 2014

2013

Collection of
Studies

Research updates most
likely to change
clinical practice

Target

2

Very Low
Quality

2013

Collection of
Studies

Research updates most
likely to change
clinical practice

Target

2

Very Low
Quality

2014

Collection of
Studies

Research updates most
likely to change
clinical practice

Target

2

Very Low
Quality

2013

Collection of
Studies

Research updates most
likely to change
clinical practice

Target

2

Very Low
Quality

2014

Collection of
Studies

Research updates most
likely to change
clinical practice

Target

2

Very Low
Quality

Ray66

Ray67

Ray68

Ray69
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Author(s) or
Organization

Title

Year

Study Type

Term(s) Used

Relationship
to Reversal

Ray70

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Advancing evidence-based
practice - a quarterly
compilation of research
updates most likely to
change clinical practice.
Winter 2012
Advancing evidence-based
practice - a quarterly
compilation of research
updates most likely to
change clinical practice.
Winter 2013
Advancing evidence-based
practice - a quarterly
compilation of research
updates most likely to
change clinical practice.
Winter 2014
Foregoing low-value care:
how much evidence is
needed to change beliefs?
Creating a list of lowvalue health care activities
in Swiss primary care
How quickly do
Systematic Reviews go out
of date? A survival
analysis
Impactful clinical trials of
2015: what you need to
know

2012

Collection of
Studies

Research updates most
likely to change
clinical practice

Target

2

Very Low
Quality

2013

Collection of
Studies

Research updates most
likely to change
clinical practice

Target

2

Very Low
Quality

2014

Collection of
Studies

Research updates most
likely to change
clinical practice

Target

2

Very Low
Quality

2013

Collection of
Studies

Low value care

Target

1

Very Low
Quality

2015

Systematic
Review

Low-value health care

Target

1

Very Low
Quality

2007

Overview
Systematic
Review

Change in evidence

Phenomenon

3

Low Quality

2016

Collection of
Studies

Trials likely to change
practice

Target

1

Very Low
Quality

Ray71

Ray72

Scott and
Elshaug73
Selby et al74
Shojania et al75

Singh and Gupta76
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Author(s) or
Organization
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Year

Study Type
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Relationship
to Reversal

Sprenger et al77

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Quantifying low-value
services by using routine
data from Austrian
primary care
Update in outpatient
general internal medicine:
practice-changing
evidence published in
2014
Update in outpatient
general internal medicine:
practice-changing
evidence published in
2015
Can trial sequential
monitoring boundaries
reduce spurious inferences
from meta-analyses?
Scientific evidence
underlying the ACC/AHA
clinical practice guidelines

2016

Systematic
Review

Target
Target

3

Low Quality

2015

Collection of
Studies

Ineffective services
Low-value health care /
services
Unnecessary waste
Practice-changing
evidence

Target
Phenomenon

5

Low Quality

2016

Collection of
Studies

Practice-changing
evidence

Phenomenon

6

High
Quality

2009

Systematic
Review

False positive results

Potential
Predictor

5

Low Quality

2009

Systematic
Review

Target

4

Low Quality

Effect sizes in cumulative
meta-analyses of mental
health randomized trials
evolved over time
U.S. Preventive Services
Task Force (USPSTF)
“Grade ‘D’
recommendations” for
preventive health services

2004

Systematic
Review

Class II
recommendation
Class III
recommendation
Unfavourable or
favourable shifts over
time

Phenomenon

1

Very Low
Quality

Current

Collection of
Studies

Grade D
Recommendations
I Statement

Target

4

Low Quality

Sundsted et al78

Szostek et al79

Thorlund et al80

Tricoci et al81

Trikalinos et al82

U.S. Preventive
Services Task
Force (USPSTF)83

XX
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Target

Author(s) or
Organization
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Year

Study Type

Term(s) Used

Relationship
to Reversal

AMSTAR
Rating
Score

AMSTAR
Quality
Rating

Venkatesh and
Schuur84

A "Top Five" list for
emergency medicine: a
policy and research agenda
for stewardship to improve
the value of emergency
care
Responses of specialist
societies to evidence for
reversal of practice
When medicine reverses
itself: avoiding practice
pitfalls
Unproven therapies in
clinical research and
practice: the necessity to
change the regulatory
paradigm

2013

Collection of
Studies

Low value practice

Target

1

Very Low
Quality

2015

Systematic
Review

Medical reversal

Phenomenon

3

Low Quality

2013

Collection of
Studies

Reversal

Phenomenon

1

Very Low
Quality

2013

Collection of
Studies

Unproven therapies

Target

1

Very Low
Quality

Wang et al85
Wellbery and
McAteer86
Wootton et al87
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APPENDIX C
AMSTAR EVALUATION FOR 87 INCLUDED ARTICLES

3. Comprehensive
literature search

4. Publication
status in inclusion

5. List of included
and excluded
studies

6. Characteristics
of included
studies

7. Quality of
included studies

8. Appropriate
conclusions

9. Appropriate
pooling of findings

10. Likelihood of
publication bias

11. Conflict of
interest

Score

Advancing Medical
Professionalism to
Improve Health
Care Foundation1
Australia
Comprehensive
Management
Framework for
Medicare Benefits
Schedule2
Brien et al3
British Medical
Journal4
Bryson5
Choosing Wisely
Canada6
Cifu and Prasad7
Davidoff 8
Doust and Del Mar9
Drazer et al10
Duckett et al11
Ebell and Grad12

2. Study selection
and data
extraction in
duplicate

Author(s) or
Organization

1. a priori design
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extraction in
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studies
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conclusions
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pooling of findings
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publication bias

11. Conflict of
interest
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Elshaug et al17
Elshaug et al18
Elshaug et al19
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Gnjidic and
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duplicate

3. Comprehensive
literature search

4. Publication
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5. List of included
and excluded
studies
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of included
studies

7. Quality of
included studies

8. Appropriate
conclusions

9. Appropriate
pooling of findings

10. Likelihood of
publication bias

11. Conflict of
interest

Score

Ioannidis et al35
Kotzeva et al36
Laiteerapong and
Huang37
Loder et al38
Macleod et al39
Makic et al40
Makic et al41
Makic et al42
Malhotra et al43
Mayer and
Nachtnebel44
McCandless et al45
McCandless et al46
McCandless et al47
Mitera et al48
Morgan et al49
National Institute
for Health and Care
Excellence (NICE)50
National Institute
for Health and Care
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Niven et al52
Paprica et al53
Polisena et al54
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and data
extraction in
duplicate

3. Comprehensive
literature search

4. Publication
status in inclusion

5. List of included
and excluded
studies

6. Characteristics
of included
studies

7. Quality of
included studies

8. Appropriate
conclusions

9. Appropriate
pooling of findings

10. Likelihood of
publication bias

11. Conflict of
interest

Score

Prasad55
Prasad and Cifu56
Prasad and Cifu57
Prasad and Cifu58
Prasad and
Ioannidis59
Prasad et al60
Prasad et al61
Prasad et al62
Rauen et al63
Ray64
Ray65
Ray66
Ray67
Ray68
Ray69
Ray70
Ray71
Ray72
Scott and Elshaug73
Selby et al74
Shojania et al75
Singh and Gupta76
Sprenger et al77
Sundsted et al78
Szostek et al79

1. a priori design

Author(s) or
Organization

No
Yes
Yes
Unclear
No

No
Unclear
Unclear
Yes
Unclear

No
Unclear
Unclear
No
Unclear

No
No
No
No
No

No
No
No
No
No

Yes
Yes
No
Yes
Yes

No
No
No
No
No

No
No
No
No
No

N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A

No
No
No
No
No

1
2
1
2
1

Yes
No
Unclear
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Unclear
Unclear
Yes
Unclear
Yes
Yes
Yes

Yes
Unclear
Yes
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Yes
Yes
Unclear
Yes
Yes
Yes

No
Unclear
No
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
No
Unclear
Unclear
No
Yes

No
Unclear
No
No
No
No
No
No
No
No
No
No
No
No
Unclear
No
Unclear
Unclear
No
Unclear

No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No

Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes

No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes

No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes

N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No

3
1
2
1
2
2
2
2
2
2
2
2
2
1
1
3
1
3
5
6
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2. Study selection
and data
extraction in
duplicate

3. Comprehensive
literature search

4. Publication
status in inclusion

5. List of included
and excluded
studies

6. Characteristics
of included
studies

7. Quality of
included studies

8. Appropriate
conclusions

9. Appropriate
pooling of findings

10. Likelihood of
publication bias

11. Conflict of
interest

Score

Thorlund et al80
Tricoci et al81
Trikalinos et al82
U.S. Preventive
Services Task Force
(USPSTF)83
Venkatesh and
Schuur84
Wang et al85
Wellbery and
McAteer86
Wootton et al87

1. a priori design

Author(s) or
Organization

Yes
Yes
Unclear
Yes

Unclear
Unclear
Unclear
Unclear

Yes
Unclear
No
Unclear

No
No
No
No

No
No
No
No

Yes
Yes
Yes
Yes

Yes
Yes
No
Yes

Yes
Yes
No
Yes

N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A

No
No
No
No

5
4
1
4

Unclear

Unclear

Unclear

No

No

Yes

No

No

N/A

N/A

No

1

Unclear
Unclear

Yes
Unclear

Unclear
Unclear

Yes
No

No
No

Yes
Yes

No
No

No
No

N/A
N/A

N/A
N/A

No
No

3
1

Unclear

Unclear

Unclear

No

No

Yes

No

No

N/A

N/A

No

1
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APPENDIX D
RATIONALE AND EXAMPLES FOR INCLUSION AND EXCLUSION
CRITERIA
CLINICAL PRACTICE, RANDOMIZED CONTROLLED TRIAL, EXISTING
PRACTICE
In “A decade of reversal: an analysis of 146 contradicted medical practices,”
Prasad et al. provided little instruction with regards to the methods used to reach their
decisions on aspects of study classification. While they had less restrictive criteria for
their review – including all studies that were published as original research articles and
all studies that tested clinical practices, regardless of study design and whether they were
new or existing – they still sorted their studies into these different categories to inform
their descriptive statistics of the ‘study’ population.
Prasad et al.’s methodology for a study’s designation as clinical practice was:
“On the basis of published abstracts, articles were classified as to whether they
addressed a clinical practice. Articles addressing a medical practice were defined as any
investigation that assesses a screening, stratifying, or diagnostic test, a medication, a
procedure or surgery, or any change in health care provision systems. Many research
articles concern the novel molecular basis of disease or novel insights in
pathophysiology. These articles were excluded. When practice information could not be
ascertained by abstract alone, full articles were read.”60
Prasad et al.’s methodology for classifying study design was:
“Two reviewers (C.T., A.V., M.C., J.R., S.Q., S.J.C., D.B., V.G., or S.S.) and V.P. read
articles addressing a medical practice in full. ... Methods were classified as one of the
following: randomized controlled trial, prospective controlled (but nonrandomized)
intervention study, observational study (prospective or retrospective), case-control study,
or other methods.”60
Prasad et al.’s methodology for determining whether a study examined new or
existing practice was:
“Two reviewers (C.T., A.V., M.C., J.R., S.Q., S.J.C., D.B., V.G., or S.S.) and V.P. read
articles addressing a medical practice in full. On the ba- sis of the abstract, introduction,
and discussion, articles were classified as to whether the practice in question was new or
existing.”60
The methodology does further explain that designation was performed in
duplicate and that a third party adjudicated any discrepancies between reviewers.
However, as is evident from the above excerpts, beyond providing the categories used,
Prasad et al. provide no direction on how they placed studies into those categories. We
took the categories that were used by Prasad et al. and created definitions and guidelines
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to inform each decision. These guidelines were followed as closely as possible, but often
there was no clear distinction between two options and the decision was made at the
discretion of the screener.
The first two levels of screening (‘clinical practice’ and ‘study design’) were not
conducted in duplicate for two reasons. Firstly, the restriction of time would have made
screening these stages in duplicate an impossibility, as many articles required careful
reading of the full text to inform a decision. Secondly, these two levels had the strongest
rationale and guidelines for following, and the distinction between whether a study
looked at a clinical practice or not, and between the different study designs, was almost
always clear. The third level of screening (‘new vs. existing practice’) was conducted in
duplicate (RQ & DS) to increase the likelihood that we would capture all trials that tested
established practices (and consequently lead to reversal or confirmation of evidence). All
discrepancies were resolved through discussion (RQ & DS) or mediator (JM). This level
was the most difficult to screen as the decision of existing or new practice was made
based on the evidence provided in each article, not based on the clinical knowledge of the
screeners.
Other researchers or clinicians who assess the same articles may designate them
differently across any of the levels, but we are confident in our decisions as they were all
made from an independent frame of mind and with all of the information presented by the
authors themselves.
Level 1 – Study subject matter
This level of screening was two-tiered, however the inclusion of articles was
based only on the first tier. In assessing the subject matter of a study, we designated the
direct intervention or thing being studied as well as the primary purpose of that
investigation. That is to say, we assessed both whether a study investigated a clinical
practice, as well as whether the goal of the study was to assess efficacy with regards to
diagnosis, harm, prevention, prognosis, or therapy. While only clinical practices were
included in our review, to follow the same methods as Prasad et al., the second-tier of
designation was performed to allow for further description of the included population of
trials and possible subgroup analyses if it was decided they might be relevant to our
outcome of interest.
•

•

•

Clinical Practice: All studies that look at: screening, stratifying, or diagnostic
tests; any medical intervention such as a medication, procedure, or surgery; or any
other change in health care provision systems that might be tested such as dietary
or behavioural interventions and vaccinations.
Non-Clinical Practice: All studies that look at a non-clinical element of medicine
including animal studies, studies to elucidate pathophysiolocal pathways, or
studies of the molecular basis of disease (e.g. genetic association).
Diagnosis: Examines the ability of a test to identify patients with or without a
selected disease or condition; or identifies the frequency of the selected disease or
condition. Patients are of two distinct groups, those with the selected disease or
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•

•

•

•

condition, and those without the selected disease or condition.
Harm: Examines the harmful effects of an intervention on measurable outcomes,
ideally patient-important outcomes. Patients cannot be randomized to one
intervention or another.
Prevention: Examines the ability of an intervention to prevent a selected disease
or condition; or the ability of a test to identify apparently healthy patients with a
selected disease or condition prior to symptom onset. Patients are apparently
healthy people examined before symptom and disease onset for whether or not
they develop the selected disease or condition after an intervention; and/or
identification of protective or risk factors.
Prognosis: Examines the clinical course of a selected disease or condition that has
been treated; or the natural history of a selected disease or condition that has not
been treated. Patients are unhealthy people examined after symptom and disease
onset for measurable outcomes – ideally patient-important outcomes (death,
disease, discomfort, disability, and dissatisfaction) – and/or prognostic factors.
Therapy: Examines the effect of an intervention (medication, procedure, or
surgery) on measurable outcomes, ideally patient-important. Patients are
unhealthy people with a selected disease or condition after symptom onset

Level 2 – Study design
In general, the different study designs were clearly discernible from author’s
writing and descriptions of their methods. If the study design was not immediately
described in the abstract, then the methods of the full text for the article were examined to
reach a conclusion. The different study designs had well defined criteria, which allowed
the decision as to a study’s designation to be reached quickly and accurately. They are:
•
•
•

•
•

Randomized controlled trial: Patients were randomized into two or more
groups.
Prospective controlled (but nonrandomized) intervention study: Patients were
placed into two or more groups but randomization did not occur.
Observational study (prospective or retrospective): Patients were not placed
into groups and randomization did not occur, or all patients received the same
intervention.
Case-control study: Patients were selected into two groups based on a certain
diagnosis or key attribute
Other: Included other study designs not listed above such as review articles, case
series, and case studies that did not fit into any of the above categories

Level 3 – New or existing practice
The designation of whether or not a trial (as all included studies by this tier were
randomized controlled trials) investigated a new or an existing practice was difficult. As
with the other classifications, it derived from what was presented by the authors in the
trial being assessed. However, authors were not always clear in their description of prior
patterns of use, and they may have over-exaggerated or under-represented a practice’s
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prior use to suit their background and rationale for conducting the study. As such, this
designation required careful assessment of the trial in question, utilizing clues from the
abstract, as well as the full text introduction, discussion, and conclusions. All
disagreements at this screening level were resolved through discussion.
To guide inclusion/exclusion at this level, both screeners (RQ & DS) used key
words and themes that were associated with trials of new or existing practices. These
were primarily used when the authors did not explicitly say whether or not a practice is
new or existing. An “existing” practice did not have to be an established standard of care
to be included: it had to be described as being in use by physicians. Thus, even practices
where there is considerable debate surrounding their use were included as the practices
themselves are established enough within the medical community to warrant that debate.
Table 4: Key words and themes that were often found in trials of…
New Clinical Practices
•
•
•
•

•
•
•
•

Citation of biological plausibility, animal
studies, or lab studies in rationale
Use of pharmacokinetic endpoints as
primary outcomes
Description of effect of intervention as
“unknown”
Description of intervention use in very
different populations (e.g. adults vs.
premature infants)
Description of the intervention as untested
in the population
Described as Phase I or II trial
Described as Phase III trial, citing only
previous Phase I or II trials
Regulatory approval for tested indication
after the start of trial recruitment

Existing Clinical Practices
•
•
•

•

•

•
•
•
•

Reference to guidelines or recommendations of
the practice
Mention of “controversy,” “debate” or
“uncertainty” within the medical literature
Reference to prior ‘epidemiological’ or
‘observational’ studies, which suggests that the
practice is seeing use outside of experimental
settings
Interventions that are dietary / behavioural /
supplemental nutrients or vitamins (as these are
often adopted before they have been rigorously
tested because they are unlikely to cause harm)
Description of intervention use in similar, but
different, populations (e.g. infants vs. premature
infants) (required careful consideration of the
description of use in both populations)
Described as Phase IV trial
References to older Phase III trials of the same
intervention
Regulatory approval for tested indication before
the start of trial recruitment
Both intervention and control group are existing
therapies or interventions that approach a
problem from different positions

While these themes were most often found in trials of the above types of
interventions, their presence in an article was not definitive in ascribing the status as new
or existing. Rather, they served as clues to help guide the decision and the search for
further evidence to inform the decision. Only in cases where the authors failed to provide
any more rationale or discussion of the interventions in question, were the above key
words and themes used as the basis for finalizing the decision to include or exclude the
trial.
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The greatest difficulty in this stage of screening arose with interventions that were
supplementary or commonly used in other settings. The testing of an intervention in a
new population was classified as a “new intervention,” and as such, it was often difficult
determine when a population had seen use before. This commonly occurred in cancer
trials where different combinations of drugs are tested for many different cancers to try
and find some degree of efficacy or effectiveness. When an intervention was described as
being tested in a different stage of cancer than it is currently used (e.g. an intervention
that is currently used for advanced metastatic breast cancer, but being tested for efficacy
loco-regionally advanced breast cancer), it was counted as a new population excluded.
However, if the stage of cancer that was being tested was similar to one where it already
sees use (e.g. an intervention that is currently used for a subcategory of Stage II breast
cancer, and being tested in the other subcategory of Stage II breast cancer), then the use
in that population was deemed established and the trial was included. The same
methodology was used to assess the similarity of other populations and interventions. For
example, if an intervention was described as currently existing in a certain population and
being tested in a similar population (e.g. childhood vaccination as common practice in a
sub-Saharan African country, and being tested in a different sub-Saharan African country
where it is not common practice), this was counted as an existing intervention and
included.
This was a difficulty in the screening that may be designated differently by other
researchers or clinicians assessing the same articles. However, it was unavoidable given
our time restriction and lack of clinical expertise. Where Prasad et al. had a team of
physicians to reach conclusions regarding the established use or novelty of practices, we
did not have the same resources available. This difficulty in assessing new populations
for existing practices was the most challenging aspect and led to the greatest number of
initial disagreements between screeners. When a practice could not be classified as new
or existing, the final decision was to include it (i.e. classify the practice as existing) so as
to increase the sensitivity of our screening and capture all potential reversals over the 17year range.
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APPENDIX E
DATA EXTRACTION AND ANALYSIS ELEMENTS
GENERAL STUDY INFORMATION, METHODOLOGY, STUDY RESULTS, STUDY CONCLUSIONS, CONFLICTS OF
INTEREST, PICOTS ASSESSMENT, RISK OF BIAS RATINGS, GRADE ASSESSMENT
Table 5: Data extraction methods (options and rationale) for database characteristics
General Study
Information

Author(s)
Title
DOI
Date of Publication
Year of Publication
Protocol Registered
Registration Number
Year of Registration
Year Started
Year of Completion
Duration between Trial Start and Trial
Registration
Duration between Trial Registration
and Publication
Duration between Trial Completion and
Publication
Duration since Publication

Methodology

Population

Authors of the study or trial.
Title of the study or trial.
Digital Object Identifier for trial or study. “N/A” if none available.
Date the trial or study was published.
Year the trial or study was published.
Was the trial or study protocol registered, published, or pre-declared?
- Yes
- No
The registration number or location of pre-specified trial or study protocol.
Year the trial or study was registered.
Year the trial or study was reported as starting.
Year the trial or study was reported as completed.
Calculated difference in years between the year the trial or study started and
when it was registered.
Calculated difference in years between the year the trial or study was
registered and when it was published.
Calculated difference in years between the year the trial or study was
reported as completed and when it was published.
Calculated difference in years between the year the trial or study was
published and the year of this review.
Population in which trial or study is conducted.
If two or more trials are reported on in the article, then use the first reported
trial or study.
If two or more populations are reported, then use the first reported
population.
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Protocol Population

Intervention Group

Did the population (including inclusion and exclusion criteria) remain
unchanged from protocol registration to publication?
- Yes
- No
If two groups are reported as intervention and control / placebo / comparison
/ currently-used-practice, then use groups as reported.
If two groups are reported, but none are labelled as control / placebo /
comparison / currently-used-practice / intervention then:
- If the two reported groups are one low dose / risk and one high dose / risk,
then use the high dose / risk group as the intervention group and the low
dose / risk group as the comparison.
- If the two reported groups are two interventions and neither is the control
/ placebo / comparison / currently-used-practice, then use the first
reported as the intervention group and the second reported as the
comparison group.
If more than two groups are reported, and one is control / placebo /
comparison / currently-used-practice, then use this as the comparison
group, and then:
- If the other reported groups are low dose / risk and high dose / risk, then
use the low dose / risk as the intervention group.
- If the other reported groups are interventions and neither are a control /
placebo / comparison / currently-used-practice, then use the first noncontrol / placebo / comparison / currently-used-practice reported as the
intervention group.
If more than two groups are reported and none are control / placebo /
comparison / currently-used-practice, then use the first mentioned group
as the intervention and the second mentioned group as the comparison
group.
If a factorial design with control / placebo / comparison / currently-usedpractice and multiple interventions, then use the double control / placebo /
comparison / currently-used-practice as the comparison group and the
first-mentioned intervention and control / placebo / comparison /
currently-used-practice group as the intervention group.
If a factorial design with no control / placebo / comparison / currently-usedpractice, then the first mentioned group is the intervention group and the
second mentioned group is the comparison group.
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Protocol Intervention Group

Comparison Group
Protocol Comparison Group

1o Outcome

Protocol Primary Outcome

Favourable or Unfavourable Primary
Outcome
Unfavourable Primary Outcome
2o Outcome (Major)

Protocol Secondary Outcome

Did the intervention group remain unchanged from protocol registration to
publication?
- Yes
- No
See group selection for intervention group.
Did the comparison group remain unchanged from protocol registration to
publication?
- Yes
- No
If only one primary outcome is reported, then use the sole reported primary
outcome.
If more than one primary outcome is reported, then use the first primary
outcome reported.
If no outcomes are reported as the primary outcome, then use the most
patient-important outcome as the primary outcome.
If primary outcomes are reported for both safety and efficacy, then use the
efficacy primary outcome.
Did the primary outcome remain unchanged from protocol registration to
publication?
- Yes
- No
Was the primary outcome favourable (e.g. survival) or unfavourable (e.g.
mortality)?
- Favourable
- Unfavorable
If the primary outcome was unfavourable, then use as reported.
If the primary outcome was favourable, then use the complementary
unfavourable outcome.
If only one secondary outcome is reported, then use the sole reported
secondary outcome.
If more than one secondary outcome is reported, then use the most patientimportant outcome. i.e. mortality
Did the secondary outcome remain unchanged from protocol registration to
publication?
- Yes
- No
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Randomization
Duration of Follow-Up

Protocol Follow-Up

Sample Size
Required Sample Size
Protocol Sample Size

Study results

Loss to Follow-Up Total

Was the trial randomized?
- Yes
- No
If the duration of follow-up for the selected primary outcome is reported, then
use this reported duration.
If the duration is not reported, but the mean or median length of follow up is,
then use the reported mean or median.
If the no duration of follow-up for the selected primary outcome is reported,
then use the duration of follow-up for the entire trial or study.
Did the time of follow-up or study or trial duration remain unchanged from
protocol registration to publication?
- Yes
- No
Total number randomized.
Required sample size calculated prior to trial start.
Did the required sample size remain unchanged from pre-specification to
publication?
- Yes
- No
Total loss to follow-up in entire trial or study. Also reported as withdrawn,
lack of outcome information, missing primary outcome data, or protocol
violations.
If the loss to follow-up is only reported for each group, this is calculated by
summing the loss to follow-up in both the selected intervention and
comparison groups.
If there are multiple groups, calculate the total loss to follow-up by summing
the loss to follow-up from all included groups
If loss to follow-up is only reported as a percentage, calculated by multiplying
the initial number of included patients by the percentage to receive a whole
number.
If loss to follow-up is not reported, calculated by the difference between initial
number of included patients and the number of observations reported for
the primary outcome.
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Loss to Follow-Up in Intervention Group

Loss to Follow-Up in Comparison Group

p-Value (1o Outcome)
Significant or Not
Reported Point Estimate

Loss to follow-up in the selected intervention group for the primary outcome.
Also reported as withdrawn, lack of outcome, missing primary outcome
data, or protocol violations.
If only the total loss to follow-up is reported, then it is assumed loss to followup is equal in all groups. This is calculated by dividing the total loss to
follow-up by the number of groups.
If loss to follow-up for the intervention group is only reported as a percentage,
calculated by multiplying the initial number of patients included in the
intervention group by the percentage to receive a whole number.
If loss to follow-up is not reported, calculated by the difference between initial
number of patients included in the intervention group and the number of
observations reported in the intervention group for the primary outcome.
Loss to follow-up in the selected comparison group for the primary outcome.
Also reported as withdrawn, lack of outcome information, missing primary
outcome data, or protocol violations.
If only the total loss to follow-up is reported, then it is assumed loss to followup is equal in all groups. This is calculated by dividing the total loss to
follow-up by the number of groups.
If loss to follow-up for the comparison group is only reported as a percentage,
calculated by multiplying the initial number of patients included in the
comparison group by the percentage to receive a whole number.
If loss to follow-up is not reported, calculated by the difference between initial
number of patients included in the comparison group and the number of
observations reported in the comparison group for the primary outcome.
Reported p-value for selected primary outcome.
If no p-value reported, then report as “N/A.”
Is the p-value significant?
- SS (p-value is significant)
- NS (p-value is not significant)
Reported point estimate of effect for selected primary outcome.
If both relative and absolute estimates are available, then use absolute values.
If crude / unadjusted and adjusted estimates are available, then use the crude
/ unadjusted values.
If no point estimate is reported (common with continuous outcomes), then
report as “Unknown.”
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Reported Confidence Interval (1o
Outcome)
Type of Outcome

Number of Events in Intervention Group
Number in Intervention Group
Intervention Group Rate

Number of Events in Comparison Group
Number in Comparison Group
Comparison Group Rate

Absolute Risk Difference Lower 95%
Confidence Interval
Absolute Risk Difference Upper 95%
Confidence Interval

Intent-to-treat analysis point estimates are used over modified-intent-to-treat
analysis point estimates which are used over per protocol analysis point
estimates
Reported confidence interval or standard deviation of selected point estimate
of effect of selected primary outcome.
If both continuous and dichotomous outcomes are reported for the selected
primary outcome, then the dichotomous outcome is preferred.
- Continuous
- Dichotomous
For dichotomous outcomes, number of events of selected primary outcome in
the selected intervention group.
Number of population randomized to selected intervention group.
If dichotomous outcome, p̂ 1 = intervention group rate:
!!
!̂! =
!!
x1 = number of events in intervention group
n1 = number of patients in intervention group
For dichotomous outcomes, number of events of selected primary outcome in
the selected comparison group.
Number of population randomized to selected comparison group.
If dichotomous outcome, p̂ 2 = comparison group rate:
!!
!̂! =
!!
x2 = number of events in comparison group
n2 = number of patients in comparison group
If dichotomous outcome, calculated using Newcombe-Wilson hybrid score
confidence intervals:
ARDLowerLimit = ( pˆ − pˆ ) − z
U (1 − U ) / n + L (1 − L ) / n
1
2
α /2 2
2 2 1
1 1

ARDUpperLimit
U =

= ( pˆ − pˆ ) + z
U (1 − U ) / n + L (1 − L ) / n
1
2
α /2 1
1 1 2
2 2

ˆ + z 2 + z z 2 + 4n( p
ˆ (1 − p
ˆ ))
2np
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2(n + z 2 )

L=

Absolute Risk Difference Point Estimate

Number Needed to Treat Lower 95%
Confidence Interval
Number Needed to Treat Upper 95%
Confidence Interval

Number Needed to Treat Point Estimate

2npˆ + z 2 − z z 2 + 4n ( pˆ (1 − pˆ ))
2( n + z 2 )

ARDLowerLimit = absolute risk difference lower CI interval
ARDUpperLimit = absolute risk difference lower CI interval
p̂ 2 = intervention group rate
n2 = number of patients in intervention group
U2 = U calculated for intervention group
L2 = L calculated for intervention group
p̂ 1 = comparison group rate
n1 = number of patients in comparison group
U1 = U calculated for comparison group
L1 = L calculated for comparison group
zɑ/2 = z score for 95% confidence interval, ɑ of 0.05 = 1.96
If dichotomous outcome, ARD = absolute risk difference:
!"# = !"# − !"#
IGR = intervention group rate
CGR = comparison group rate
- Absolute Risk Decrease if Positive
- Absolute Risk Increase if Negative
If dichotomous outcome, calculated by:
1
1
!!!!"#$%!&'&( =
!!!!""#$%&'&( =
!"!!""#$%&'&(
!"!!"#$%!&'&(
NNTLowerLimit = number needed to treat lower CI interval
NNTUpperLimit = number needed to treat upper CI interval
ARDUpperLimit = absolute risk difference upper CI interval
ARDLowerLimit = absolute risk difference lower CI interval
If the 95% confidence intervals for absolute risk difference have opposing
signs (one is negative and one is positive), then report as “N/A.”
If dichotomous outcome, NNT = number needed to treat:
1
!!" =
!"#
ARD = absolute risk difference
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Total Number of Events

Relative Risk Difference

Fragility Index (FI)
Reverse Fragility Index (RFI)

Reported Intervention Group Mean or
Median
Reported Intervention Group Standard
Deviation or Interquartile Range

- Number Needed to Benefit if Positive
- Number Needed to Harm if Negative
If dichotomous outcome, X = total number of events:
! = !! + !!
x1 = number of events in intervention group
x2 = number of events in comparison group
If dichotomous outcome, RRR = relative risk difference:
!"#
!!! =
!̂!
ARD = absolute risk difference
p̂ 2 = comparison group rate
- Relative Risk Decrease if Positive
- Relative Risk Increase if Negative
If dichotomous outcome with a significant p-value, FI calculated by
recalculating the two-sided p-value for Fischer’s exact test after adding an
event to the group with the fewer reported events while subtracting a nonevent from that group. This process continues iteratively until the
calculated p-value becomes greater or equal to 0.05. The number reported
in this review is the number of added events required to change the p-value
from significant to non-significant. (Calculated using:
www.fragilityindex.com)
If dichotomous outcome with a non-significant p-value, RFI calculated by
recalculating the two-sided p-value for Fischer’s exact test after subtracting
an event from the group with the most reported events while adding a nonevent from that group. This process continues iteratively until the
calculated p-value becomes less than 0.05. The number reported in this
review is the number of subtracted events required to change the p-value
from non-significant to significant. (Calculated using the reverse fragility
index in the ‘fragility index’ R package: https://cran.rproject.org/web/packages/fragilityindex/README.html)
If continuous outcome, the reported mean or median for the selected primary
outcome in the selected intervention group.
If continuous outcome, the reported standard deviation or interquartile range
for the selected primary outcome in the selected intervention group.
If uneven CI around estimate, use the more conservative limit
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Reported Control Group Mean or
Median
Reported Control Group Standard
Deviation or Interquartile Range
Pooled Standard Deviation

If continuous outcome, the reported mean or median for the selected primary
outcome in the selected comparison group.
If continuous outcome, the reported standard deviation or interquartile range
for the selected primary outcome in the selected comparison group.
If uneven CI around estimate, use the more conservative limit
If continuous outcome, !! = pooled standard deviation:
!! =

Standard Effect Size Lower 95%
Confidence Interval (continuous)
Standard Effect Size Upper 95%
Confidence Interval (continuous)
Note: Not calculated for dichotomous
outcomes
Standard Effect Size Point Estimate

Adequacy of Power (AP)

!! − 1 !!! + !! − 1 !!!
!! + !! − 2

n1 = number in intervention group
s1 = standard deviation for intervention group
n2 = number in comparison group
s2= standard deviation for comparison group
If continuous outcome, calculated by:
!"#$%!&'&( = ! − !ɑ ! !!

1
1
1
1
+
!""#$%&'&( = ! + !ɑ ! !!
+
!! !!
!! !!

n1 = number in intervention group
n2 = number in comparison group
d = standard effect size
!! = pooled standard deviation
zɑ/2 = z score for 95% confidence interval, ɑ of 0.05 = 1.96
If continuous: dc = standard effect size; if dichotomous: dd = standard es
!! − !!
!"#!"#$%&#!
!! ∗ !!" !! ∗ !!"
!! =
!! =
!"#!"#$"%&' =
+
!!
!!!
!!!
!"#!"#$"%&'
!! = pooled standard deviation
Te / Ce = Treated / control events

!! = mean for intervention group Tne / Cne = Treated / control non-events
!! = mean for comparison group nT / nC = Treated / control sample

If dichotomous outcome, fails to meet AP if (in decreasing order of
importance):
- Risk Difference 95% CI includes delta in either direction.
- No delta is reported
- Doesn’t meet sample size calculation provided in article.
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If continuous, fails to meet AP if (in decreasing order of importance):
- Standard effect size 95% CI includes a standard effect size greater or equal
to 0.5 in either direction.
- Doesn’t meet sample size calculation provided in article

Author’s
conclusions

End Point Conclusions

Conclusion
Does the article contradict current
medical practice?

How does the article contradict current
medical practice?
Did the abstract conclusion report the
primary outcome?
Was the abstract conclusion based on
subgroup analysis?
Was the abstract conclusion based on a
secondary outcome?
Was the article withdrawn or retracted?

Positive conclusions
o If selected intervention group is reported as beneficial / better than the
selected comparison group, then report as “Positive.”
- Negative conclusions or No difference
o If selected intervention group is reported as not beneficial / harmful / no
different than the selected comparison group, then report as “Negative or
No Difference.”
Abstract conclusion / article discussion
Based on abstract conclusion and article introduction, results, and discussion.
If new practice versus current practice / placebo beneficial, then yes.
If new practice versus current practice / placebo not beneficial / harmful / no
different, then no.
If current practice versus prior / inferior practice not beneficial / harmful / no
different, then yes.
If current practice versus prior / inferior practice beneficial, then no.
o Yes
o No
Abstract background / article introduction / article discussion
-

Based on abstract conclusion.
o Yes
o No
Based on abstract conclusion.
o Yes
o No
Based on abstract conclusion.
o Yes
o No
Was the article withdrawn or retracted?
o Yes
o No
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If article was withdrawn or retracted,
why?
Conclusion
*based on trial authors’ conclusions not
systematic review.
Reversal Type

True Reversal
Conflict(s) of
Interest

Patient

If the conclusion is a reversal, then report if the reversal is due to “Harm
outweighs benefits,” “Not effective,” “Less effective, but still beneficial,” or
“Beneficial if thought harmful/not-effective/inferior.” Otherwise report as
“N/A”
o Yes: GRADE Rating is High Quality
o No: GRADE Rating is not High Quality
If both industry and non-industry reported, then use industry.
o Industry
o Non-Industry
o None Disclosed
Listed sources of funding

Conflicts of Interest

Sources of Funding
PICOTS
Assessment

Reason article was withdrawn.
Separate retraction article or from Retraction Watch website
http://retractionwatch.com/
- Reversal: current research shows current practice is ineffective or harmful.
- Confirmation: current research shows current practice is superior to previous
standard of practice/ is effective/ is beneficial.

Description

Sufficient:
o The ‘right’ patient population is identified.
o The patient population is appropriately generalizable or restricted, included
or excluded.
o The ‘right’ setting is identified.
o The setting is appropriately generalizable or restricted (multi-centre or
single-centre).
o Appropriately similar to protocol registration.
Insufficient:
o The ‘right’ patient population is not identified.
o The patient population is inappropriately generalizable or restricted,
included or excluded.
o The ‘right’ setting is not identified.
o The setting is inappropriately generalizable or restricted (multi-centre or
single-centre).
o Inappropriately different from protocol registration.
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Reason
Sample Size

Description

Reason
Intervention

Description

Reason
Comparator

Description

Reasons behind the “Sufficient” or “Insufficient” judgement call using the
above justification(s).
Sufficient:
o Actual sample size is greater or equal to required sample size.
Insufficient:
o Actual sample size is less than required sample size.
Reasons behind the “Sufficient” or “Insufficient” judgement call using the
above justification(s).
Sufficient:
o An appropriate intervention is identified.
o The dosage used is specified and scientifically justified.
o The frequency of treatment is specified and scientifically justified.
o Appropriately similar to protocol registration.
Insufficient:
o An appropriate intervention is not identified.
o The dosage used is not specified or scientifically justified.
o The frequency of treatment is not specified or scientifically justified.
o Inappropriately different from protocol registration.
Reasons behind the “Sufficient” or “Insufficient” judgement call using the
above justification(s).
Sufficient:
o The comparator is appropriate.
o Next best alternative to intervention
o Competing alternative to intervention
o Standard of care
o Gold standard
o The placebo is appropriate.
o Appears similar to intervention
o The dosage used is specified and scientifically justified.
o The frequency of treatment is specified and justified.
o Appropriately similar to protocol registration.
Insufficient:
o The comparator is inappropriate.
o Inferior to other alternatives / standards of care
o Placebo used instead of an existing standard of care
o The dosage used is not specified or scientifically justified.
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Reason
Outcomes

Description

o The frequency of treatment is not specified or justified.
o Inappropriately different from protocol registration.
Reasons behind the “Sufficient” or “Insufficient” judgement call using the
above justification(s).
Sufficient:
o The primary outcome is valid. The secondary outcome(s) are valid.
o Patient-important, clinically relevant, hard
§ Affect how a patient functions / feels / survives.
o Appropriate surrogate (validated)
§ Surrogate is correlated with the hard outcome of interest.
§ Surrogate fully captures the net effect of treatment on the hard
outcome of interest.
o Appropriate composite (validated)
§ Component endpoints of similar importance to patients.
§ Component endpoints occur with similar frequency.
§ Component endpoints are likely to have similar relative risk
reductions and narrow confidence intervals.
o If disease-specific mortality is measured, then so is all-cause mortality.
o The timing / duration of outcome measurement are appropriate.
o Appropriately similar to protocol registration.
Insufficient:
o The primary outcome is invalid. The secondary outcome(s) are invalid.
o Not patient-important, or a patient important outcome is missed.
o Inappropriate surrogate (validated)
§ Surrogate is not correlated with the hard outcome of interest.
§ Surrogate does not fully capture the net effect of treatment on the
hard outcome of interest.
o Inappropriate composite (validated)
§ Component endpoints are not of similar importance to patients.
§ Component endpoints do not occur with similar frequency.
§ Component endpoints are not likely to have similar relative risks
reductions and narrow confidence intervals.
o If morality is measured, only cause-specific or x-year survival is
measured.
o The timing / duration of outcome measurement are inappropriate.
o Inappropriately different from protocol registration.
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Reason
Type

Study Design

Description

Reason
Study Purpose

Description

Reasons behind the “Sufficient” or “Insufficient” judgement call using the
above justification(s).
o Hard (Patient-Important): Outcomes that affect how a patient functions /
feels / survives by improving a patient’s quality of life or increasing length
of life.
o Surrogate: Outcomes that do not affect how a patient functions / feels /
survives, but are associated with those outcomes.
o Composite: A grouping of outcomes with varying importance to the
patients.
Sufficient:
o The study design is appropriate and the best possible scenario to
answer the question.
o Diagnosis: Case-Control Study (All patients receive both the gold
standard test and new proposed test regardless of their actual
diagnosis).
o Prognosis: Observational Study
o Therapy: Randomized Controlled Trial
o Prevention: Randomized Controlled Trial
o Harm: Case-Control or Observational Study
o Appropriately similar to protocol registration
Insufficient:
o The study design is inappropriate or not the best possible scenario to
answer the question.
o Inappropriately different from protocol registration.
Reasons behind the “Sufficient” or “Insufficient” judgement call using the
above justification(s).
Sufficient:
o Purpose / question is easily detectable and clearly phrased.
o Should [intervention] be used for [health problem]?
o Should [intervention] versus [comparison] be used for [health
problem]?
o Should [intervention] be used in [population]?
o Should [intervention] versus [comparison] be used in [population]?
o Appropriately similar to protocol registration.
Insufficient
o Purpose / question is not detectable or clearly phrased.
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Reason
Overall

Risk of Bias
(ROB)
Assessment

Sequence
Generation

Description

o Inappropriately different from protocol registration.
Reasons behind the “Sufficient” or “Insufficient” judgement call using the
above justification(s).
Sufficient:
o All PICOTS were sufficient.
Somewhat Insufficient:
o One or two PICOTS were insufficient in way(s) that would not likely affect
the outcome of the study.
Clearly Insufficient:
o One or more PICOTS were insufficient in way(s) that could likely affect the
outcome of the study.
Method used to generate the allocation sequence is described sufficient detail
to allow an assessment of whether it should produce comparable groups.
- Definitely Low Risk of Bias
o The investigators describe a random component in the sequence
generation process: random number table, computer random number
generator, coin tossing, shuffling cards/envelopes, throwing dice,
drawing lots.
- Probably Low Risk of Bias
o Sequence generation process is not described but it is clear that the
investigators used a random component in their process.
- Probably High Risk of Bias
o Insufficient information about sequence generation process to permit
judgment.
o Sequence generation process is not described and it is unclear whether
the investigators used a random component in their process.
- Definitely High Risk of Bias
o The investigators describe a non-random component in the sequence
generation process.
o Usually, the description involves some systematic, non-random
approach: odd/even date of birth, day/date of admission,
hospital/clinic record number.
o Other: judgment of clinician, preference of participant, results of laboratory
test/series of tests, availability of intervention.
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Reason
Allocation
Concealment

Description

Reason
Blinding

Description

Reasons behind the Risk Level of Bias judgement call using the above
justification(s).
Method used to conceal the allocation sequence is described in sufficient
detail to determine whether intervention allocations could have been
foreseen in advance or, or during, enrolment.
- Definitely Low Risk of Bias
o Participants and investigators enrolling participants could not foresee
assignments because one of the following, or an equivalent method,
was used to conceal allocation: central allocation (telephone/ webbased/ pharmacy-controlled randomization); sequentially numbered
drug containers of identical appearance; sequentially numbers, opaque,
sealed envelopes.
- Probably Low Risk of Bias
o Allocation Concealment is not described in complete detail but it is
clear that the investigators used a method of concealment.
- Probably High Risk of Bias
o Insufficient information to permit judgment.
o This is usually the case if method of concealment is not described or not
described in sufficient detail to allow a definite judgment.
- Definitely High Risk of Bias
o Participants or investigators enrolling participants could possibly foresee
assignments and thus introduce selection bias: open random allocation
schedule, assignment envelopes (missing sequential numbers, opaque or
sealed), alternation/rotation, date of birth, case record number, any other
explicitly unconcealed procedure.
Reasons behind the Risk Level of Bias judgement call using the above
justification(s).
Described all measures used, if any, to blind study participants, personnel, and
outcome assessors from knowledge of which intervention a participant
received.
Provided any information relating to whether the intended blinding was
effective.
- Definitely Low Risk of Bias
o No blinding, but authors judge the outcome and the outcome
measurement are not likely to be influenced by lack of blinding.
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Reason
Incomplete
Outcome Data

Description

o Blinding of participants and key study personnel; and unlikely that
blinding could have been broken.
o Either participants or some key study personnel were not blinded, but
outcome assessment was blinded and the non-blinding of others is
unlikely to introduce bias.
- Probably Low Risk of Bias
o Blinding is not described in detail but it is clear that appropriate
blinding has been used.
- Probably High Risk of Bias
o Insufficient information to permit judgment.
o The study did not address this outcome.
- Definitely High Risk of Bias
o No blinding or incomplete blinding, and outcome or outcome measure
is likely to be influenced by lack of blinding.
o Blinding of key study and personnel attempted, but likely that blinding
could have been broken.
o Either participants or key study personnel were not blinded, and the nonblinding of others is likely to introduce bias.
Reasons behind the Risk Level of Bias judgement call using the above
justification(s).
Described the completeness of outcome data for each main outcome, including
attrition and exclusions from the analysis.
Stated whether attrition and exclusions were reported, the numbers in each
intervention group (compared with total randomized participants), reasons
for attrition/ exclusions were reported, and any re-inclusions in analyses
performed by authors.
- Definitely Low Risk of Bias
o No missing outcome data.
o Reasons for missing outcome data unlikely to be related to true
outcome.
o Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups.
o Missing data have been imputed using appropriate methods.
- Probably Low Risk of Bias
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Reason
Selective Outcome

Description

o For dichotomous outcome data, the proportion of missing outcomes
compared with observed event rate not enough to have a clinically
relevant impact on the intervention effect estimate.
o For continuous outcome data, plausible effect size (difference in means
or standardized difference in means) among missing outcomes not
enough to have a clinically relevant impact on observed effect size.
- Probably High Risk of Bias
o Insufficient reporting of attrition/exclusions to permit judgment.
o The study did not address this outcome.
- Definitely High Risk of Bias
o Reason for missing outcome data likely to be related to the true
outcome, with either imbalance in numbers or reasons for missing data
across intervention groups.
o For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate.
o For continuous outcome data, plausible effect side among missing
outcomes enough to induce clinically relevant bias in observed effect
size.
o ‘As-treated” analysis done with substantial departure of the
intervention received from that assigned at randomization.
o Potentially inappropriate application of simple imputation.
o Loss to follow-up and failure to adhere to the intention to treat principle
when indicated.
Reasons behind the Risk Level of Bias judgement call using the above
justification(s).
Stated how the possibility of selective outcome reporting was examined by
the authors, and what was found.
- Definitely Low Risk of Bias
o The study protocol is available and all of the study’s pre-specified (1o
and 2o) outcomes that are of interest in the review have been reported
in the pre-specified way.
- Probably Low Risk of Bias
o The study protocol is not available, but it is clear the published reports
include all expected outcomes, including those that were pre-specified.

XLIX

Probably High Risk of Bias
o The study protocol is not available, and it is unclear if the published
reports include all expected outcomes, including those that were prespecified.
o Insufficient information to permit judgment.
- Definitely High Risk of Bias
o Not all of the study’s pre-specified primary outcomes have been
reported.
o One or more primary outcomes are reported using measurements,
analysis methods, or subsets / subgroups of the data that were not prespecified. Continuous measurements that have been: measured
multiple times; transformed from “final scores” to “changes from
baseline”; or dichotomized to a cut-off in ways that were not prespecified.
o One or more reported primary outcomes of interest in the review are
reported incompletely such that they cannot be entered in a metaanalysis.
o The study fails to include results for a key outcome that would be
expected to have been reported in such a study.
o Reporting some outcomes and not others on the basis of the results. Primary
outcomes reported as secondary or secondary outcomes reported as primary.
Reasons behind the Risk Level of Bias judgement call using the above
justification(s).
Stated any important concerns about bias not addressed in other domains in
the tool.
- Definitely Low Risk of Bias
o The study appears to be free of other sources of bias.
- Probably Low Risk of Bias
o It is unclear if the study is completely free of other sources of bias but
any potential bias is not enough to have a clinically relevant impact.
- Probably High Risk of Bias
o Insufficient information to assess whether an important risk of bias
exists.
o Insufficient rationale or evidence that an identified problem will induce
bias.
o Unexplained industry involvement
-

Reason
Other Sources of
Bias

Description

L

Definitely High Risk of Bias
o Potential source of bias related to the specific study design used.
o Stopped early due to some data-dependent process (including formalstopping rule).
o Extreme baseline imbalance.
o Claimed to have been fraudulent.
o Carry-over effects in cross-over trials.
o Use of un-validated patient-reported outcomes.
o Evidence of potential commercial exploitation (e.g. Industry role in trial
design/conduct/analysis)
Reasons behind the Risk Level of Bias judgement call using the above
justification(s).
- Definitely Low Risk of Bias
o All risk of bias items are judged as definitely low risk of bias.
o Most risk of bias items are judged as definitely low risk of bias but one
or two are probably low risk of bias in way(s) that would not likely
affect the outcome of the study.
- Probably Low Risk of Bias
o Most risk of bias items are judged as definitely low risk of bias or
probably low risk of bias but one or two are probably high risk of bias
in way(s) that would not likely affect the outcome of the study.
- Probably High Risk of Bias
o At least one risk of bias item is judged as probably high risk of bias in
way(s) that could likely affect the outcome of the study.
o One risk of bias item is judged as definitely high risk of bias in a way
that would not likely affect the outcome of the study.
- Definitely High Risk of Bias
o At least one risk of bias item is judged as definitely high risk of bias in
way(s) that could likely affect the outcome of the study.
-

Reason
Overall Risk of Bias

GRADE
Assessment

Study Design

Type

Risk of Bias

Initial Level of
Confidence
Description

Trial: Study design was determined to be a “Randomized Controlled Trial” or
“Prospective Controlled Intervention Study”
High: Study type is a “Trial”
Overall ROB Assessment
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Downgrade

Directness and
Applicability

Description
Downgrade

Imprecision

Description
Downgrade

Publication Bias Modified

Description
Downgrade

Total Downgrades
Overall Quality of Evidence

Downgrade of 0
o Overall ROB Assessment is judged to be “Definitely Low Risk of Bias” or
“Probably Low Risk of Bias”
Downgrade of -1
o Overall ROB Assessment is judged to be “Probably High Risk of Bias”
Downgrade of -2
o Overall ROB Assessment is judged to be “Definitely High Risk of Bias”
Overall PICOTS Assessment
Downgrade of 0
o Overall PICOTS Assessment is judged as “Sufficient”
Downgrade of -1
o Overall PICOTS Assessment is judged as “Somewhat Insufficient”
Downgrade of -2
o Overall PICOTS Assessment is judged as “Clearly Insufficient”
Adequacy of Power (AP)
Downgrade of 0
o Meets mOIS threshold.
Downgrade of -1
o Does not meet mOIS threshold.
Presence of Selective Outcome Bias
Downgrade of 0
o Selective Outcome Bias is undetected and judged as “Definitely Low
Risk of Bias” or “Probably Low Risk of Bias”
Downgrade of -1
o Selective Outcome Bias is suspected and judged as “Probably High Risk
of Bias
Downgrade of -2
o Selective Outcome Bias is detected and judged as “Definitely High Risk of
Bias”
Calculated sum of all the downgrades.
Trials begin initially at High Quality and can only be downgraded from there.
o Total downgrade of 0: High Quality
o Total downgrade of -1: Moderate Quality
o Total downgrade of -2: Low Quality
o Total downgrade of ≤-3: Very Low Quality
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APPENDIX F
STATA DO-FILE 1
SETTING UP THE DATABASE FOR ANALYSES
/* Before importing the file, the first row which specifies the headings of
each section of the extraction must be deleted. This will not remove any of
the names of the variables, but will allow STATA to use the 'firstrow' command.
Import the excel file, titled "ThesisAnalyses." Use 'firstrow' to specify that
the first row is the variable names. */
import excel "/Users/Riaz/Desktop/EvidenceReversalDataExtraction.xlsx", sheet("Data
Extraction") firstrow
/* There are 161 variables in the excel file, but we have only 20 potential
predictors that we are interested in and an additional 12 that we are using in
our descriptive statistics. Instead of using 'drop' and specifying all
non-included variables, we will use 'keep' to specify the list of variables
that we want to keep in the dataset. Note that although it will not be used in
the regression, DOI and ID will be kept as identifiers. */
keep ID DOI YearofPublication Registered RegistrationnumberorPreSpecif
Durationbetweenstartandregist Durationbetweentrialcompletion
DurationofFollowUpinWeeks DurationofFollowUpinWeeksI FavourableorUnfavourable
SampleSize RequiredSampleSize LosstoFollowUpproportionof
ImputedLosstoFollowUpProport pValuemainoutcome Alteredpvalue SignificantorNot
MeasureofEffect TypeofOutcome TotalNumberofEventsAdjustment FragilityIndex
StandardEffectSizeAll StandardEffectSizeImputed AP EndPointConclusions
Contradictcurrentmedicalpracti PrimaryOutcomereportedinabstr
Basedonsubgroupanalysis Basedonsecondaryoutcome ReversalType Funding Type
Overall OverallBias QualityofEvidence
/* The data has mostly been imported as string variables and must be converted
appropriately. Numeric variables will be converted using the 'destring'
command, while categorical variables will be converted to numeric using the
'encode' command. All original variables will be kept and the newly generated
"converted" variables will be used for the analyses. */
encode Registered, generate (Registration)
encode RegistrationnumberorPreSpecif, generate (RegistrationNumber)
destring Durationbetweenstartandregist, ignore("N/A") generate (Time_StartandReg)
destring Durationbetweentrialcompletion, ignore("N/A") generate (Time_EndandPub)
encode FavourableorUnfavourable, generate (Unfavourable)
destring DurationofFollowUpinWeeks, ignore("N/A") generate (FollowUpTime)
destring RequiredSampleSize, ignore("N/A") force generate (NRequired) /* 'force'
is required as STATA is recognizing a non-numeric character somewhere in the
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extraction file, other than N/A. However upon close inspection of the data,
only the trials with N/A are converted to missing, so the use of 'force' does
not have any impact on the data-conversion with 'destring' */
destring LosstoFollowUpproportionof, ignore("N/A") generate (LosstoFollowUp)
destring pValuemainoutcome, ignore("N/A") generate (PValue)
encode SignificantorNot, generate (Significant)
encode MeasureofEffect, generate (EffectMeasure)
encode TypeofOutcome, generate (Dichotomous)
destring TotalNumberofEventsAdjustment, ignore("N/A") generate (TotalEvents)
destring FragilityIndex, ignore("N/A") generate (Fragility)
destring StandardEffectSizeAll, ignore("N/A" "Unknown") generate (StandardES)
encode AP, generate (AdequacyofPower)
encode EndPointConclusions, generate (Conclusions)
encode Contradictcurrentmedicalpracti, generate (Reversal)
encode PrimaryOutcomereportedinabstr, generate (AbstractOutcomePrimary)
encode Basedonsubgroupanalysis, generate (AbstractOutcomeSubgroup)
encode Basedonsecondaryoutcome, generate (AbstractOutcomeSecondary)
encode ReversalType, generate (ReasonforReversal)
encode Funding, generate (ConflictsofInterest)
encode Type, generate (OutcomeType)
encode Overall, generate (PICOTS)
encode OverallBias, generate (ROB)
encode QualityofEvidence, generate (GRADE)
/* Several variables were imported, not as string, but as numeric because they
contained only numeric data. These will be renamed to more easily identify
them */
rename YearofPublication YearPublished
rename DurationofFollowUpinWeeksI FollowUpTimeImputed
rename SampleSize NTotal
rename Alteredpvalue PValueImputed
rename ImputedLosstoFollowUpProport LosstoFollowUpImputed
rename StandardEffectSizeImputed StandardESImputed
/* When using the 'encode' command, numeric values are assigned alphabetically.
This means that the ordinal variables will need to be fixed so that the quality
ratings appear in the correct order, with the categories that have the highest
quality having the highest number. PICOT is in the correct order, but for ROB,
"Definitely Low" has a value of 2, "Probably High" has a value of 3, and
"Probably Low" has a value of 4, when they should respectively have values of
4, 2, and 3. This same recoding will be applied to the individual components
of the ROB. Similarly, for GRADE, "High" has a value of 1, "Moderate" has a
value of 3, "Low" has a value of 2, and "Very Low" has a value of 4, when
they should respectively have 4, 3, 2, 1. */
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recode ROB (2 = 4) (3 = 2) (4 = 3) (1 = 1), generate (ROB_Overall)
recode GRADE (1 = 4) (3 = 3) (4 = 1) (2 = 2), generate (GRADE_Overall)
/* The recode command is also necessary for most of our binary covariates, for
which all "No" responses have been given values of 1, and all "Yes" responses
were given values of 2. Similarly, other binary variables will be recoded so
that the '0' corresponds to the state of non-interest as follows: Dichotomous
(1) vs. continuous (0) outcome; Conclusions that are positive (1) vs. negative
or no difference (0); */
recode Registration (1 = 0) (2 = 1), generate (_Registration)
recode RegistrationNumber (97 = 0) (1/600 = 1), generate (RegistrationAvailable)
recode Unfavourable (1 = 0) (2 = 1), generate (_Unfavourable)
recode Significant (1 = .) (2 = 0) (3 = 1), generate (_Significant)
recode Dichotomous (1 = 0) (2 = 1), generate (_Dichotomous)
recode AdequacyofPower (1 = 0) (2 = 1), generate (SufficientAP)
recode Conclusions (1 = 0) (2 = 1), generate (_Conclusions)
recode Reversal (1 = 0) (2 = 1), generate (_Reversal)
recode AbstractOutcomePrimary (1 = 0) (2 = 1), generate (_AbsOutcomePrimary)
recode AbstractOutcomeSubgroup (1 = 0) (2 = 1), generate (_AbsOutcomeSubgroup)
recode AbstractOutcomeSecondary (1 = 0) (2 = 1), generate (_AbsOutcomeSecondary)
/* The database should be set for the analyses at this time. Please see the
do-file in APPENDIX G for the STATA code to conduct all descriptive and
logistic regression analyses. */
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APPENDIX G
STATA DO-FILE 2
CONDUCTING DESCRIPTIVE AND LOGISTIC REGRESSION ANALYSES
/* With the database set up after running the do-file from APPENDIX F, this
do-file conducts all of the analyses presented in the Chapter 5: Results. */
/* First set of commands collects all of the information necessary to present
the descriptive statistics found in Tables 5.2, 5.3, and half of Table 5.1.
The first statistics found in Table 5.1 come from the three tiers of screening
and correspond with the PRISMA flow diagram found in Figure 5.1. */
/* Table 5.1: */
table Conclusions
table Reversal
/* Table 5.2: Overall population descriptive statistics */
table Registration
table RegistrationAvailable if _Registration == 1
mean Time_StartandReg
table Unfavourable
mean FollowUpTime
mean NTotal
mean NRequired
mean LosstoFollowUp
table Significant
table EffectMeasure
table Dichotomous
table OutcomeType
table AbstractOutcomePrimary
table AbstractOutcomeSubgroup
table AbstractOutcomeSecondary
table ReasonforReversal
table PICOTS
table ROB
table GRADE
/* Table 5.3: Descriptive statistics for reversals and reaffirmations */
sort _Reversal
by _Reversal: table Registration
by _Reversal: table RegistrationAvailable if _Registration==1
by _Reversal: summarize Time_StartandReg
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by _Reversal: table Unfavourable
by _Reversal: summarize FollowUpTime NTotal NRequired LosstoFollowUp
by _Reversal: table Significant
by _Reversal: table EffectMeasure
by _Reversal: table Dichotomous
by _Reversal: table OutcomeType
by _Reversal: table AbstractOutcomePrimary
by _Reversal: table AbstractOutcomeSubgroup
by _Reversal: table AbstractOutcomeSecondary
by _Reversal: table PICOTS
by _Reversal: table ROB
by _Reversal: table GRADE
/* The second set of commands perform all of the regression analyses: first
the relationship that each potential predictor may have with the outcome is
looked at individually, then all covariates are included into an overallmultivariable logistic regression, and then a backwards-stepwise model is
created from all of the covariates of interest. */
/*Table 5.4: Univariable Logistic Regressions for all potential predictors. Also
included are the 'contrast' commands which test the overall significance of the
individual factor variables. To generate the table of beta-coefficients, found
in APPENDIX H, replace each "logistic" command with "logit." */
logistic _Reversal LosstoFollowUp
logistic _Reversal FollowUpTime
logistic _Reversal PValue
logistic _Reversal NTotal
logistic _Reversal TotalEvents
logistic _Reversal Fragility
logistic _Reversal SufficientmOIS
logistic _Reversal StandardES
logistic _Reversal YearPublished
logistic _Reversal Time_StartandReg
logistic _Reversal Time_EndandPub
logistic _Reversal _Registration
logistic _Reversal _AbsOutcomePrimary
logistic _Reversal _AbsOutcomeSubgroup
logistic _Reversal _AbsOutcomeSecondary
logistic _Reversal i.ConflictsofInterest
testparm i.ConflictsofInterest
logistic _Reversal ib3.OutcomeType
testparm i.OutcomeType
logistic _Reversal i.PICOTS
testparm i.PICOTS
logistic _Reversal i.ROB_Overall
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testparm i. ROB_Overall
logistic _Reversal i.GRADE_Overall
testparm i.GRADE_Overall
/* Conduct univariable logistic regressions for the predictors that have missing
data imputed to determine if the imputation effects the relationship. If not,
then the imputed data are used in place of the missing data. */
logistic _Reversal LosstoFollowUpImputed
logistic _Reversal FollowUpTimeImputed
logistic _Reversal PValueImputed
logistic _Reversal StandardESImputed
/* Check the correlation among all of the non-factor variables to see if any of
them have a high degree of correlation and warrant the removal of one from the
overall model. */
correlate LosstoFollowUpImputed FollowUpTimeImputed PValueImputed NTotal
StandardESImputed YearPublished _AbsOutcomePrimary _AbsOutcomeSubgroup
_AbsOutcomeSecondary
/* Full Multivariable Logistic Regression including all covariates; the 'estat gof'
command tests the goodness-of-fit of the model with Pearson; use of 'group(10)'
performs the Hosmer-Lemeshow goodness-of-fit test. */
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest ib3.OutcomeType
i.PICOTS i.ROB_Overall i.GRADE_Overall
estat gof
estat gof, group(10)
/* Conduct the likelihood ratio tests necessary to determine the overall effect
of each factor variable in the model. */
estimates store overall
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary
_AbsOutcomeSubgroup _AbsOutcomeSecondary ib3.OutcomeType i.PICOTS
i.ROB_Overall i.GRADE_Overall
lrtest overall
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest i.PICOTS
i.ROB_Overall i.GRADE_Overall
lrtest overall
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logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest ib3.OutcomeType
i.ROB_Overall i.GRADE_Overall
lrtest overall
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest ib3.OutcomeType
i.PICOTS i.GRADE_Overall
lrtest overall
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest ib3.OutcomeType
i.PICOTS i.ROB_Overall
lrtest overall
/* Backwards-Selection Model building with an exit significance level of 0.5.
The use of 'xi' command is necessary because the stepwise procedure does not
allow for factor variables. 'Xi' creates dummy variables that can then be used
in the overall model estimation procedure. */
xi i.ConflictsofInterest i.OutcomeType i.PICOTS i.ROB_Overall i.GRADE_Overall
stepwise, pr(0.5): logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed
PValueImputed NTotal StandardESImputed YearPublished _Registration
_AbsOutcomePrimary _AbsOutcomeSubgroup _AbsOutcomeSecondary (_IConflicts_2
_IConflicts_3) (_IPICOTS_2 _IPICOTS_3) (_IROB_Overa_2 _IROB_Overa_3
_IROB_Overa_4) (_IGRADE_Ove_2 _IGRADE_Ove_3 _IGRADE_Ove_4)
estat gof
estat gof, group(10)
/* Conduct the likelihood ratio tests to find the overall significance of the
two factor variables that are included in the model. */
logistic _Reversal LosstoFollowUpImputed PValueImputed StandardESImputed
_AbsOutcomeSubgroup i.PICOTS i.ROB_Overall
estimates store backwards
logistic _Reversal LosstoFollowUpImputed PValueImputed StandardESImputed
_AbsOutcomeSubgroup i.ROB_Overall
lrtest backwards
logistic _Reversal LosstoFollowUpImputed PValueImputed StandardESImputed
_AbsOutcomeSubgroup i.PICOTS
lrtest backwards
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APPENDIX H
RESULTS
SUPPLEMENTARY TABLES AND FIGURES FOR EXTENDED ANALYSES
Table 6. Comparison of population statistics between reversals and reaffirmations
Descriptive Population Statistic
Trials registered
Protocol / registration accessible
Mean time between trial start and registration (years)
Trials with a primary outcome oriented around harm
Mean duration of follow up (weeks)
Mean sample size
Mean required sample size (where provided)
Mean loss to follow up (% total sample size)
Trials with significant primary outcomes (P < 0.05)
Trials with a primary outcome measure of effect:
HR (Hazard Ratio)
RR (Relative Risk)
AR (Absolute Risk)
OR (Odds Ratio)
ES / MD (Effect Size / Mean Difference)
RRR (Relative Risk Reduction)
NNT / NNH (Number Needed to Treat / Harm)
N/A (Not Available)
Trials with a dichotomous primary outcome
Trials with a primary outcome that is:
Hard (patient-important)
Composite
Surrogate
Trials reporting abstract conclusions based on:
Primary outcome
Secondary outcome
Subgroup analyses
Trials with overall PICOTS designation:
Sufficient
Somewhat insufficient
Clearly insufficient
Trials with overall ROB designation:
Definitely low risk of bias
Probably low risk of bias
Probably high risk of bias
Definitely high risk of bias
Trials with overall GRADE level of evidence:
High
Moderate
Low
Very low
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Reversals
(n = 331)

Reaffirmation
(n = 280)

293 (88%)
257 (88%)
1.08 (2.45)
253 (76%)
111.99 (162.47)
3430 (11900.5)
2205 (5221.36)
0.062 (0.086)
114 (34%)

249 (89%)
207 (83%)
1.35 (2.67)
191 (68%)
119.27 (169.90)
3157 (11154.23)
2158 (4586.71)
0.079 (0.103)
162 (58%)

99 (30%)
75 (23%)
54 (16%)
23 (7%)
33 (10%)
2 (1%)
0 (0%)
45 (14%)
267 (81%)

67 (24%)
40 (14%)
49 (18%)
26 (9%)
32 (12%)
3 (1%)
0 (0%)
63 (23%)
207 (74%)

156 (47%)
109 (33%)
66 (20%)

121 (43%)
83 (30%)
76 (27%)

282 (85%)
120 (36%)
20 (6%)

238 (85%)
112 (40%)
32 (11%)

130 (39%)
162 (49%)
39 (12%)

113 (40%)
132 (47%)
35 (13%)

104 (31%)
114 (34%)
85 (26%)
28 (9%)

61 (22%)
98 (35%)
82 (29%)
39 (14%)

41 (12%)
100 (30%)
71 (22%)
119 (36%)

44 (16%)
69 (25%)
75 (27%)
102 (36%)

Table 7. Correlation between potential predictors (not including factor variables)

Table 8. Logistic regression beta-coefficient estimates for potential predictors.
Covariate
Percent participants lost to follow up (imputed)
Duration of follow up (imputed)
P-value (imputed)
Sample size
Standardized effect size (imputed)
Total number of events
Fragility Index
Sufficient Adequacy of Power
Year of publication
Years between trial start and trial registration
Years between trial completion and publication
Protocol registered
Abstract conclusion based on primary outcome
Abstract conclusion based on subgroup
analyses
Abstract conclusion based on secondary
outcome
Conflicts of interest
Non-industry vs. Industry
None-reported vs. Industry
Type of outcome
Hard vs. Surrogate
Composite vs. Surrogate
Overall PICOTS
Sufficient vs. Clearly insufficient
Somewhat insufficient vs. Clearly insufficient
Overall ROB
Definitely low ROB vs. Definitely high ROB
Probably low ROB vs. Definitely high ROB
Probably high ROB vs. Definitely high ROB
Overall GRADE
High vs. Very low
Moderate vs. Very low
Low vs. Very low

Logistic Regression Analyses
Uni-variable
Overall
Backwards-stepwise
-1.91898
-0.00026
1.74083
2.08e-06
-0.11555
-0.00011
0.00137
0.03801
0.01094
-0.04203
0.01348
-0.04088
0.01549
-0.69637

-0.99256
-0.00027
1.50488
1.89e-06
-0.07462
N/A
N/A
N/A
0.00768
N/A
N/A
-0.15311
0.12919
-0.59737

-1.33550
N/A
1.50628
N/A
-0.07196
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.62669

-0.15890

-0.06959

N/A

0.09531
0.22699

-0.14225
-0.01820

0.39514
0.41359

0.38554
0.37397

0.03193
0.09658

-0.35935
-0.24238

-0.36662
-0.20837

0.86487
0.48259
0.36729

0.86599
0.47941
0.29949

0.74019
0.41797
0.30504
N/A

0.23725
0.32250
0.19852

-0.16315
-0.00172
0.03025

N/A
N/A
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Calculating Odds Ratios for relevant unit differences for continuous covariates
OR = e^(β*difference)
95% CI = e^(β lower limit*difference) to e^(β upper limit*difference)
Univariable analyses:
10% increase in ‘Percent of participants lost to follow up’ = e(-1.92021*0.1) = 0.83
95% CI = e(-3.71201*0.1) to e(-0.12841*0.1) = 0.69 to 0.99
Imputed 10% increase in ‘Percent of participants lost to follow up’ = e(-1.91898*0.1) = 0.83
95% CI = e(-3.70893*0.1) to e(-0.12903*0.1) = 0.69 to 0.99
52 week increase in “Duration of follow up’ = e(-0.00026*52) = 0.99
95% CI = e(-0.00123*52) to e(0.00070*52) = 0.94 to 1.04
Imputed 52 week increase in “Duration of follow up’ = e(-0.00026*52) = 0.99
95% CI = e(-0.00123*52) to e(0.00070*52) = 0.94 to 1.04
0.10 increase in ‘P-value’ = e(1.67535*0.1) = 1.18
95% CI = e(1.06172*0.1) to e(2.28898*0.1) = 1.11 to 1.26
Imputed 0.10 increase in ‘P-value’ = e(1.74083*0.1) = 1.19
95% CI = e(1.14766*0.1) to e(2.33400*0.1) = 1.12 to 1.26
100 subject increase in ‘Sample size’ = e(2.08e-06*100) = 1.00
95% CI = e(-0.00001*100) to e(0.00002*100) = 1.00 to 1.00
50 event increase in ‘Total number of events’ = e(-0.00011*50) = 1.00
95% CI = e(-0.00029*50) to e(0.00008*50) = 1.00 to 1.00
5 event increase in ‘Fragility index’ = e(0.00137*5) = 1.01
95% CI = e(-0.01459*5) to e(0.01734*5) = 0.93 to 1.09
5-year increase in ‘Year of publication’ = e(0.01094*5) = 1.06
95% CI = e(-0.02245*5) to e(0.04433*5) = 0.89 to 1.25
5-year increase in ‘Years between start and registration = e(-0.04203*5) = 0.81
95% CI = e(-0.11807*5) to e(0.03401*5) = 0.55 to 1.19
5-year increase in ‘Years between end and publication’ = e(0.01348*5) = 1.07
95% CI = e(-0.11346*5) to e(0.14043*5) = 0.57 to 2.02
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Overall logistic analyses:
10% increase in ‘Percent of participants lost to follow up’ = e(-0.99255*0.1) = 0.91
95% CI = e(-2.85571*0.1) to e(0.87060*0.1) = 0.75 to 1.09
52 week increase in “Duration of follow up’ = e(-0.00027*52) = 0.99
95% CI = e(-0.00136*52) to e(0.00081*52) = 0.93 to 1.04
0.10 increase in ‘P-value’ = e(1.50488*0.1) = 1.16
95% CI = e(0.87718*0.1) to e(2.13258*0.1) = 1.09 to 1.24
100 subject increase in ‘Sample size’ = e(1.89e-06*100) = 1.00
95% CI = e(-0.00001*100) to e(0.00002*100) = 1.00 to 1.00
5-year increase in ‘Year of publication’ = e(0.00768*5) = 1.04
95% CI = e(-0.03373*5) to e(0.04910*5) = 0.85 to 1.28
Backwards-Stepwise analyses:
10% increase in ‘Percent of participants lost to follow up’ = e(-1.33550*0.1) = 0.88
95% CI = e(-3.16240*0.1) to e(0.49141*0.1) = 0.73 to 1.05
0.10 increase in ‘P-value’ = e(1.506278*0.1) = 1.16
95% CI = e(0.88772*0.1) to e(2.12484*0.1) = 1.09 to 1.24
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APPENDIX I
A PROPOSED TOOLBOX FOR REVERSAL
PROPOSED METHODS FOR ASSESSING SUFFICIENCY AND STABILITY IN
RELATION TO REVERSAL
Sufficiency and Stability for the Identification of Evidence Reversal
Reducing the impact of unnecessary reversals will require the identification of
practices that have immature evidence among practices that regularly see use, and those
for which the adoption process is underway. The evidence base for questionable existing
practices must be assessed to support or contradict continued use, and new practices must
provide a matured evidence base before recommending their adoption. To this end, we
propose several different methods or tools for describing the sufficiency and stability of
evidence among both new and established practices. These include: cumulative metaanalysis, trial sequential analysis / monitoring, Bayesian analysis, value of information
analysis, GRADE (Grades of Recommendation Assessment, Development, and
Education), and the fragility index.
Table 9. Proposed Tools for determining stability and sufficiency of evidence
Proposed Tool

Description

Cumulative metaanalysis

A series of sequential meta-analyses that shows the cumulative evidence for a
research question with each new piece of evidence. Very clear visual indicator
of both sufficiency and stability.

Trial sequential
analysis / monitoring

A statistical method for assessing the conclusions made by cumulative metaanalyses that accounts for multiple testing by creating monitoring boundaries
calculated from an optimal information size based on the assumption that all
participants are from a single meta-analysis. Very clear statistical indicator of
sufficiency.

Bayesian analysis

Incorporates measures of sufficiency and stability (i.e. invariance) into the
calculation of likelihoods based on the prior available information. When
evidence is sufficient and stable, inferences are good estimators of the truth.
Complex indicator of sufficiency and stability.

Value of information
analysis

A model for decision-making that utilizes the number of dependent information
sources, precision of those sources, and consequent value of information gained
from a source (with greater numbers of sources often being redundant and
providing lower value). Complex indicator of sufficiency and stability.

GRADE

“Grades of Recommendation, Assessment, Development, and Evaluation” is a
quality assessment tool for rating individual studies or collections of studies
using biases and study characteristics. Qualitative indicator of sufficiency and
stability.

Fragility index

A measure of the fragility of a study’s significance based on how few events
(switching from event to non-event) would be required to change a statistically
significant result a non-significant result. When applied over several studies in
support of a claim, a clear indicator of sufficiency.
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Cumulative meta-analysis to identify medical reversal
While improving the development of clinical guidelines and increasing
knowledge translation are approaches to reducing the prevalence of medical reversals
before they are identified, there remains the issue of identifying practices that should be
reversals and are needing de-implementation. There is general agreement in the medical
literature that the best means of assessing the efficacy and effectiveness of an intervention
or practice is a meta-analysis of RCTs.81 While there are weaknesses in the process of
collecting the evidence for a meta-analysis, it is an established statistical method for
integrating the results of multiple studies to determine the overall effect of an
intervention.88,89 Applied to the context of medical reversal, where it is necessary to not
only understand the efficacy of a practice but whether enough evidence has accumulated
to make a decision, an appropriate technique is cumulative meta-analysis.
Where traditional meta-analysis combines all studies into a single summative
estimate, cumulative meta-analysis (CM-A) is a process whereby a series of sequential
meta-analyses are performed – one each time a new study is conducted on the topic –
thereby generating a running estimate that shows the cumulative strength of the evidence
for an effect with each additional study.90 Cumulative meta-analysis is ideal for
determining whether we can trust the evidence for an intervention by allowing for the
exploration of two values of research that are not addressed by traditional meta-analysis:
sufficiency and stability.90
A 1992 paper by Lau et al demonstrates the difference in approach between a
traditional meta-analysis and a cumulative meta-analysis of the same database.91 The
authors sought to showcase the technique and the value that it provides to practitioners
and policy makers in providing more definitive evidence for an intervention’s efficacy
that is current with each new piece of evidence. As an example for the technique, the
authors examined the use of intravenous streptokinase – compared to placebo or no
treatment – as a method of reducing total mortality after MI.91 The total database included
33 trials conducted between 1959 and 1988, with a total of 36974 patients enrolled and
randomized to intervention or control.91 The authors found that the cumulative evidence
showed that intravenous streptokinase provided a statistically significant reduction in
mortality for acute MI after only eight trials – and a total of 2432 patients (odds ratio =
0.74, 95% CI: 0.59 to 0.92, P = 0.007).91
The difference between these statistical techniques is clear, as are the
characteristics of sufficiency and stability. While both the conventional and final
cumulative MA found strong support favouring the use of intravenous streptokinase
versus placebo or no treatment, in reducing total mortality from acute MI (Z = -8.16, P <
0001), the results from the individual studies in the conventional meta-analysis appear to
jump around and there is no definitive pattern on which to base a judgement before the
final estimate.91 On the other hand, the cumulative meta-analysis depicts a strong trend
for significance in favour of streptokinase by the 8th study, and all further studies only
serve to narrow the confidence intervals of the estimate.91 The cumulative MA approach
suggests that more than 20 trials were conducted unnecessarily, and upwards of 30000
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patients were randomized to not receive life-saving treatment. If researchers in the late
1970s had only looked at the cumulative evidence for the intervention, they may have
seen the efficacy that was evident in the cumulative trends but not apparent with the
conventional meta-analysis, and streptokinase may have been implemented earlier, with
fewer resources and patient lives wasted in the pursuit of unnecessary evidence.
Cumulative meta-analysis is a demonstrably powerful technique for identifying
whether the evidence for the efficacy of an intervention is stable and sufficient enough to
warrant a reversal. This makes it ideal for the identification of current practices that need
to be reversed. However, cumulative MA is not the most ideal tool for identifying
medical reversals before implementation because it requires that enough evidence exists
to exhibit stability and sufficiency to support a decision. This characteristic of cumulative
MA could be considered unethical for a practice that is trending towards ineffectiveness
or harm but has not yet reached a point of maturity.
Trial sequential analysis / monitoring
While cumulative meta-analyses provide a clear visual indication of whether or
not evidence for a claim is sufficient and stable, the conclusions are at an increased risk
of being spuriously significant (P < 0.05) as a result of repeated testing for significance as
data accumulates.80,92 Trial sequential analysis is a statistical technique that is applied to
cumulative meta-analysis to account for this multiple testing by using monitoring
boundaries that are based upon an optimal information size.80,92
The “information size” (IS) of a meta-analysis is the anticipated number of
subjects (i.e. sample size) that is required to detect a pre-specified intervention effect,
based on desired risks of Type I and II Error and the expected heterogeneity among
included trials, in an adequately powered trial.80,92 The information size for a metaanalysis should be the same as expected for a single randomized controlled trial, and any
meta-analysis conducted before reaching its IS must be evaluated in a way that accounts
for the increased risk of Type I Error (i.e. by calculating and utilizing monitoring
boundaries).80,92
Trial Sequential Monitoring Boundaries provide the limits for significance of
effect in meta-analyses that have sparse data.80,92 Meta-analyses that meet or exceed their
IS are considered to have sufficient evidence to support their conclusions.80,92
Bayesian analysis
Bayesian analysis is a method of determining the likelihood of future events
occurring based on the information that is currently available.93 The goals of Bayesian
analysis are akin to meta-analysis in that it aims to predict or inform decisions based on
what is known. The biggest difference between the two approaches (respectively:
Bayesian and Frequentist) is the use of existing evidence and prior beliefs to make
inferences about probabilities as opposed to basing probabilities off of average values
that are conditional on the null hypothesis.93
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Bayesian analysis is commonly used in clinical decision making and could
possibly be used for the identification of targets for reversal.93 If the available evidence
for a claim is neither sufficient nor stable enough to make an inference of acceptable
probability (i.e. the probability of intervention X being an appropriate solution to problem
Y is less than [threshold percentage]), then it should be tested with an appropriate RCT
and studied until the evidence is mature enough, such that the inference reaches the predetermined threshold.
Value-of-information analysis
Decision-making is often a complex process and it is generally accepted that the
more evidence is available to inform a decision, the better any inferences based on that
evidence will be.94 However, when multiple sources of data are dependent on one
another, the redundancy in data actually decreases the expected value of information
gained by the multiple sources if they had been independent of one another.94 Value of
information analysis is a Bayesian model for decision-making where the posterior
distribution density and likelihood function – and consequently the posterior estimate –
are calculated based on the number of information sources, the value estimates, and the
dependence of the errors (i.e. precision) of the estimate.94
Given the usefulness that value of information analysis has for determining the
expected contribution of new information sources to an evidence base, it been suggested
as a formal tool for determining the value of proposed randomized trials in moving
towards the de-implementation of practices that have been established as “unproven” and
are consequently potential targets for reversal.59 It logically follows that if a proposed
trial was determined to not provide any new information of value, then the existing
evidence base would be considered sufficient and stable enough to inform a decision.
GRADE
The Grades of Recommendation, Assessment, Development, and Education tool
is a measure of study quality.95 It is largely based on the biases that are present in a study
and the methodology employed to study a clinical question – often expressed as the sum
of four parts of interest: population, intervention, comparison, and outcome (PICO).95
While GRADE can be used to provide a quality score for a single article, it is also
frequently used in the generation of clinical guidelines: assimilating multiple studies into
a cohesive conclusion.96 The GRADE tool has eight criteria for rating the quality of
evidence – the presence of which can either lower or raise the confidence in study
conclusions: risk of bias, inconsistency of results, indirectness of evidence, imprecision,
probability of publication bias, magnitude of effect, dose-response curve, and residual
confounding supporting conclusions.97 GRADE is well established as being a valid and
reliable tool for evaluating the level and quality of evidence, and it therefore would be
appropriate as a measure of both sufficiency and stability to identify an evidence
reversal.40,95
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Fragility Index
The Fragility Index is tool that is used to quantify how fragile the results of a
controlled trial are by identifying the change in the number of events required to turn a
significant result into a non-significant result.98 There is also an analogue to the fragility
index that provides the fragility of a trial in the opposite direction. The Reverse Fragility
Index is the number of subjects in a trial that would be required to experience a non-event
to take a conclusion from significant to non-significant. This minimum number of
patients who would need to have a change of status from non-event to event, or visaversa, can be compared between trials, with smaller numbers of events indicating a more
fragile finding.98 In an analysis of 399 RCTs published in high-impact journals, the
median Fragility Index was 8, 25% of trials had a Fragility Index of 3 or less, and in 53%
of trials, the Fragility Index was lower than the number lost to follow up.98 If the Fragility
Index were applied over multiple studies it could provide a potential measure of the
sufficiency of evidence as very low numbers would indicate that not enough evidence has
been accumulated to support a claim.
Prioritizing the Identification of Targets for Reversal
Each of the above tools has applicability in the field of evidence reversals in
establishing whether or not the evidence has matured enough to declare the practice a
reversal. These are necessary because concluding the reversal or reaffirmation of a
practice on the basis of a single study or trial is inappropriate. However, in having these
tools to find practices that should be de-implemented, there remains the logistic problem
of identifying the practices upon which to apply these tools. To this end, Prasad and
Ioannidis have proposed seven factors for consideration in assigning priority to the
testing of unproven medical practices.59 We support the use of this framework in future
reversal research, in conjunction with our proposed toolbox of reversal, and our proposed
framework of reversibility.
1. Priority should be given to test practices for which the current evidence base is
weakest
2. Priority should be given to interventions which result in significant net financial
burden on health payers
3. Priority should be given to practices that have multiple alternative options,
especially if the alternatives are of lower cost or less likely to be overturned
because of a separate mechanism of action or stronger supporting evidence
4. Priority should be given to test practices with established harms that confer
substantial morbidity
5. Priority should be given to test practices for which the cost of testing is far less
than ongoing expenditures of the practice
6. Priority should be given to test practices where negative results may have a large
impact
7. Priority should be based on the expected value of information to be gained by
funding a particular study, at the proposed size and cost, that may inform the deimplementation of a practice
LXXXII
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